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A B S T R A C T
Background
The role of gefitinib for the treatment of advanced non-small cell lung cancer (NSCLC) is evolving. We undertook a systematic review
to evaluate the available evidence from all randomised trials.
Objectives
To determine the effectiveness and safety of gefitinib as first-line, second-line or maintenance treatment for advanced NSCLC.
Search methods
We performed searches in CENTRAL, MEDLINE and Embase from inception to 17 February 2017. We handsearched relevant
conference proceedings, clinical trial registries and references lists of retrieved articles.
Selection criteria
We included trials assessing gefitinib, alone or in combination with other treatment, compared to placebo or other treatments in the
first- or successive-line treatment of patients with NSCLC, excluding compassionate use.
Data collection and analysis
We used the standard Cochrane methodology. Two authors independently assessed the search results to select those with sound
methodological quality. We carried out all analyses on an intention-to-treat basis. We recorded the following outcome data: overall
survival, progression-free survival, toxicity, tumour response and quality of life. We also collected data for the following subgroups:
Asian ethnicity and positive epidermal growth factor receptor (EGFR) mutation.
Main results
We included 35 eligible randomised controlled trials (RCTs), which examined 12,089 patients.
General population
Gefitinib did not statistically improve overall survival when compared with placebo or chemotherapy in either first- or second-line
settings. Second-line gefitinib prolonged time to treatment failure (TTF) (hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.75
to 0.90, P < 0.0001) when compared with placebo. Maintenance gefitinib improved progression-free survival (HR 0.70, 95% CI 0.53
to 0.91, P = 0.007) after first-line therapy.
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Studies in patients of Asian ethnicity or that conducted subgroup analyses
Second-line gefitinib prolonged overall survival over placebo (HR 0.66, 95% CI 0.48 to 0.91, P = 0.01). In the first-line setting,
progression-free survival was improved with gefitinib over chemotherapy alone (HR 0.65, 95% CI 0.43 to 0.98, P = 0.04, moderate
quality of evidence). Gefitinib given in combination with a chemotherapy regimen improved progression-free survival versus either
gefitinib alone or chemotherapy alone (HR 0.69, 95% CI 0.49 to 0.96, P = 0.03; HR 0.69, 95% CI 0.62 to 0.77, P < 0.00001,
respectively). In the second-line setting, progression-free survival was superior in patients given gefitinib over placebo or chemotherapy
(HR 0.69, 95% CI 0.52 to 0.91, P = 0.009; HR 0.71, 95% CI 0.57 to 0.88, P = 0.002; moderate quality of evidence, respectively).
Combining gefitinib with chemotherapy in the second-line setting was superior to gefitinib alone (HR 0.65, 95% CI 0.43 to 0.97, P
= 0.04). As maintenance therapy, gefitinib improved progression-free survival when compared with placebo (HR 0.42, 95% CI 0.33
to 0.54, P < 0.00001).
Patients with EGFR mutation-positive tumours
Studies in patients with EGFR mutation-positive tumours showed an improvement in progression-free survival in favour of gefitinib
over first-line and second-line chemotherapy (HR 0.47, 95% CI 0.36 to 0.61, P < 0.00001; HR 0.24, 95% CI 0.12 to 0.47, P <
0.0001, respectively). Gefitinib as maintenance therapy following chemotherapy improved overall and progression-free survival (HR
0.39, 95% CI 0.15 to 0.98, P = 0.05; HR 0.17, 95% CI 0.07 to 0.41, P < 0.0001, respectively) in one phase III study when compared
to placebo.
Toxicities from gefitinib included skin rash, diarrhoea and liver transaminase derangements. Toxicities from chemotherapy included
anaemia, neutropenia and neurotoxicity.
In terms of quality of life, gefitinib improved Functional Assessment of Cancer Therapy-Lung (FACT-L) (standardised mean difference
(SMD) 10.50, 95% CI 9.55 to 11.45, P < 0.000001), lung cancer subscale (SMD 3.63, 95% CI 3.08 to 4.19, P < 0.00001) and Trial
Outcome Index (SMD 9.87, 95% CI 1.26 to 18.48, P < 0.00001) scores when compared with chemotherapy.
Authors’ conclusions
This systematic review shows that gefitinib, when compared with standard first- or second-line chemotherapy or maintenance therapy,
probably has a beneficial effect on progression-free survival and quality of life in selected patient populations, particularly those with
tumours bearing sensitising EGFR mutations.
Patients with EGFR mutations lived longer when given maintenance gefitinib than those given placebo.
One study conducted subgroup analysis and showed that gefitinib improved overall survival over placebo in the second-line setting
in patients of Asian ethnicity. All other studies did not detect any benefit on overall survival. The data analysed in this review were
very heterogenous. We were limited in the amount of data that could be pooled, largely due to variations in study design. The risk of
bias in most studies was moderate, with some studies not adequately addressing potential selection, attrition and reporting bias. This
heterogeneity may have an impact on the applicability of the results
Combining gefitinibwith chemotherapy appears to be superior in improving progression-free survival to either gefitinib or chemotherapy
alone, however further data and phase III studies in these settings are required.
Gefitinib has a favourable toxicity profile when compared with current chemotherapy regimens. Although there is no improvement in
overall survival, gefitinib compares favourably with cytotoxic chemotherapy in patients with EGFR mutations with a prolongation of
progression-free survival and a lesser side effect profile.
P L A I N L A N G U A G E S U M M A R Y
A comparison of gefitinib with no therapy or chemotherapy for non-small cell lung cancer
Review question
Do patients with non-small cell lung cancer live longer if they are given gefitinib?
Background
Non-small cell lung cancer (the most common type of lung cancer) is a leading cause of cancer death worldwide. People diagnosed
with advanced lung cancer may be offered chemotherapy.
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Some lung cancers have been found to have a gene mutation, which is an alteration in the chromosome sequence inside the cells. This
mutation affects the epidermal growth factor receptor (EGFR), which is a switch on the surface of the cell leading to uncontrolled
growth and spread. Gefitinib is a drug that targets cells with mutated EGFR, thus stopping their growth. Studies have found that this
mutation is more commonly found in people who are non-smokers, female, of Asian heritage and with adenocarcinoma (a type of lung
cancer).
Study characteristics
We searched for relevant trials up to 17 February 2017. There were a total of 35 studies conducted between 2000 and 2017, evaluating
12,089 participants from multiple countries including North America, Europe and Asia.
Key results
This review showed that patients with advanced lung cancer do not live longer when treated with gefitinib when compared with no
other treatment or chemotherapy. In people whose lung cancer has worsened after initial therapy, gefitinib may prolong the time before
the cancer progresses further, but only in a selected group of patients of Asian ethnicity or with EGFR mutations. Combining gefitinib
with chemotherapy probably increases the time to cancer progression over either gefitinib or chemotherapy alone. For EGFR-mutation
positive patients who are stable after chemotherapy, ongoing gefitinib has been shown to improve survival when compared to placebo.
Severe side effects, such as low red and white blood cell counts and nerve symptoms, occurred more frequently in patients given
chemotherapy compared to those given gefitinib. Side effects caused by gefitinib included a skin rash, diarrhoea and liver dysfunction.
Quality of life may be improved in favour of gefitinib when compared with chemotherapy.
Quality of the evidence
When comparing gefitinib as a first- and second-line treatment with chemotherapy, we downgraded the quality of the evidence to
moderate for the outcomes overall survival and progression-free survival because the results were not precise and they may not be
applicable to all patients due to the inclusion of a population only over 70 years of age. However, the quality of the evidence when we
compared toxicities from gefitinib with chemotherapy was high.
3Gefitinib for advanced non-small cell lung cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Gefitinib compared to chemotherapy for first- line treatment of advanced NSCLC
Patient or population: advanced NSCLC
Settings: f irst-line treatment
Intervention: gef it inib
Comparison: chemotherapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Chemotherapy Gefitinib
Overall survival (OS) The mean OS ranged
across control groups
f rom 3.5 to 8 months
The mean OS in
the intervent ion group
ranged f rom 2.2 to 5.9
months
HR 0.98 (0.91 to 1.46) 275
(2 RCTs)
⊕⊕⊕©
MODERATE1
OS similar in the Asian
(HR 0.94, 0.82 to 1.06)
and EGFRmutat ion pos-
it ive subgroups (HR 0.
97, 0.77 to 1.21)
Progression-f ree sur-
vival (PFS)
The PFS ranged across
control groups f rom 2
to 2.9 months
The mean PFS in
the intervent ion group
ranged f rom 1.9 to 2.7
months
HR 1.19 (0.86 to 1.65) 275
(2 RCTs)
⊕⊕⊕©
MODERATE1
PFS improved with gef i-
t inib in the Asian sub-
group (HR 0.65, 0.43
to 0.98) and the EGFR
mutat ion posit ive sub-
group (HR 0.47, 0.36 to
0.61)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; EGFR: epidermal growth factor receptor; HR: hazard rat io; NSCLC: non-small cell lung cancer; OS: overall survival; PFS: progression-f ree survival; RCT:
randomised controlled trial
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1We downgraded the quality of evidence by one level because of serious indirectness as one study included only elderly
pat ients (> 70 years old).
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B A C K G R O U N D
Description of the condition
Non-small cell lung cancer (NSCLC) accounts for 14% of all can-
cer-related deaths and is by far the leading cause of cancer death
among both men and women. In the United States, it was pre-
dicted that about 234,030 new cases of NSCLC would be diag-
nosed, and 154,050 deaths would result from NSCLC in 2018
(ACS 2018). The survival rate for people diagnosed with NSCLC
will vary according to the extent (stage) of the cancer. People with
locally advanced NSCLC (stage III or more) have a five-year sur-
vival rate of 5% to 36%, and survival estimates do vary according
to stage at diagnosis (ACS 2018). Active treatment of NSCLC
consists of surgery, radiotherapy and chemotherapy, given as sin-
gle therapies or in combination. Although there have been major
medical therapeutic advances in recent times, these have not been
sufficient to significantly affect the high mortality and morbidity
rates associated with lung cancer.
The pathogenesis of lung neoplasms is multifactorial, however
most can be directly attributed to tobacco smoke exposure.
NSCLC arising in smokers has a different spectrum of molecular
abnormalities from those in non-smokers, suggesting differences
in aetiology, pathogenesis and possibly prognosis. Mutations of
tumour suppressor genes such as p53 and retinoblastoma; stim-
ulation of proto-oncogenes such as K-ras, c-myc and c-raf; and
production of autocrine growth factors are some of the potential
pathogenic mechanisms so far described in the development of
lung cancer. Recent research has identified two oncogenic drivers,
epidermal growth factor receptor (EGFR) mutation and EML4/
ALK fusion, for which targeted therapies are available.
Description of the intervention
The epidermal growth factor receptor (EGFR) family of genes
encodes a widely expressed transmembrane molecule that is fre-
quently expressed in solid tumours. Overexpression of EGFR has
been associated with the pathogenesis, proliferation, invasion and
metastasis of various solid tumours, including NSCLC. EGFR
is overexpressed in around 40% to 80% of documented cases of
primary NSCLC and around 88% of advanced cases of NSCLC
(Smith 2005).
Tyrosine kinase inhibitors (TKIs) bind to the intracellular domain
of the tyrosine kinase and may inhibit EGFR downstream sig-
nalling. Inhibition of tyrosine kinase may, therefore, block EGFR-
mediated cancer cell propagation. TKIs may be classified as re-
versible or irreversible, and as selective against EGFR or active
against other members of the receptor family. Somatic mutations
in the region of EGFR that encodes the tyrosine kinase domain
of the receptor (exons 18 through 21) have been identified in
lung cancer. Such mutations occur more frequently in patients
with NSCLC who have the adenocarcinoma sub-type, women,
Asian people and those who have never smoked (Kosaka 2004;
Paez 2004). EGFR mutations are associated with both increased
growth factor signalling and increased responsiveness to tyrosine
kinase inhibitors (Mok 2011).
How the intervention might work
Gefitinib (Iressa, ZD 1839) is an orally active anilinoquinazoline
that selectively and reversibly inhibits intracellular EGFR tyro-
sine kinase activity. Two large, randomised phase II clinical tri-
als assessed the efficacy and safety of gefitinib monotherapy in
patients with locally advanced or metastatic NSCLC who failed
previous chemotherapy regimens (Fukuoka 2003 IDEAL I; Kris
2003 IDEAL II). Both showed no added benefit in terms of sur-
vival, time toprogressionor response rates comparedwith standard
chemotherapy alone. However these monotherapy trials demon-
strated a favourable safety profile. A phase III trial comparing gefi-
tinib to placebo in advanced NSCLC patients who had received
prior chemotherapy showed an improvement in progression-free
survival but no prolongation in overall survival (Thatcher 2005
ISEL). Since these early trials, a number of other randomised con-
trolled trials (RCTs) have examined the effectiveness of gefitinib
versus placebo or chemotherapy, or in combination with chemo-
therapy in the first- and second-line settings. Several studies have
also examined its role as maintenance therapy following treatment
in patients with advanced NSCLC.
Why it is important to do this review
The precise clinical effectiveness of gefitinib in a range of clinical
situations remains to be established.This reviewwill bring together
all the current evidence of effectiveness, in order to guide clinical
management and the discussion of treatment risks and benefits in
patients with NSCLC.
O B J E C T I V E S
To determine the effectiveness and safety of gefitinib as first-line,
second-line or maintenance treatment for advanced NSCLC.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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We considered all published and unpublished randomised, con-
trolled, phase II and phase III clinical trials of gefitinib as first-
or second-line or maintenance therapy in advanced NSCLC. We
included any placebo-controlled trials and trials using compara-
tors. Trials with random allocation, double-blinding and inten-
tion-to-treat analysis were preferred.We excluded cross-over stud-
ies, studies that were quasi-randomised and those that investigated
the compassionate use of gefitinib.
Types of participants
Eligible trials included adult participants aged 18 years or older of
either sex with histologically or cytologically confirmed NSCLC
(stage IIIB/IV) not curable with surgery.
Types of interventions
We considered any administration of gefitinib for advanced
NSCLC. This included the use of any dosage of gefitinib as first-
or second-line therapy or maintenance therapy:
1. Gefitinib at any dose compared with placebo or best
supportive care.
2. Gefitinib at any dose compared with chemotherapeutic
agents.
3. Gefitinib at a specific dose versus gefitinib at a different
dose.
4. Gefitinib versus gefitinib combined with a chemotherapy
regimen.
5. Gefitinib at any dose in combination with
chemotherapeutic agents versus the same chemotherapy agents
alone.
6. Gefitinib at any dose in combination with
chemotherapeutic agents versus a different combination of
chemotherapeutic agents.
Types of outcome measures
Primary outcomes
• Overall survival (OS), assessed from date of randomisation
to date of patient death (time to death).
• Progression-free survival (PFS):
◦ Measured from the date of randomisation to the date
of objective disease progression, based on Response Evaluation
Criteria in Solid Tumours (RECIST), the revised version of the
International Union Against Cancer/WHO criteria (Therasse
2000).
◦ Time to treatment failure (TTF): measured from the
date of randomisation to the date of study discontinuation (for
any reason). This may be reported instead of PFS in some studies.
• Toxicity (graded according to the National Cancer Institute
Common Toxicity Criteria or the World Health Organization
criteria (NCI CTCAE 2010).
◦ However, we accepted whatever definitions had been
used in the individual trials. A risk ratio (RR) significantly greater
than 1 (RR > 1) is a positive response in favour of gefitinib.
Secondary outcomes
• Median overall survival (OS) and progression-free survival
(PFS).
• Survival rate at one year (1YSR).
• Tumour response - defined according to the RECIST
criteria (Therasse 2000):
◦ Complete response (CR) defined as the disappearance
of all target lesions.
◦ Partial response (PR) defined as at least a 30%
decrease in the sum of the longest diameter of target lesions.
◦ Overall response rate (ORR) taken as the sum of
complete response (CR) rate and partial response (PR) rates.
◦ Stable disease (SD) defined as neither sufficient
shrinkage to qualify for partial response nor sufficient increase to
qualify for progressive disease.
◦ Disease control rate (DCR) defined as the sum of the
ORR and SD rate. This represents all lesions that have either
responded to the treatment or stabilised as a result of treatment.
• Quality of life (QOL) and symptom response measured by
the Functional Assessment of Cancer Therapy-Lung (FACT-L)
quality of life instrument, the lung cancer subscale (LCS), the
Trial Outcome Index (TOI) and the Pulmonary Symptom Index
(PSI) (Cella 1995).
Search methods for identification of studies
Electronic searches
We electronically searched for eligible studies using:
• The Cochrane Central Register of Controlled Trials
(CENTRAL 2017, Issue 2) (Appendix 1);
• MEDLINE via PubMed (1966 to 17 February 2017)
(Appendix 2);
• Embase via OVID (1980 to Week 08, 2017) (Appendix 3).
We developed the search string for MEDLINE according to the
Cochrane Highly Sensitive Search Strategy, sensitivity-maximis-
ing version (2008 version) as referenced in Chapter 6.4.11.1 and
detailed in box 6.4.b of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011).
Searching other resources
The authors (ES, IY) also screened reference lists of included and
excluded studies, attempted to contact authors of relevant stud-
ies and examined registers of ongoing trials: ClinicalTrials.gov (
ClinicalTrials.gov) and Current Controlled Trials (isrctn.com) to
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locate all significant published and unpublished data. We also re-
viewed conference proceedings of the American Society of Clin-
ical Oncology, the European Cancer Conference, the European
Society of Medical Oncology and the International Association
for the Study of Lung Cancer, from January 1990 to February
2017. When two articles or more used the same data, we only
used the most updated article, unless we found some additional
information in that article.
Data collection and analysis
Selection of studies
We assessed the eligibility of retrieved articles from the title and
abstract. Two investigators (ES, IY) reviewed potential trials for
inclusion and extracted data from the published manuscripts. We
resolved disagreements about relevance either by consensus or by
referral to a third investigator (RWB). There was no blinding of
the authors as to origin or conclusions of the articles for eligibil-
ity assessment, data extraction or ’Risk of bias’ assessment. We
sought data for all patients randomised in all eligible randomised
trials. Two review authors (ES, IY) independently carried out data
extraction using a specifically designed data extraction form. We
recorded study details, including year of publication, numbers of
people randomised and analysed per arm, age, sex, race/ethnic-
ity of participants, staging and histological cell type, performance
status and any previous treatment. We also recorded the dose and
duration of gefitinib treatment, as well as the use of any chemo-
therapeutic agents. We double-checked all data for consistency,
plausibility and integrity of randomisation and follow-up.
Data extraction and management
We extracted data from included studies using the guidelines set
out in the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011).
Assessment of risk of bias in included studies
Two authors (ES, IY) independently assessed the risk of bias of
included studies according to the areas and criteria proposed in
the Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011).We considered studies to be at low risk of bias when
true randomisation occurred, when there was blinding of assessors
to treatment received, when all patients were accounted for and
included in the analysis on an ’intention-to-treat’ basis and when
all outcome measures were reported. We also considered studies
that were terminated early to have a source of bias of interest.
The results of these judgements are presented in the ’Risk of bias’
tables (Characteristics of included studies).
(1) Sequence generation (checking for possible selection
bias)
For each included study, we assessed the method used to generate
the allocation sequence in sufficient detail to allow an evaluation
of whether it should produce comparable groups.
We assessed risk of bias as:
• Low risk: any truly random process, e.g. random number
table, computer random number generator.
• High risk: any non-random process, e.g. odd or even date
of birth, hospital or clinic record number.
• Unclear risk: insufficient information about sequence
generation process to permit judgement of risk.
(2) Allocation concealment (checking for possible selection
bias)
For each included study, we assessed the method used to conceal
the allocation sequence to determine whether intervention allo-
cations could have been foreseen in advance of, or during, enrol-
ment.
We assessed risk of bias as:
• Low risk: e.g. central or telephone allocation, sequentially
numbered drug containers of identical appearance.
• High risk: e.g. open random allocation, unsealed or non-
opaque envelopes, alternation or rotation, date of birth.
• Unclear risk: insufficient information to permit judgement
of ’low risk’ or ’high risk’ or the study did not address this
outcome.
(3) Blinding (checking for possible performance bias)
For each included study, we described the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received.
We assessed risk of bias as:
• Low risk: blinding of participants and key study personnel
was ensured and it was unlikely that the blinding could have
been broken, or there was no blinding of outcome measurement,
but outcome measurement is unlikely to be influenced by the
lack of blinding.
• High risk: no blinding or incomplete blinding and the
outcome is likely to be influenced by lack of blinding.
• Unclear risk: insufficient information to permit judgement
of ’low risk’ or ’high risk’ or the study did not address this
outcome.
(4) Incomplete outcome data (checking for attrition bias)
For each included study, we reported the completeness of data
including attrition and exclusions, the numbers included in the
analysis at each stage and the reasons for attrition or exclusion.
We assessed risk of bias as:
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• Low risk: e.g. if there were any missing outcome data, the
reasons for missing outcome data were unlikely to be related to
true outcome.
• High risk: e.g. reasons for missing outcome data are likely
to be related to true outcome.
• Unclear risk: insufficient reporting of attrition/exclusions to
permit judgement of ’low risk’ or ’high risk’ or the study did not
address this outcome.
(5) Selective reporting (checking for whether the
prespecified outcomes were met)
For each included study, we assessed if the study’s protocol was
available and that the study’s prespecified (primary and secondary)
outcomes had been reported in the prespecified way, utilising pre-
specified measurements and analysis methods.
We assessed risk of bias as:
• Low risk: e.g. the study protocol was available and all of the
study’s prespecified (primary and secondary) outcomes that are
of interest in the review have been reported in the prespecified
way, or if the protocol was not available, that the published
report included all expected outcomes.
• High risk: e.g. not all prespecified outcomes are reported,
primary outcomes are reported using measurements or analysis
methods that were not prespecified, the primary outcome
reported was not prespecified, incomplete reporting of any
outcomes, failure to include results for a key outcome that would
be expected to have been reported.
• Unclear risk: insufficient information available to permit a
judgement of ’low risk’ or ’high risk’.
(6) Other bias
For each included study, we assessed for bias due to problems are
not covered elsewhere in the table.
We assess risk of bias as:
• Low risk: e.g. study appears free of other bias.
• High risk: e.g. there is at least one important risk of bias,
such as a potential source of bias related to study design, or the
study has been claimed to have been fraudulent.
• Unclear risk: insufficient information or evidence that an
identified problem will introduce bias.
Measures of treatment effect
Treatment effects are divided into quantitative data and patient-
reported outcomes. We analysed quantitative data such as survival
and toxicity as dichotomous outcomes using the risk ratio (RR).
We pooled time-to-event outcomes, such as hazard ratios (HR)
for overall survival and progression-free survival, provided that au-
thors had analysed data using a Cox proportional hazards model.
We summarised proportional outcomes, such as the proportion
who survived, using a risk ratio (RR). We combined continuous
outcomes with the inverse variance method. We combined qual-
ity of life outcomes if the same validated instrument was used,
otherwise we utilised a descriptive approach. If data were com-
bined, we presented the change from baseline as the standardised
mean difference (SMD). All measures of effect included a 95%
confidence interval (CI), P values and for pooled measures the I2
statistic value.
Assessment of heterogeneity
We performed tests for heterogeneity with Review Manager
(RevMan 2014) using the I2 statistic and interpreting the I2 value
using the guidance in the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011). An I2 value of greater than
75% is likely to represent considerable heterogeneity, a value of
50% to 90% is likely to represent substantial heterogeneity and a
value of 30% to 60% represents moderate heterogeneity.
Data synthesis
We combined quantitative data using Review Manager 5.3
(RevMan 2014). We calculated hazard ratios (HR) for data pre-
sented as survival curves using logrank expected number of events
and variance. We pooled hazard ratios across trials using a fixed-
effect model. We combined continuous data, where the mean,
standard deviation (SD) and number of participants in each arm
were available, generating a mean difference (MD) and 95% CI.
We planned to use a fixed-effect model in the meta-analysis if het-
erogeneity was deemed to be small (an I2 value of less than 50%).
We applied a random-effectsmodel to comparisons demonstrating
significant heterogeneity (with an I2 value of greater than 50%).
GRADE and ’Summary of findings’ tables
We employed the GRADE approach to interpret findings (
Schünemann 2011). We used GRADEProGDT (GRADEpro
GDT2015) to import data fromReviewManager (RevMan 2014)
to create ’Summary of findings’ tables for major comparisons in
this review. These tables provide information concerning the over-
all quality of the evidence from the included studies, the magni-
tude of the effect of the interventions and the sum of available
data on the primary outcome and selected secondary outcomes.
We selected the most relevant comparison for presentation in the
’Summary of findings’ tables and we selected the following out-
comes that we considered important to clinical decision-making
for inclusion in these tables:
• Overall survival.
• Progression-free survival.
• Toxicity.
Subgroup analysis and investigation of heterogeneity
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We performed subgroup analyses for the outcomes of survival and
tumour response. We categorised data from included studies into
the following subgroups:
• Asian population: if the study presented data specifically
from patients who were of Asian ethnicity.
• EGFR mutation positive: if the study presented data
specifically from patients who were found to have EGFR
activating mutations.
We undertook these subgroup analyses to determine whether there
are differences between treatment groups depending on these bi-
ological and genomic factors.
Sensitivity analysis
Where applicable, we planned to perform a sensitivity analysis
based on study quality, to assess the effect of this on the reported
outcomes. We also applied a random-effects model as part of our
sensitivity analysis.
R E S U L T S
Description of studies
Results of the search
The search strategy yielded 5703 studies or abstracts of which 127
studies were possibly eligible. Of these, we included 62 publica-
tions in this review, representing 35 primary studies and 27 publi-
cations that presented data from their respective primary studies.
Fifty-six were published in abstract form only and we found the
remaining nine studies to be ineligible (Figure 1).
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Figure 1. Study flow diagram for searches 1966-2017.(EGFR: epidermal growth factor receptor)
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Included studies
We included a total of 35 separate primary studies in this re-
view and these trials randomised a total of 12,089 patients. Sev-
enteen of the eligible studies were multicentre, phase III trials
(Gaafar 2011 EORTC08021; Giaccone 2004 INTACT I; Han
2012 First SIGNAL;Herbst 2004 INTACTII;Kelly2008 SWOG
S0023; Kim 2008 INTEREST; Lee 2010 ISTANA; Maemondo
2010 NEJ002; Maruyama 2008 V-15-32; Mitsudomi 2010
WJTOG3405; Mok 2009 IPASS; Soria 2015 IMPRESS; Sun
2012 KCSG-LU08-01; Takeda 2010 WJTOG0203; Thatcher
2005 ISEL; Yang 2014; Zhang 2012 INFORM). The remaining
18 were phase II studies (Ahn 2012; An 2016; Chen 2007; Chen
2011; Cheng 2016; Crino 2008 INVITE; Cufer 2006 SIGN;
Dai 2013; Fukuoka 2003 IDEAL I; Goss 2009 INSTEP; Kim
2016; Kris 2003 IDEAL II; Li 2010; Lou 2014; Morere 2010
IFCT-0301; Xu 2015; Xue 2015; Yu 2014). A summary of the 35
included primary studies is presented in Table 1. An additional 14
publications analysed data from their respective primary studies
(Bell 2005; Boye 2016; Cella 2005; Chang 2006; Douillard 2010;
Fukuoka 2011; Hirsch 2006; Herbst 2005; Inoue 2013; Oizumi
2012; Sekine 2009; Thongprasert 2011; Yamamoto 2010; Yang
2015). If we used data from these secondary studies, we did not
duplicate with data from the respective primary studies and vice
versa.
The duration of gefitinib therapy varied between studies. Most
studies continued therapy until there was disease progression, un-
acceptable toxicity or withdrawal. Two studies administered gefi-
tinib for six or eightweeks (Chen2007;Morere 2010 IFCT-0301).
The shortest reported median duration of treatment was 50 days
(Goss 2009 INSTEP) and the longest 308 days (Maemondo 2010
NEJ002).
Please refer to the Characteristics of included studies for full de-
tails of included studies. Study characteristics have also been sum-
marised in Table 1.
The various comparisons can be seen in the Data and analyses
section.
1. Gefitinib at any dose compared with placebo or best
supportive care for NSCLC
• General population (Comparison 1)
Three phase III studies (Gaafar 2011 EORTC08021; Kelly 2008
SWOG S0023; Thatcher 2005 ISEL) and a single phase II study
(Goss 2009 INSTEP) compared gefitinib with placebo. The ISEL
(Thatcher 2005 ISEL), INSTEP (Goss 2009 INSTEP), EORTC
08021 (Gaafar 2011 EORTC08021) and SWOGS0023 (Kelly
2008 SWOG S0023) trials examined survival outcomes, objec-
tive response rates and toxicity in the general population. The
INSTEP study randomised chemotherapy-naive patients to 250
mg of gefitinib or placebo as first-line therapy. The ISEL study
studied its effects as second-line therapy in advanced NSCLC.
Detailed subgroup analysis was conducted in the ISEL popula-
tion and subsequently published. These two studies are also pre-
sented below as subgroup analyses (Chang 2006; Hirsch 2006).
Subgroups were assessed for evidence by subgroup interactions,
thus ensuring that outcomes were indeed different. Pre-planned
subgroup analysis of patients of Asian ethnicity was presented in
Chang 2006 and analysis of molecular predictors of outcome was
presented in Hirsch 2006. The SWOGS0023 and EORTC08021
studies assessed the effect of gefitinib versus placebo as mainte-
nance therapy after initial treatment. In the SWOGstudy, patients
were included after receiving concurrent cisplatin/etoposide che-
motherapy with thoracic radiation (45 Gy, 1.8 Gy per fraction).
The EORTC08021 trial included patients not progressing after
first-line platinum doublet chemotherapy. We studied a total of
2605 patients in this group.
• Asian population (Comparison 2)
The INFORM study assessed the use of gefitinib as maintenance
therapy in an East Asian patient group (Zhang 2012 INFORM).
These patients had achieved disease control after first-line plat-
inum-based chemotherapy. Chang 2006 selected only ISEL pa-
tients who were of Asian ethnicity. This subgroup represented
20% of the original ISEL population, a total of 342 patients. We
included a total of 638 patients in this group.
• EGFR mutation positive population (Comparison 3)
Zhang 2012 INFORM performed planned subgroup analysis on
EGFR mutation positive patients and 30 of 79 (38%) tissue tu-
mour samples were positive for EGFR mutations. Hirsch 2006
analysed ISEL tumour biopsy samples to examine the relation-
ships between biomarkers and clinical outcome after gefitinib ad-
ministration. Two-hundred and fifteen of 1692 patients (12.7%)
in the ISEL trial were assessable for mutation detection. Of these,
26 (12.1%) patients were positive for EGFR mutations. Other
biomarkers examined included EGFR gene copy number, EGFR
and p-Akt protein expression and KRAS and BRAF mutations.
Data from these other biomarkers are beyond the scope of this
review.
2. Gefitinib at any dose compared with other
chemotherapeutic agents
We included 18 primary studies in this analysis (Ahn 2012; Crino
2008 INVITE; Cufer 2006 SIGN; Dai 2013; Han 2012 First
SIGNAL; Kim 2008 INTEREST; Kim 2016; Lee 2010 ISTANA;
Li 2010; Lou 2014; Maemondo 2010 NEJ002; Maruyama 2008
V-15-32; Mitsudomi 2010 WJTOG3405; Mok 2009 IPASS;
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Morere 2010 IFCT-0301; Sun 2012 KCSG-LU08-01; Xu 2015;
Yang 2014). Nine of these studies were multicentre, randomised,
phase III trials.
These 18 primary studies randomised a total of 5400 patients.
• General population (Comparison 4)
Four studies, SIGN (Cufer 2006 SIGN), INTEREST (Kim 2008
INTEREST), INVITE (Crino 2008 INVITE) and IFCT-0301
(Morere 2010 IFCT-0301), compared gefitinib with chemother-
apy in 1888 patients and data from these are presented in Com-
parison 4. Two studies compared gefitinib with first-line chemo-
therapy (Crino 2008 INVITE; Morere 2010 IFCT-0301) and
the other two studies compared it with second-line chemotherapy
(Cufer 2006 SIGN; Kim 2008 INTEREST). ’Iressa in NSCLC
versus Vinorelbine Investigation in the Elderly’ (INVITE) was a
randomised, multicentre, phase II trial that compared gefitinib
with vinorelbine as first-line therapy in elderly patients (Crino
2008 INVITE). IFCT-0301 compared gefitinib, gemcitabine and
docetaxel in chemotherapy-naive patients with a performance sta-
tus of 2 or 3 (Morere 2010 IFCT-0301). SIGN (Second-line Indi-
cation of Gefitinib in NSCLC) was a phase II, randomised study
comparing gefitinib with docetaxel as second-line therapy (Cufer
2006 SIGN). INTEREST (Iressa NSCLC Trial Evaluating Re-
sponse and Survival again Taxotere) was a phase III trial, which
assessed the non-inferiority of gefitinib to docetaxel as second-line
therapy (Kim 2008 INTEREST). Douillard 2010 performed a
preplanned secondary analysis to investigate the relationship be-
tween biomarkers and clinical outcomes in the INTEREST pop-
ulation. We included a total of 1888 patients in this group.
• Asian population (Comparison 5)
Fourteen studies selected Asian patients only (Ahn 2012; Dai
2013; Han 2012 First SIGNAL; Kim 2016; Lee 2010 ISTANA;
Li 2010; Lou 2014; Maruyama 2008 V-15-32; Mok 2009 IPASS;
Mitsudomi 2010 WJTOG3405; Maemondo 2010 NEJ002; Sun
2012 KCSG-LU08-01; Xu 2015; Yang 2014), of which all except
six (Ahn 2012; Dai 2013; Kim 2016; Li 2010; Lou 2014; Xu
2015) were phase III studies. We included a total of 3512 patients
in this group.
First-line studies
Five phase III studies (Han 2012 First SIGNAL;Maemondo 2010
NEJ002;Mitsudomi 2010WJTOG3405;Mok 2009 IPASS; Yang
2014) and one phase II study (Lou 2014) compared gefitinib
with first-line chemotherapy. IPASS compared gefitinib with car-
boplatin-paclitaxel, but in Asian patients with adenocarcinoma
who were light or never-smokers (Mok 2009 IPASS). Maemondo
2010 NEJ002 randomised Asian chemotherapy-naive patients
with EGFR mutations to receive gefitinib or carboplatin-pacli-
taxel. WJTOG3405 compared gefitinib with cisplatin plus doc-
etaxel in Asian patients with EGFR mutations (Mitsudomi 2010
WJTOG3405). First-SIGNAL compared first-line gefitinib with
gemcitabine plus cisplatin in Asian never-smokers with lung ade-
nocarcinoma (Han 2012 First SIGNAL). The phase III study by
Yang 2014 compared first-line pemetrexed and cisplatin followed
by gefitinib maintenance therapy with gefitinib monotherapy
alone in Asian non-smoking patients. Patients were randomised at
trial entry to either gefitinib or pemetrexed plus cisplatin chemo-
therapy. Patients in both arms then continued with maintenance
gefitinib. Data were analysed in the intention-to-treat population
and only data from the first phase of the study were included in
this analysis. In the phase II study by Lou 2014, gefitinib was
compared with carboplatin and paclitaxel in Asian patients who
were either non-smokers or light ex-smokers.
We analysed a total of 2224 patients from the six studies in this
group.
Second-line studies
Three phase III studies (Lee 2010 ISTANA; Maruyama 2008
V-15-32; Sun 2012 KCSG-LU08-01) and three phase II stud-
ies (Dai 2013; Kim 2016; Li 2010) compared gefitinib with sec-
ond-line chemotherapy. ISTANA (Lee 2010 ISTANA), V-15-32
(Maruyama 2008 V-15-32) and the phase II study by Li 2010 in-
cluded patients of Asian ethnicity but where mutation status was
not always known, and compared gefitinib with docetaxel. KCSG-
LU08-01 (Sun 2012 KCSG-LU08-01), Dai 2013 and Kim 2016
selected Asian patients with unknown EGFR status and com-
pared gefitinib with second-line pemetrexed. Secondary studies
published by Sekine 2009 and Yamamoto 2010 conducted analy-
ses on quality of life and disease control respectively in the V-15-
32 trial.
We analysed a total of 1030 patients from the six studies in this
group.
Maintenance studies
Two phase II studies compared the role of gefitinib as mainte-
nance to chemotherapy. Ahn 2012 randomised Asian non-smok-
ers not progressing after first-line pemetrexed-cisplatin, to receive
either gefitinib or pemetrexed ± cisplatin, in a two-staged study
design. Xu 2015 compared single-agent pemetrexed with gefitinib
in Asian patients not progressing after four to eight cycles of first-
line chemotherapy.
We analysed 258 patients in this group.
• EGFR mutation positive population (Comparison 6)
Nine studies were included in this group, six of which were first-
line studies (Crino 2008 INVITE; Han 2012 First SIGNAL;
Maemondo 2010 NEJ002;Mitsudomi 2010WJTOG3405;Mok
2009 IPASS; Yang 2014) and three of which were second-line
studies (Kim 2008 INTEREST; Maruyama 2008 V-15-32; Sun
2012 KCSG-LU08-01).
We included a total of 879 patients in this group.
Two phase III studies selected patients of Asian ethnicity who
were also positive for EGFR mutations and compared gefitinib
with first-line carboplatin and paclitaxel or cisplatin and doc-
etaxel respectively (Maemondo 2010 NEJ002; Mitsudomi 2010
WJTOG3405). In contrast, the IPASS (Mok 2009 IPASS) and
First-SIGNAL (Han 2012 First SIGNAL) studies selected Asian
patients with adenocarcinomas, and conducted planned subgroup
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analyses on the EGFR mutation positive patients. IPASS com-
pared first-line gefitinib with carboplatin and paclitaxel and First-
SIGNAL compared gefitinib with gemcitabine and cisplatin. Yang
2014 conducted a post-hoc analysis of EGFR mutation positive
patients and compared first-line pemetrexed and cisplatin followed
by gefitinib maintenance with gefitinib alone. The INVITE phase
II study in elderly patients that compared first-line gefitinib with
vinorelbine also conducted analysis of EGFR mutation positive
patients but this study did not include any data that could be
pooled (Crino 2008 INVITE).
We analysed a total of 802 patients in this group.
A further three phase III studies compared second-line gefi-
tinib with chemotherapy and conducted subgroup analyses in
the EGFR mutation positive patients (Kim 2008 INTEREST;
Maruyama 2008 V-15-32; Sun 2012 KCSG-LU08-01). INTER-
EST and V-15-32 compared gefitinib with docetaxel and KCSG-
LU08-01 compared gefitinib with pemetrexed in this second-line
setting. The INTEREST study also analysed other biomarkers,
such as EGFR gene copy number, EGFR protein expression and
KRAS mutations, in addition to EGFRmutations. One study did
not publish data that could be pooled (Maruyama 2008 V-15-32)
and thus we included a total of 77 patients in this group.
3. Gefitinib at a specific dose versus a different dose
(Comparison 7)
Three phase II studies compared the effect of two different doses
of gefitinib, 250 mg and 500 mg in 527 patients (Fukuoka 2003
IDEAL I; Kris 2003 IDEAL II; Xue 2015). IDEAL I (Fukuoka
2003 IDEAL I) and IDEAL II (Kris 2003 IDEAL II) were multi-
centre, randomised, double-blind, phase II studies that evaluated
two doses of gefitinib (250 mg/day and 500 mg/day) as second-
or third-line therapy.
We analysed 431 patients in this group.
The third study randomised 96 patients who were stable after one
month of gefitinib (250 mg/day) to either 250 mg/day or 500 mg/
day as maintenance therapy (Xue 2015).
4. Gefitinib versus gefitinib combined with a chemotherapy
regimen (Comparison 8)
Four studies compared gefitinib alone or in combination with che-
motherapy. Two recently published studies examined the addition
of chemotherapy to gefitinib versus gefitinib alone in the first-
line setting. A small study by An 2016 recruited 90 East Asian
patients with an EGFRmutation and randomised them to receive
gefitinib or gefitinib plus pemetrexed (500 mg/m2). In this study,
pemetrexed or placebo was administered via intravenous infusion
on day 1 of a 21-day cycle. Gefitinib 250 mg was administered
on days 2 to 16. A multicentre, phase II study by Cheng 2016
also compared gefitinib with and without pemetrexed as first-line
therapy. This study recruited 191 East Asian patients from China,
Japan, Korea and Taiwan with advanced non-squamous NSCLC
with an activating EGFR mutation. Patients either received gefi-
tinib 250 mg per day or gefitinib plus pemetrexed (500 mg/m2)
infusion on day 1 of a 21-day cycle.
We included a total of 281 patients in this group.
Chen 2007 compared 250 mg of daily oral gefitinib with gefitinib
plus vinorelbine (15 mg/m2) every two weeks in 48 patients of
Asian ethnicity with stage IV adenocarcinoma who had failed at
least two lines of chemotherapy. Chen 2011 compared gefitinib
alone with the combination of gefitinib plus tegafur (100 mg)/
uracil (224 mg) in 115 Taiwanese patients with stage IIIB or IV
adenocarcinoma who had failed first-line chemotherapy.
We included a total of 163 patients in this group.
5. Gefitinib at any dose in combination with other
chemotherapeutic agents versus the same chemotherapy
agents alone (Comparison 9)
Five studies examined survival outcomes, objective response rates
and toxicity (Giaccone 2004 INTACT I; Herbst 2004 INTACT
II; Soria 2015 IMPRESS; Takeda 2010 WJTOG0203; Yu 2014).
Overall, we included a total of 3110 patients.
INTACT I (Giaccone 2004 INTACT I) and INTACT II (Herbst
2004 INTACT II) were large, multicentre trials that examined the
effect of the addition of two different doses of gefitinib to a chemo-
therapy regimen with the chemotherapy alone in chemotherapy-
naive patients. INTACT I compared the effect of the addition of
gefitinib to a chemotherapy regimen that included gemcitabine
and cisplatin and INTACT II a paclitaxel and carboplatin regime.
WJTOG0203 compared the addition of 250 mg of gefitinib to
platinum-doublet chemotherapy in chemotherapy-naive Japanese
patients (Takeda 2010 WJTOG0203). In this study, patients were
randomised to receive platinum doublet chemotherapy (Arm A)
or platinum-doublet chemotherapy for three cycles followed by
gefitinib until disease progression (Arm B). The phase II study by
Yu 2014 examined the addition of gefitinib to a first-line peme-
trexed and cisplatin chemotherapy schedule in Asian patients who
were non-smokers or light ex-smokers.
In this group, we included 2845 patients.
The IMPRESS study was a phase III, multicentre study conducted
across Europe and the Asia-Pacific region (Soria 2015 IMPRESS).
This study selected patients with EGFR mutation positive ad-
vanced NSCLC who had failed first-line therapy with gefitinib.
This study compared second-line gefitinib plus chemotherapy (cis-
platin and pemetrexed) with placebo plus the same chemotherapy
regimen (cisplatin and pemetrexed). Two hundred and sixty-five
patients were included in this trial.
6. Gefitinib at any dose in combination with other
chemotherapeutic agents versus a different combination of
chemotherapeutic agent (Comparison 10)
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No studies compared gefitinib in combination with a chemother-
apeutic regime with a different regime of agents.
Data for all endpoints were not available in all published reports.
A summary of efficacy and survival data is presented in Table 2.
Risk of bias in included studies
We included trials that met our inclusion criteria. We checked all
data extracted for accuracy and final database entries. We resolved
any discrepancies through discussion. Overall, the risk of bias in
the 35 included studies was moderate. The results of the ’Risk of
bias’ assessment are depicted graphically in Figure 2.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
Seventeen of the 35 included studies reported adequate se-
quence generation (Ahn 2012;Cheng 2016;Crino 2008 INVITE;
Cufer 2006 SIGN; Gaafar 2011 EORTC08021; Giaccone 2004
INTACT I; Goss 2009 INSTEP; Kim 2008 INTEREST;
Maruyama 2008 V-15-32; Mitsudomi 2010 WJTOG3405; Mok
2009 IPASS; Morere 2010 IFCT-0301; Soria 2015 IMPRESS;
Sun 2012 KCSG-LU08-01; Thatcher 2005 ISEL; Yang 2014;
Zhang 2012 INFORM). The remaining 18 studies were all de-
scribed as randomised, but none provided any further informa-
tion and so we classified them as having an uncertain risk of bias
(An 2016; Chen 2007; Chen 2011; Dai 2013; Fukuoka 2003
IDEAL I; Han 2012 First SIGNAL; Herbst 2004 INTACT II;
Kelly 2008 SWOG S0023; Kim 2016; Kris 2003 IDEAL II; Lee
2010 ISTANA; Li 2010; Lou 2014; Maemondo 2010 NEJ002;
Takeda 2010 WJTOG0203; Xu 2015; Xue 2015; Yu 2014).
Allocation concealment
Allocation concealment was adequate in 11 of the included stud-
ies (Ahn 2012; Cufer 2006 SIGN; Gaafar 2011 EORTC08021;
Goss 2009 INSTEP; Kim 2008 INTEREST; Mitsudomi 2010
WJTOG3405; Soria 2015 IMPRESS; Sun 2012 KCSG-LU08-
01; Thatcher 2005 ISEL; Yang 2014; Zhang 2012 INFORM).
Most of these studies used aminimisationmethodor centralised al-
location procedure. The remaining studies did not report whether
allocation was concealed and so are possibly at risk of bias.
Blinding
Of the 35 included trials, we judged blinding to be adequate in
all studies. Eight studies blinded participants and investigators us-
ing an identical placebo (Fukuoka 2003 IDEAL I; Gaafar 2011
EORTC08021; Giaccone 2004 INTACT I; Goss 2009 INSTEP;
Soria 2015 IMPRESS; Thatcher 2005 ISEL; Yang 2014; Zhang
2012 INFORM). The remaining 27 studies were unblinded or
open-label (for example comparing gefitinibwith intravenous che-
motherapy), but we judged that this would not affect themeasured
outcomes.
Incomplete outcome data
Themajority of studies adequately addressed incomplete outcome
data. Of the 35 included trials, 28 had a low risk of bias from
incomplete outcome data. Studies cited reasons such as death,
disease progression and drug toxicity for dropouts. Five phase II
studies did not address withdrawals or patients lost to follow-up
and thus are potentially at high risk of bias (Chen 2007; Chen
2011; Giaccone 2004 INTACT I; Kim 2016; Xu 2015). Two
studies did not provide adequate outcome data and so are at a risk
of bias from incomplete outcome data analysis (An 2016;Herbst
2004 INTACT II).
Selective reporting
We judged 33 of the 35 included studies as at low risk of reporting
bias. One study reported an outcome (progression-free survival)
that was not pre-specified (Cufer 2006 SIGN). We judged this as
an unclear risk of bias. Another study did not report an outcome
that was prespecified in the methods (“survival time”), with no
reason provided for this in the paper (Xu 2015). We judged this
as a high risk of bias
Other potential sources of bias
Three trials were stopped early (Kelly 2008 SWOG S0023;
Maemondo 2010 NEJ002; Mitsudomi 2010 WJTOG3405),
whichmay be another source of bias. The SWOGS0023 study was
stopped because an unplanned interim analysis concluded that the
alternate hypothesis of improved survival would not be met. The
NEJ002 and WJTOG3405 studies were concluded early follow-
ing the presentation of contemporary data showing a progression-
free survival benefit in EGFRmutated patients. These studies were
then closed to accrual.
We judged the remaining studies as having an unclear risk of
bias listed due to conflicts of interest, in particular pharmaceu-
tical funding or significant affiliations, or because they did not
adequately declare any conflicts of interest (Ahn 2012; An 2016;
Chen 2007; Cheng 2016; Crino 2008 INVITE; Cufer 2006
SIGN; Dai 2013; Fukuoka 2003 IDEAL I; Goss 2009 INSTEP;
Han 2012 First SIGNAL; Kelly 2008 SWOG S0023; Kim 2008
INTEREST;Kim 2016; Kris 2003 IDEAL II; Li 2010;Mok 2009
IPASS; Soria 2015 IMPRESS; Sun 2012 KCSG-LU08-01; Yang
2014; Zhang 2012 INFORM).
Effects of interventions
See: Summary of findings for the main comparison Gefitinib
compared to chemotherapy for first-line treatment of advanced
NSCLC; Summary of findings 2 Gefitinib compared to
chemotherapy for second-line treatment of advanced NSCLC;
Summary of findings 3Gefitinib compared to chemotherapy for
advanced NSCLC - toxicity
See: Summary of findings for the main comparison (’Gefitinib
compared to chemotherapy for first-line treatment of advanced
NSCLC’); Summary of findings 2 (’Gefitinib compared to che-
motherapy for second-line treatment of advanced NSCLC’);
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Summary of findings 3 (’Gefitinib compared to chemotherapy for
advanced NSCLC - toxicity’).
1. Gefitinib versus placebo or best supportive care
Survival
See Analysis 1.1; Analysis 1.2; Analysis 1.3.
Four studies compared gefitinib with placebo in a general popu-
lation (Gaafar 2011 EORTC08021; Goss 2009 INSTEP; Kelly
2008 SWOG S0023; Thatcher 2005 ISEL). The data presented
examines the effect of gefitinib compared with placebo in the first-
line, second-line and maintenance settings. Total pooling of data
was not conducted for first- or second-line therapy as only sin-
gle studies were included. Pooling of data was only possible for
maintenance treatment, as two studies were included (Gaafar 2011
EORTC08021; Kelly 2008 SWOGS0023). Gefitinib did not im-
prove overall survival when compared with placebo, either when
administered as first-line (Goss 2009 INSTEP; hazard ratio (HR)
0.84, 95% confidence interval (CI) 0.62 to 1.14, P = 0.27), sec-
ond-line (Thatcher 2005 ISEL; HR 0.89, 95% CI 0.79 to 1.01,
P = 0.06) or maintenance therapy (Gaafar 2011 EORTC08021;
Kelly 2008 SWOGS0023; pooledHR1.14, 95%CI 0.61 to 2.14,
P = 0.69, I2 = 85%, random-effects model).
One-year survival rates were improved by administration of gefi-
tinib versus placebo as second-line therapy (risk ratio (RR) 1.28,
95% CI 1.05 to 1.57, P = 0.02), but not as maintenance therapy
(RR 0.90, 95% CI 0.78 to 1.04, P = 0.15). Progression-free sur-
vival was not improved when gefitinib was compared with placebo
as first-line therapy and median progression-free survival was re-
ported as 1.4 months in both groups (HR 0.82, 95% CI 0.60 to
1.12, P = 0.21). Time to treatment failure was improved in favour
of gefitinib as second-line therapy, with a HR of 0.82 (95% CI
0.75 to 0.90, P < 0.0001): median progression-free survival was
3 months with gefitinib, 2.6 months with placebo. Maintenance
use of gefitinib after first-line treatment improved progression-free
survival (HR 0.70, 95% CI 0.53 to 0.91, P = 0.007, I2 = 32%).
Toxicity
See Analysis 1.4; Analysis 1.6.
We have pooled reported toxicity data from three studies in
this comparison so as to examine the differences in toxicity be-
tween gefitinib and placebo or best supportive care (Gaafar 2011
EORTC08021; Goss 2009 INSTEP; Thatcher 2005 ISEL). Ad-
ministration of gefitinib was significantly associated with Com-
mon Toxicity Criteria (CTC) grade 3 to 4 events such as skin rash
(RR 7.92, 95%CI 1.46 to 43.03, P = 0.02, I2 = 0%) and diarrhoea
(RR 2.48, 95% CI 1.15 to 5.35, P = 0.02, I2 = 0%). One study
reported a statistically significant increase in alanine aminotrans-
ferase (ALT) with gefitinib (RR 9.11, 95% CI 1.18 to 70.32, P =
0.03). The risk of all other adverse events was either not estimable
or not significantly different between the two groups.
Efficacy
See Analysis 1.22; Analysis 1.23.
Response was reported in only three of the four included studies
(Gaafar 2011 EORTC08021;Goss 2009 INSTEP;Thatcher 2005
ISEL). We did not pool the data as the INSTEP study compared
gefitinib with placebo as first-line therapy, ISEL did so as second-
line therapy and the EORTC08021 trial as maintenance therapy.
As first-line therapy, gefitinib did not improve the overall response
rate (RR 6.06, 95% CI 0.74 to 49.43, P = 0.09) or the disease
control rate (RR 1.36, 95% CI 0.86 to 2.16, P = 0.19). This
was reported as an overall response rate of 6% and 1% in the
gefitinib and placebo groups, respectively, and the disease control
rate was 31% and 23%, respectively. As second-line therapy, the
overall response rate was higher for gefitinib-treated cases than for
placebo (RR 6.42, 95% CI 2.82 to 14.64, P < 0.00001) and the
disease control rate was also significantly higher for gefitinib (RR
1.24, 95% CI 1.06 to 1.44, P = 0.006). The overall response rate
was 8% in the gefitinib group and 1% in the placebo group, and
the disease control rate was 40% and 32%, respectively. Similarly,
gefitinib improved the overall response rate and the disease control
rate when used as maintenance therapy (RR 10.12, 95% CI 1.32
to 77.33, P = 0.03; RR 1.21, 95% CI 1.00 to 1.46, P = 0.05,
respectively).
Quality of life and symptom improvement scores
Thatcher 2005 ISEL reported that the addition of gefitinib to “best
supportive care” produced no significant changes in the quality
of life subscale of the Functional Assessment of Cancer Therapy-
Lung (FACT-L) questionnaire when compared with best support-
ive care alone. Gefitinib was associated with a statistically signifi-
cant improvement in the symptom score (mean change from base-
line -0.86 to -1.38; P = 0.019), but this did not meet predefined
criteria. As described by Cella 2002, for changes in disease-related
symptoms to be classed as clinically relevant, the score must in-
crease by two points. Goss 2009 INSTEP reported improvements
in FACT-L quality of life, FACT-L Trial Outcome Index (TOI),
lung cancer subscale (LCS) and Pulmonary Symptom Index (PSI)
that were statistically non-significant.
Subgroup analysis: Asian population
See Analysis 2.1; Analysis 2.2; Analysis 2.3; Analysis 2.4.
The INFORMstudy prospectively recruited patients of East Asian
ethnic origin without disease progression after first-line chemo-
therapy (Zhang 2012 INFORM). Pre-planned subgroup analysis
in the ISEL trial found marked heterogeneity in survival between
patient groups (Thatcher 2005 ISEL).
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The ISEL study conducted a subgroup analysis in 342 patients of
Asian ethnicity who were enrolled in the ISEL trial. Two hundred
and thirty-five patients received second-line gefitinib and 107 re-
ceived placebo. Pre-planned analysis reported that gefitinib sig-
nificantly improved overall survival (HR 0.66, 95% CI 0.48 to
0.91, P = 0.01), the one-year survival rate (RR 1.75, 95% CI
1.20 to 2.55, P = 0.004) and progression-free survival (HR 0.69,
95% CI 0.52 to 0.91, P = 0.009) compared to placebo. Median
overall survival was 9.5 months for gefitinib compared with 5.5
months for placebo. Covariate analysis of demographic subgroups
further demonstrated a survival advantage across multiple sub-
groups. Overall survival in this Asian subgroup of patients was
also greater in never-smokers (HR 0.37, 95% CI 0.21 to 0.64,
P = 0.0004) compared with smokers (HR 0.85, 95% CI 0.58 to
1.25, P = 0.40); females (HR 0.46, 95% CI 0.26 to 0.79, P =
0.0045) compared with males (HR 0.80, 95% CI 0.54 to 1.18,
P = 0.26); and patients with adenocarcinoma (HR 0.66, 95% CI
0.45 to 0.97, P = 0.04) compared with non-adenocarcinoma (HR
0.86, 95% CI 0.50 to 1.47, P = 0.58). Objective response rates
were higher in Asian patients treated with gefitinib compared with
placebo (RR 6.03, 95% CI 1.46 to 24.91, P = 0.01).
The INFORM study showed that gefitinib in the maintenance
setting did not improve overall survival (HR 0.88, 95% CI 0.68
to 1.14, P = 0.335). However, gefitinib improved progression-
free survival over placebo (HR 0.42, 95% CI 0.33 to 0.54, P
< 0.00001), and median progression-free survival was improved
from 2.6 months to 4.8 months. The objective response rate was
greater with gefitinib (RR 35.00, 95% CI 4.86 to 252.15, P =
0.0004). There was no difference in reported toxicities.
Quality of life improvement rates were higher in those admin-
istered gefitinib compared with placebo, as measured by FACT-
L (improvement rates 55% versus 24%, P < 0.001), TOI (51%
versus 21%, P < 0.001) and LCS (50% versus 22%, P < 0.001)
in the INFORM study (Zhang 2012 INFORM). Gefitinib also
increased the time-to-worsening of quality of life when compared
with placebo (FACT-L: 2.8 months versus 1.4 months, P = 0.019;
TOI: 3.5 months versus 1.4 months P = 0.006; LCS: 2.8 months
versus 1.4months P=0.028). The relationship between the change
in quality of life score and prognosis was also analysed in the IN-
FORM study. Patients with an improvement in quality of life had
significantly longer progression-free survival and overall survival
when compared with those that had a stable or worsened quality of
life (FACT-L: 9.4 months versus 2.8 months versus 2.7 months, P
< 0.001 and 25.4 months versus 19.9 months versus 14.4 months,
P = 0.003, respectively).
Subgroup analysis: biomarker
See Analysis 3.1; Analysis 3.2.
Subgroup analysis of patients from the ISEL trial reported that the
overall response rate was higher in patients with epidermal growth
factor receptor (EGFR) mutations (37.5%; 6 of 16 patients) than
those who were EGFR mutation negative (2.6%; 3 of 116 pa-
tients).
The INFORM study reported improved overall survival in 30 pa-
tients with EGFRmutations (HR 0.39, 95% CI 0.15 to 0.98, P =
0.036) withmedian overall survival improving from20.97months
to 46.87 months when given gefitinib versus placebo. Whilst this
subgroup only contained a very small number of patients, the
study was able to show that gefitinib doubled the median overall
survival. However, those with no detectable EGFR mutation or
an unknown EGFRmutation status did not benefit from gefitinib
maintenance therapy (HR 1.27, 95% CI 0.7 to 2.3, P = 0.431;
HR 0.92, 95% CI 0.68 to 1.25, P = 0.603, respectively).
Progression-free survival was also improved with gefitinib (HR
0.17, 95%CI 0.07 to 0.41, P < 0.0001) over placebo.Median pro-
gression-free survival improved from 2.8 months to 16.6 months
in this subgroup analysis of the INFORM trial.
2. Gefitinib versus chemotherapy
Survival
See Analysis 4.1; Analysis 4.2; Analysis 4.3.
Gefitinib versus first-line chemotherapy
As first-line therapy, only one study reported hazard ratios for
survival (Crino 2008 INVITE). Gefitinib did not prolong overall
survival (HR 0.98, 95% CI 0.66 to 1.46, P = 0.92, moderate
quality of evidence) or progression-free survival (HR 1.19, 95%
CI 0.86 to 1.65, P = 0.30, moderate quality of evidence) when
compared with vinorelbine in this general population of patients
aged at least 70 years. This study selected patients over the age of
70 years old, therefore this limits the applicability of the data to
other patients and thus we downgraded the quality of evidence to
moderate.
Two studies reported selected survival outcomes comparing gefi-
tinib with first-line chemotherapy (Crino 2008 INVITE; Morere
2010 IFCT-0301). When we pooled data from these two studies
there was no difference in one-year survival rates between gefitinib
and first-line chemotherapy (RR 0.93, 95% CI 0.63 to 1.38, P
= 0.73, I2 = 26%). Median overall survival ranged from 2.2 to
5.9 months and 3.5 to 8 months in the gefitinib and chemother-
apy groups, respectively. Median progression-free survival ranged
from 1.9 to 2.7 months and 2.0 to 2.9 months in the gefitinib and
chemotherapy groups, respectively.
Gefitinib versus second-line chemotherapy
The SIGN and INTEREST studies compared gefitinib with do-
cetaxel as second-line therapy (Cufer 2006 SIGN; Kim 2008
INTEREST). Only Kim 2008 INTEREST reported survival out-
comes and neither overall survival (HR 1.02, 95% CI 0.91 to
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1.15, P = 0.74, moderate quality of evidence) nor progression-
free survival (HR 1.04, 95% CI 0.92 to 1.17, P = 0.51, moderate
quality of evidence) were prolonged by gefitinib. Median overall
survival ranged from 7.5 to 7.6 months and 7.1 to 8 months in
the gefitinib and chemotherapy groups, respectively. There was no
difference in the one-year survival rate (RR 0.94, 95% CI 0.82
to 1.09, P = 0.44). Median progression-free survival in the non-
selected population ranged from 2.2 to 3 months and 2.7 to 3.4
months in the gefitinib and chemotherapy groups, respectively.
Cufer 2006 SIGN randomised patients to either second-line gefi-
tinib or docetaxel, however the trial was not formally powered to
detect any statistical differences for any endpoint. We judged this
to be at risk of serious imprecision and thus downgraded it one
level.
Toxicity
See Analysis 4.4; Analysis 4.5; Analysis 4.6; Analysis 4.7; Analysis
4.8; Analysis 4.9; Analysis 4.10; Analysis 4.11.
We combined data to compare the toxicity profile of gefitinib with
chemotherapy for first- and second-line therapy to assess the over-
all effect in both groups.Data fromCufer2006 SIGN,Crino 2008
INVITE, Kim 2008 INTEREST and Morere 2010 IFCT-0301
were included. Gefitinib was generally better tolerated than che-
motherapy. Gefitinib was associated with an increased risk of skin
rash when compared with chemotherapy (RR 2.40, 95% CI 1.08
to 5.31, P = 0.03, I2 = 4.7%, high quality of evidence). Gefitinib
was associatedwith a decreased risk of constipation (RR 0.41, 95%
CI 0.17 to 0.97, P = 0.04, I2 = 0%, high quality of evidence),
fatigue (RR 0.16, 95% CI 0.03 to 0.88, P = 0.04, I2 = 8.2%,
moderate quality of evidence), asthenia (RR 0.51, 95%CI 0.35 to
0.75, P = 0.0007, I2 = 0%, high quality of evidence), neurotoxicity
(RR 0.07, 95% CI 0.01 to 0.34, P = 0.001, I2 = 0%, high quality
of evidence), neutropenia (RR 0.04, 95% CI 0.02 to 0.06, P <
0.00001, I2 = 43.1%, high quality of evidence), leukopenia (RR
0.03, 95% CI 0.00 to 0.22, P = 0.0005, I2 = 0%, high quality
of evidence) and febrile neutropenia (RR 0.12, 95% CI 0.06 to
0.23, P < 0.00001, I2 = 0%, high quality of evidence). There were
no differences between groups for any other measured adverse side
effects including pruritus, diarrhoea, vomiting, anorexia, stom-
atitis, arthralgia, peripheral oedema, respiratory tract infection,
dyspnoea, cough, anaemia, thrombocytopenia, hypokalaemia or
pyrexia.
We assessed most of the toxicity outcomes as high-quality evi-
dence. We downgraded one outcome, fatigue, to a moderate qual-
ity of evidence as the study by Crino 2008 INVITE enrolled only
190 patients who were older than 70 years old, thus there was a
risk of serious indirectness.
Efficacy
See Analysis 4.26; Analysis 4.27.
Only one first-line study presented data on disease control rates
and there was no reported improvement when administering gefi-
tinib versus vinorelbine (RR 0.82, 95% CI 0.61 to 1.10, P = 0.19)
(Crino 2008 INVITE). Disease control rates were 43.3% and
53.5% for gefitinib and chemotherapy, respectively. Two second-
line studies reported efficacy data (Cufer 2006 SIGN; Kim 2008
INTEREST). Pooled data showed that there was no improvement
in overall response rate when comparing gefitinib and docetaxel
as second-line therapy (RR 1.16, 95% CI 0.85 to 1.59, P = 0.35,
I2 = 0%). Overall response rates were 9% to 13% for both the
gefitinib and chemotherapy groups.
Quality of life and symptom improvement scores
See Analysis 4.28; Analysis 4.29; Analysis 4.30; Analysis 4.31.
We pooled data from the INVITE (Crino 2008 INVITE) and IN-
TEREST (Kim 2008 INTEREST) studies. Patients who received
gefitinib reported statistically significant improvements in quality
of life as assessed by scores on the FACT-L (standardised mean
difference (SMD) 10.50, 95% CI 9.55 to 11.45, P < 0.00001, I2
= 21%), LCS (SMD 3.63, 95% CI 3.08 to 4.19, P < 0.00001, I2
= 0%) and TOI (SMD 9.87, 95% CI 1.26 to 18.48, P = 0.02, I2
= 59%). One study also described an improvement in PSI scores
(SMD 5.60, 95% CI 3.55 to 7.65, P < 0.00001) in patients who
received gefitinib (Crino 2008 INVITE).
Subgroup analysis: Asian population
Survival
See Analysis 5.1; Analysis 5.2; Analysis 5.3; Analysis 5.4; Analysis
5.5; Analysis 5.6; Analysis 5.7.
Gefitinib versus first-line chemotherapy
Five phase III studies compared gefitinib with first-line platinum
doublet chemotherapy (Han 2012 First SIGNAL; Maemondo
2010 NEJ002; Mitsudomi 2010 WJTOG3405; Mok 2009
IPASS; Yang 2014). The IPASS (Mok 2009 IPASS) and NEJ002
(Maemondo 2010 NEJ002) studies compared gefitinib with car-
boplatin-paclitaxel. The WJTOG3405 study compared gefitinib
with cisplatin-docetaxel (Mitsudomi 2010 WJTOG3405). The
First-SIGNAL study compared gefitinib with gemcitabine-cis-
platin (Han 2012 First SIGNAL). The study by Yang 2014 com-
pared gefitinib monotherapy with pemetrexed-cisplatin followed
by gefitinib maintenance.
Pooled analysis showed that gefitinib did not improve overall sur-
vival (HR 0.94, 95% CI 0.82 to 1.06, P = 0.31, I2 = 0%) or the
one-year survival rate (RR 1.03, 95% C 0.97 to 1.09, P = 0.33, I2
= 1%). One study reported median overall survival as 22 months
in both groups. Progression-free survival was higher in the gefi-
tinib group than in the chemotherapy group (HR 0.65, 95% CI
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0.43 to 0.98, P = 0.04, I2 = 93%). Median progression-free sur-
vival ranged from 5.5 to 6.4 months with chemotherapy to 5.7 to
10.4 months with gefitinib. Please refer to Figure 3 for the pooled
progression-free survival data from first-line studies that included
Asian patients.
Figure 3. Progression-free survival: Gefitinib versus first-line chemotherapy in an Asian population (Analysis
5.4).
Gefitinib versus second-line chemotherapy
Two phase III studies compared gefitinib with second-line do-
cetaxel in patients of Asian ethnicity (Lee 2010 ISTANA;
Maruyama 2008 V-15-32) and one phase III study compared gefi-
tinib with pemetrexed (Sun 2012 KCSG-LU08-01). In pooled
analysis of these three trials, there was no benefit on either overall
survival or the one-year survival rate for gefitinib over second-line
chemotherapy (HR 0.94, 95%CI 0.79 to 1.12, P = 0.50, I2 = 0%;
RR 0.94, 95% CI 0.81 to 1.11, P = 0.48, I2 = 0%, respectively).
Progression-free survival was prolonged (HR 0.71, 95% CI 0.57
to 0.88, P = 0.002, I2 = 40%; see Figure 4) in favour of gefitinib.
Median progression-free survival was 2 to 6.8 months with sec-
ond-line chemotherapy, and 2 to 10 months with gefitinib in the
second-line setting.
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Figure 4. Progression-free survival: Gefitinib versus second-line chemotherapy in an Asian population
(Analysis 5.5).
Gefitinib versus maintenance chemotherapy
Twophase II studies comparedmaintenance gefitinib with chemo-
therapy, however only one of them presented survival data (Ahn
2012). There was no difference in overall survival (HR 2.15, 95%
CI 0.83 to 5.55, P = 0.11) or progression-free survival (HR 0.53,
95% CI 0.27 to 1.04, P = 0.06) between the gefitinib and chemo-
therapy treatment arms. There was an improved one-year survival
rate (RR 0.79, 95% CI 0.65 to 0.98, P = 0.03) with maintenance
gefitinib over chemotherapy.
Toxicity
See Analysis 5.8; Analysis 5.9; Analysis 5.10; Analysis 5.11;
Analysis 5.12; Analysis 5.13; Analysis 5.14; Analysis 5.15; Analysis
5.16; Analysis 5.17; Analysis 5.18; Analysis 5.19; Analysis 5.20;
Analysis 5.21; Analysis 5.22; Analysis 5.23.
Gefitinib was generally well tolerated in this population. We
pooled toxicity data from all studies. Compared to chemother-
apy, the gefitinib group reported fewer adverse side effects such
as nausea (RR 0.34, 95% CI 0.17 to 0.64, P = 0.001, I2 = 0%),
vomiting (RR 0.19, 95% CI 0.05 to 0.77, P = 0.02, I2 = 56%,
random-effects model), anorexia (RR 0.36, 95% CI 0.27 to 0.49,
P < 0.00001, I2 = 18%), fatigue (RR 0.32, 95%CI 0.22 to 0.46, P
< 0.00001, I2 = 50%), arthralgia (RR 0.14, 95% CI 0.03 to 0.61,
P = 0.009, I2 = 0%), asthenia (RR 0.22, 95% CI 0.08 to 0.58,
P = 0.002, I2 = 13%), neurotoxicity (RR 0.07, 95% CI 0.02 to
0.24, P < 0.0001, I2 = 0%), neutropenia (RR 0.11, 95% CI 0.05
to 0.27, P < 0.00001, I2 = 82%, random-effects model), anaemia
(RR 0.18, 95% CI 0.12 to 0.29, P < 0.00001, I2 = 4%), leukope-
nia (RR 0.07, 95% CI 0.02 to 0.23, P < 0.00001, I2 = 77%, ran-
dom-effects model), thrombocytopaenia (RR 0.32, 95% CI 0.14
to 0.72, P = 0.006, I2 = 22%) and febrile neutropenia (RR 0.09,
95% CI 0.03 to 0.28, P < 0.0001, I2 = 0%). Other side effects
were seen more frequently in the gefitinib group. Skin rash (RR
3.11, 95% CI 1.28 to 7.55, P = 0.01, I2 = 60%, random-effects
model), diarrhoea (RR 2.79, 95% CI 1.57 to 4.94, P = 0.0005,
I2 = 0%), increased alanine aminotransferase (ALT) (RR 10.03,
95% CI 5.23 to 19.26, P < 0.00001, I2 = 37%) and increased
aspartate transaminase (AST) (RR 7.73, 95% CI 2.78 to 21.46, P
< 0.0001, I2 = 0%) were more frequent in gefitinib-treated cases.
Efficacy
See Analysis 5.24; Analysis 5.25; Analysis 5.26.
Objective response rates were higher in the gefitinib group when
compared with first-line chemotherapy (RR 1.43, 95% CI 1.13
to 1.82, P = 0.003, I2 = 76%, random-effects model). The overall
response rate ranged from 43% to 62.1% in the gefitinib group
and 30.7% to 32.2% in the chemotherapy group. There was no
effect on the disease control rate (RR 0.99, 95%CI 0.86 to 1.13, P
= 0.86, I2 = 80%, random-effects model): 73% to 94% and 78%
to 81%, respectively.
The overall response ratewas not significantly improved in the gefi-
tinib group compared with second-line chemotherapy (RR 1.43,
95% CI 0.92 to 2.22, P = 0.11, I2 = 46%). Two studies found that
overall response rates were poor overall, but the gefitinib group
performed better (23% to 28%) than the second-line chemother-
apy group (8% to 13%) (Lee 2010 ISTANA; Maruyama 2008
V-15-32). The disease control rate (RR 0.99, 95% CI 0.78 to
1.25, P = 0.92, I2 = 46%) was statistically similar for both groups
(34% and 33%, respectively).
Pooled data from two maintenance studies found that gefitinib
improved the stable disease rate and the disease control rate (RR
0.64, 95% CI 0.44 to 0.93, P = 0.02; RR 0.65, 95% CI 0.49 to
0.85, P = 0.002, respectively). There was no improvement in the
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overall response rate with maintenance gefitinib (RR 0.88, 95%
CI 0.41 to 1.87, P = 0.06, I2 = 73%, random-effects model).
Quality of life and symptom improvement scores
Three studies explored the impact of gefitinib versus chemother-
apy on quality of life, but unfortunately the data could not be
pooled (Lee 2010 ISTANA;Maruyama 2008 V-15-32;Mok 2009
IPASS). All three studies reported significantly improved quality
of life in patients who received gefitinib as measured by the Trial
Outcome Index (TOI). Mok 2009 IPASS and Maruyama 2008
V-15-32 stated that improvements as measured by FACT-L were
significant, but none recorded significant improvements on the
lung cancer subscale (LCS).
Subgroup analysis: EGFR mutation positive
population
Survival
See Analysis 6.1; Analysis 6.2; Analysis 6.3; Analysis 6.4.
Gefitinib versus first-line chemotherapy
Five studies compared gefitinib with first-line chemotherapy.
Two of these studies selected patients with EGFR mutations
(Maemondo 2010NEJ002;Mitsudomi 2010WJTOG3405), and
the others selected patients based on clinical features and con-
ducted subgroup analyses on patients positive for EGFR muta-
tions (Han 2012 First SIGNAL; Mok 2009 IPASS; Yang 2014).
We have separately analysed studies that selected EGFR mutants
and those that selected patients based on clinical features then
conducted subgroup analyses and progression-free survival results
are presented in Figure 5.
Figure 5. Progression-free survival: Gefitinib versus first-line chemotherapy in an EGFR mutation positive
population (Analysis 6.3).
The two biomarker driven studies did not show any improvement
in overall survival (HR 0.98, 95% CI 0.72 to 1.33, P = 0.90, I2
= 54%). Progression-free survival was significantly increased with
gefitinib compared with first-line chemotherapy (HR 0.39, 95%
CI 0.26 to 0.59, P < 0.00001, I2 = 66%, random-effects model).
Three phase III studies conducted subgroup analyses inEGFRmu-
tation positive patients. There was no improvement in overall sur-
vival (HR 0.95, 95% CI 0.68 to 1.33, P = 0.75, I2 = 20%). How-
ever, there was a statistically significant improvement in progres-
sion-free survival (HR 0.53, 95% CI 0.41 to 0.70, P < 0.00001,
I2 = 9%).
Pooled analysis of all first-line studies that examined EGFR mu-
tation positive patients showed that there was no difference in
overall survival (HR 0.97, 95% CI 0.77 to 1.21, P = 0.76, I2 =
15%). However, pooled data from these five studies showed that
gefitinib was able to prolong progression-free survival when com-
pared with first-line chemotherapy (HR 0.47, 95% CI 0.36 to
0.61, P < 0.00001, I2 = 53%, random-effects model), withmedian
progression-free survival improving from 5.5 to 6.3 months in the
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chemotherapy group to 9.2 to 10.4 months in the gefitinib group.
Gefitinib versus second-line chemotherapy
When comparing gefitinib with second-line chemotherapy, data
were available from two studies (Kim 2008 INTEREST; Sun 2012
KCSG-LU08-01). This showed that gefitinib did not improve
overall survival (HR 0.83, 95% CI 0.41 to 1.66, P = 0.60). There
was a statistically significant improvement in progression-free sur-
vival (HR 0.24, 95% CI 0.12 to 0.47, P < 0.0001, I2 = 0%)
in EGFR mutation positive patients. Progression-free survival for
this analysis is presented in Figure 6.
Figure 6. Progression-free survival: Gefitinib versus second-line chemotherapy in an EGFR mutation
positive population (Analysis 6.4).
Efficacy
See Analysis 6.5; Analysis 6.6; Analysis 6.7.
Gefitinib versus first-line chemotherapy
Pooled analysis comparing first-line gefitinib with chemotherapy
showed that the overall response rate was significantly improved
in favour of gefitinib. The two studies that selected patients with
EGFR mutations (Maemondo 2010 NEJ002; Mitsudomi 2010
WJTOG3405), as well as the phase III studies that conducted sub-
group analyses on EGFRmutation positive patients found signifi-
cant improvements in overall response rate (RR2.23, 95%CI 1.75
to 2.85, P < 0.00001, I2 = 0% and RR 1.45, 95% CI 1.05 to 1.99,
P = 0.02, I2 = 53%, random-effects model, respectively). Pooled
analysis of all studies showed that first-line gefitinib improved the
overall response rate over chemotherapy (RR 1.73, 95% CI 1.29
to 2.31, P = 0.002, I2 = 70%, random-effects model) and overall
response rates ranged from 62% to 76% in the gefitinib group,
compared with 31% to 47% in the first-line chemotherapy group.
The stable disease rate was improved in favour of first-line che-
motherapy (RR 0.52, 95% CI 0.28 to 0.97, P = 0.04, I2 = 66%,
random-effects model) but there was no difference in the disease
control rate (RR 1.06, 95% CI 0.91 to 1.22, P = 0.46, I2 = 82%,
random-effects model).
Gefitinib versus second-line chemotherapy
Gefitinib as second-line therapy did not result in a significant
difference in overall response rate (RR 1.65, 95% CI 0.88 to 3.09,
P = 0.12). Overall response rates were reported as 67% in the
gefitinib group and 46% in the chemotherapy group.
3. Gefitinib at a specific dose versus gefitinib at a
different dose
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Survival
See Analysis 7.1.
Two multicentre, randomised, double-blind, phase II studies eval-
uated differing doses of gefitinib (250 mg and 500 mg) in the
second-line setting (Fukuoka 2003 IDEAL I; Kris 2003 IDEAL
II). There was no significant effect on one-year survival (RR 0.83,
95% CI 0.61 to 1.11, P = 0.21, I2 = 0%). HRs were not available
for meta-analysis. Median overall survival ranged from 7 to 7.6
months in patients given 250 mg, and 6 to 8months in those given
500 mg of gefitinib. Median progression-free survival ranged from
2.7 to 7 months and from 2.8 to 6 months in patients given 250
mg and 500 mg, respectively.
One study examined the effect of a higher dose of gefitinib in pa-
tients that had been stable after one month of 250 mg/day dosing
of gefitinib (Xue 2015). In this study, there was no difference in
progression-free or overall survival with a higher dose of gefitinib
(500 mg/day versus 250 mg/day: median progression-free survival
5.30 months versus 6.23 months, P = 0.167; median overall sur-
vival 13.70 months versus 18.87 months, P = 0.156).
Toxicity
See Analysis 7.2; Analysis 7.3; Analysis 7.4; Analysis 7.5; Analysis
7.6; Analysis 7.7; Analysis 7.8; Analysis 7.9.
Data from all three studies were available for pooling (Fukuoka
2003 IDEAL I; Kris 2003 IDEAL II; Xue 2015). A gefitinib dose
of 500 mg had a marginally worse toxicity profile when compared
with the lower dose of 250 mg. This higher dose was associated
with an increased rate of diarrhoea (RR 8.36, 95% CI 1.58 to
44.34, P = 0.01, I2 = 0%) and skin rash (RR 8.13, 95% CI 1.51 to
43.72, P = 0.01, I2 = 0%). Other reported side effects such as pru-
ritus, acne, vomiting, anorexia, asthenia, neutropenia, leukopenia
and dyspnoea were not significantly different between doses.
Efficacy
See Analysis 7.10; Analysis 7.11.
Pooled analysis of two studies found no significant difference in
overall response rate (RR 0.92, 95% CI 0.58 to 1.46, P = 0.72, I2
= 0%) between doses (Fukuoka 2003 IDEAL I; Kris 2003 IDEAL
II). Overall response rates in the 250mg arm were reported as
18% and 12% in the IDEAL I and IDEAL II trials respectively,
compared with ORR rates of 19% and 9% respectively, in patients
receiving 500mg of gefitinib. Complete and partial response rates
were only reported individually in the IDEAL I paper, and were
10% and 18.1%, respectively.
A higher dose of gefitinib as maintenance treatment did not im-
prove the overall response rate (12.5% versus 12.5%, P = 1) (Xue
2015).
Quality of life and symptom improvement scores
See Analysis 7.12; Analysis 7.13.
Two studies reported changes in quality of life and symptom im-
provement scores (Fukuoka 2003 IDEAL I; Kris 2003 IDEAL II).
Quality of life improvements were also measured using the Trial
Outcome Index (TOI), a summary score of the physical and func-
tional domains of FACT-L and the lung cancer subscale (a vali-
dated subscale of the FACT-L questionnaire). No statistically sig-
nificant difference was found between 250 mg and 500 mg of gefi-
tinib in the rate of change of the FACT-L and TOI scales (SMD
3.70, 95% CI -7.28 to 14.69; P = 0.51, I2 = 0% and SMD 7.38,
95% CI -2.30 to 17.05; P = 0.14, I2 = 0%, respectively). Unfor-
tunately, extractable data from the published papers were incon-
sistently reported and thus not all data were pooled for analysis.
Data from the IDEAL II study further correlated symptom im-
provement with objective response and survival. When given a
dose of 250 mg of gefitinib, all patients who experienced a partial
response also experienced symptom improvement. Patients with
stable or progressive disease who experienced symptom improve-
ment also had a longer median survival time compared to those
in the same tumour progression category without symptom im-
provement.
Subgroup analysis
Both studies performed subgroup analyses.
Fukuoka 2003 IDEAL I found that the objective tumour response
rate was higher for Japanese patients versus non-Japanese patients
(27.5% versus 10.4%; odds ratio (OR) 3.27; P = 0.0023). A
planned subgroup multivariate analysis revealed seven factors that
predicted response in Japanese patients: baseline lung cancer sub-
scale, body mass index, performance status, prior radiotherapy,
histology, prior immuno/hormonal therapy and gender. After ac-
counting for all the baseline imbalances, the odds ratio indicated
that Japanese patients had response rates 1.64 times that of non-
Japanese patients, but this was not considered statistically signifi-
cant.
Kris 2003 IDEAL II reported observation of symptom improve-
ment and radiographic responses in all patient subgroups. Multi-
variate analysis identified female gender to be predictive of both
symptom improvement and radiographic responses.
Symptom improvement was rapid, with a median time to onset of
less than two weeks: 10 days in the 250 mg group (95% CI 8 to
22 days) and 9 days (95% CI 9 to 16 days) in the 500 mg group.
It was also reported that patients receiving third-, fourth- and fifth-
line and above therapy had similar rates of symptom improvement
both for 250 mg and 500 mg doses of gefitinib. Post-hoc analysis
showed that RRs for symptom improvement for the subgroup of
patients who had previously received a platinum and taxane were
24% at 250 mg and 28% at 500 mg and for patients who had
previously received platinum and docetaxel, 24% and 26% for the
250 mg and 500 mg groups, respectively.
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4. Gefitinib versus gefitinib plus chemotherapy
Survival
See Analysis 8.1; Analysis 8.2; Analysis 8.3.
In the first-line setting, two studies compared gefitinib alone with
gefitinib plus pemetrexed (An 2016; Cheng 2016). One study
reportednodifference inmedian survival between the gefitinib and
gefitinib plus chemotherapy group (32 months versus 34 months
respectively) (An 2016). The other study did not present survival
data (Cheng 2016). There was, however, a statistically significant
improvement in progression-free survival in favour of gefitinib
plus chemotherapy over gefitinib alone (HR 0.69, 95% CI 0.49
to 0.96; P = 0.03; median progression-free survival 12.6 months
versus 18.3 months) (Cheng 2016).
In the second-line or greater setting, median overall survival im-
proved from 13.3 months (Chen 2007) and 18.3 months (Chen
2011) to 23.4 months and 23.6 months, respectively. This im-
provement was not statistically significant. Combining gefitinib
with either vinorelbine or tegafur/uracil did not improve the one-
year survival rate (RR 1.15, 95% CI 0.92 to 1.43; P = 0.22; I2 =
43%). Gefitinib plus chemotherapy improved one-year progres-
sion-free survival (RR 2.29, 95% CI 1.38 to 3.80; P = 0.001).
However, the HR for progression-free survival was only presented
in Chen 2011 (HR 0.65, 95% CI 0.43 to 0.97; P = 0.04: median
progression-free survival improved from 7.1 months (Chen 2007)
and 5.3 months (Chen 2011) to 12.8 months and 8.3 months,
respectively).
Toxicity
See Analysis 8.4; Analysis 8.5; Analysis 8.6; Analysis 8.7; Analysis
8.8; Analysis 8.9; Analysis 8.10; Analysis 8.11; Analysis 8.12;
Analysis 8.13; Analysis 8.14; Analysis 8.15.
We pooled toxicity data from three studies (An 2016; Chen 2007;
Cheng 2016). Both regimens were well tolerated with no signif-
icant difference in rates of skin rash, diarrhoea, constipation, fa-
tigue, blood counts, nausea or vomiting.
Pooled data from both first-line studies did show that the addition
of pemetrexed chemotherapy to gefitinib resulted in higher rates
of raised ALT (RR 2.57, 95%CI 1.09 to 6.04; P = 0.03; I2 = 63%)
but not AST (RR 1.47, 95% CI 0.56 to 3.88; P = 0.44; I2 = 0%).
Efficacy
See Analysis 8.16; Analysis 8.17; Analysis 8.18.
When comparing gefitinib alone to gefitinib plus chemotherapy
as first-line therapy, there was no improvement in overall response
rate (RR 1.02, 95% CI 0.89 to 1.17; P = 0.73; I2 = 26%) or rate
of stable disease (RR 0.67, 95% CI 0.39 to 1.16; P = 0.16; I2 =
0%).
In the second-line setting, the addition of chemotherapy to gefi-
tinib did not result in an improvement in either partial radiologi-
cal response (RR 1.02, 95% CI 0.71 to 1.47; P = 0.92; I2 = 0%)
or stable disease (RR 1.30, 95% CI 0.84 to 2.03; P = 0.24; I2 =
16%).
5. Gefitinib plus chemotherapy versus chemotherapy
Survival
See Analysis 9.1; Analysis 9.2; Analysis 9.3.
Meta-analysis of two phase II, first-line trials examining 1411 pa-
tients showed that the addition of gefitinib (250 mg/day) to a
chemotherapy regimen in chemotherapy-naive patients did not
change the one-year survival rate (RR 0.95, 95% CI 0.84 to 1.08,
P = 0.44, I2 = 0%) (Giaccone 2004 INTACT I; Herbst 2004
INTACT II).
Two trials compared the addition of first-line gefitinib to chemo-
therapy with chemotherapy alone in Asian patients only (Takeda
2010 WJTOG0203; Yu 2014). There was no improvement in
overall survival (HR 0.86, 95% CI 0.72 to 1.02, P = 0.08, I2 =
0%), however there was a statistically significant improvement in
progression-free survival (HR 0.69, 95% CI 0.62 to 0.77, P <
0.00001, I2 = 18%).
A single phase III trial recruited only EGFRmutation positive pa-
tients who had failed prior first-line gefitinib, and the addition of
gefitinib to chemotherapy did not improve progression-free sur-
vival (HR 0.86, 95% CI 0.65 to 1.13, P = 0.28) (Soria 2015
IMPRESS). Overall survival appeared to be better in the chemo-
therapy alone group (HR 1.62, 95% CI 1.05 to 2.50, P = 0.03).
Toxicity
See Analysis 9.4; Analysis 9.5; Analysis 9.6.
Pooled data from all five trials showed that the addition of gefitinib
to a chemotherapeutic regimen resulted in increased rates of skin
rash (RR 2.98, 95% CI 1.54 to 5.77, P = 0.001, I2 = 28%), acne
(RR 4.95, 95%CI 1.09 to 22.51, P = 0.04, I2 = 0%) and diarrhoea
(RR 2.04, 95% CI 1.17 to 3.58, P = 0.01, I2 = 17%). Other
measured side effects such as pruritus, vomiting, nausea, anorexia,
asthenia, dyspnoea, anaemia, neutropenia and leukopenia were
not significantly increased.
Efficacy
See Analysis 9.16.
In the first-line setting, the addition of gefitinib to chemotherapy
did not effect the overall response rate in either the unselected
population (RR 1.07, 95% CI 0.94 to 1.22, P = 0.28, I2 = 0%) or
the Asian population (RR 1.14, 95% CI 0.93 to 1.40, P = 0.20,
I2 = 0%). The overall response rate ranged from 30% to 51% in
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the gefitinib plus chemotherapy group and 29% to 50% in the
chemotherapy group.
There was also no improvement in the overall response rate in the
second-line setting (RR 0.93, 95% CI 0.66 to 1.31, P = 0.66, I2
= 0%), and the overall response rate was 32% in the gefitinib plus
chemotherapy group and 34% in the chemotherapy alone group.
Quality of life and symptom improvement scores
In the first-line setting, theWJTOG0203 study reported a disease-
related symptoms assessment (Takeda 2010 WJTOG0203). Se-
quential administration of gefitinib was reported to provide better
symptom control, however these differences were not statistically
significant. The adjusted mean of initial summed scores of the
lung cancer subscale were 20.3 for Arm A and 20.6 for Arm B.
The adjusted lung cancer subscale scores at 12 and 18 weeks were
21 and 20.9 for Arm A and 21.8 and 21.2 for Arm B, respectively.
In the second-line setting, the IMPRESS study reported that the
improvements in quality of life were no different when gefitinib
plus chemotherapywas compared toplaceboplus chemotherapy as
measured by the Trial Outcome Index (TOI) (29% versus 30.2%,
respectively), FACT-L (35.5% versus 38%, respectively) or lung
cancer subscale (43.5% versus 42.6%, respectively) (Soria 2015
IMPRESS). There was also no difference in the time to worsening
of health-related quality of life as measured by the TOI, FACT-L
and lung cancer subscale.
These data could not be pooled for meta-analysis.
Subgroup analysis
A planned exploratory subgroup analysis in Japanese patients of
overall survival by histological group reported that patients with
adenocarcinoma that were given sequential gefitinib had better
outcomes than patients given chemotherapy alone (n = 467; pro-
gression-free survival: HR 0.79, 95% CI 0.65 to 0.98, P = 0.03;
overall survival:HR0.60, 95%CI0.50 to 0.73, P <0.001) (Takeda
2010 WJTOG0203). There was no difference in overall survival
or progression-free survival in those with non-adenocarcinoma
(overall survival: HR 1.24, 95% CI 0.85 to 1.79, P = 0.25 and
progression-free survival: HR 1.14, 95% CI 0.80 to 1.62, P =
0.47). This study also reported that smokers also experienced im-
proved survival with sequential gefitinib (HR 0.79, 95% CI 0.64
to 0.98), as opposed to non-smokers (HR 0.94, 95% CI 0.66 to
1.33), however P values were not published.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Gefitinib compared to chemotherapy for second- line treatment of advanced NSCLC
Patient or population: advanced NSCLC
Settings: second-line therapy
Intervention: gef it inib
Comparison: chemotherapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Chemotherapy Gefitinib
Overall survival (OS) The mean OS ranged
across control groups
f rom 7.1 to 8 months
The mean OS in
the intervent ion group
ranged f rom 7.5 to 7.6
months
HR 1.02 (0.91 to 1.15) 1607
(2 RCTs)
⊕⊕⊕©
MODERATE 1
OS similar in Asian pa-
t ients (HR 0.94, 0.79
to 1.12) and EGFR mu-
tat ion posit ive pat ients
(HR 0.83, 0.41 to 1.66)
Progression-f ree sur-
vival (PFS)
The mean PFS ranged
across control groups
f rom 2.7 to 3.4 months
The mean PFS in
the intervent ion group
ranged f rom 2.2 to 3
months
HR 1.04 (0.92 to 1.17) 1607
(2 RCTs)
⊕⊕⊕©
MODERATE 1
PFS signif icant ly im-
proved in Asian pa-
t ients (HR 0.71, 0.57 to
0.88) and in pat ients
posit ive for EGFRmuta-
t ion (HR 0.24, 0.12 to 0.
47) (ranged f rom 2.7 to
4.1 months versus 4.5
to 7 months)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; EGFR: epidermal growth factor receptor; HR: hazard rat io; NSCLC: non-small cell lung cancer; OS: overall survival; PFS: progression-f ree survival; RCT:
randomised controlled trial
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1We downgraded the quality of evidence by one level because of imprecision based on the wide conf idence interval.
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Gefitinib compared to chemotherapy for advanced NSCLC
Patient or population: advanced NSCLC
Settings: f irst-line and second-line therapy
Intervention: gef it inib
Comparison: chemotherapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95%CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Chemotherapy Gefitinib
Skin rash Study populat ion RR 2.40
(1.08 to 5.31)
1858
(4 RCTs)
⊕⊕⊕⊕
HIGH
9 per 1000 21 per 1000
(9 to 46)
Const ipat ion Study populat ion RR 0.41
(0.17 to 0.97)
1719
(3 studies)
⊕⊕⊕⊕
HIGH
19 per 1000 8 per 1000
(3 to 18)
Fat igue Study populat ion RR 0.16
(0.03 to 0.88)
275
(2 studies)
⊕⊕⊕©
MODERATE1
65 per 1000 10 per 1000
(2 to 57)
Asthenia Study populat ion RR 0.51
(0.35 to 0.75)
1773
(3 studies)
⊕⊕⊕⊕
HIGH
79 per 1000 40 per 1000
(28 to 60)
Neurotoxicity Study populat ion RR 0.07
(0.01 to 0.34)
1529
(2 studies)
⊕⊕⊕⊕
HIGH
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29 per 1000 2 per 1000
(0 to 10)
Neutropenia Study populat ion RR 0.04
(0.02 to 0.06)
1857
(4 studies)
⊕⊕⊕⊕
HIGH
505 per 1000 20 per 1000
(10 to 30)
Febrile neutropenia Study populat ion RR 0.12
(0.06 to 0.23)
1768
(3 studies)
⊕⊕⊕⊕
HIGH
92 per 1000 11 per 1000
(6 to 21)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1We downgraded the quality of evidence by one level because of serious indirectness as one study included only elderly
pat ients (> 70 years old).
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D I S C U S S I O N
This meta-analysis examined published data on the effectiveness
and safety of gefitinib in patients with non-small cell lung can-
cer (NSCLC). We performed an extensive search of electronic
databases and carried out handsearching, and 35 randomised stud-
ies fulfilled the inclusion criteria. Some were phase II, open-la-
bel design trials and limited pooling of data was possible due to
methodological differences between studies.
Summary of main results
A total of 35 studies were included in this review.
Five studies compared gefitinib with placebo: one study in the
first-line, one study in the second-line and three studies in the
maintenance setting. Gefitinib did not improve survival in the
first-line setting in a general population of NSCLC patients. The
ISEL study found that gefitinib as a second-line therapy was able
to reduce the risk of disease progression by 18%, and improve
the objective response rate from 1% to 6% when compared to
placebo (Thatcher 2005 ISEL). Three studies compared gefitinib
with placebo in the maintenance setting. Gefitinib reduced the
risk of disease progression by 31%.
In patients of Asian ethnicity, preplanned subgroup analysis in the
ISEL study found that second-line gefitinib improved overall and
progression-free survival by 34% and 31%, respectively (Chang
2006). The INFORM study compared gefitinib with placebo in
the maintenance setting and selected patients of Asian ethnicity
(Zhang 2012 INFORM). This study found that gefitinib pro-
longed progression-free survival by 58% and the overall response
rate improved from 1% to 24%. Quality of life analysis from the
INFORM study also showed that improvement rates as measured
by the Functional Assessment of Cancer Therapy-Lung (FACT-
L), Trial Outcome Index (TOI) and lung cancer subscale were
higher in the patients who were given gefitinib as maintenance
therapy. These patients also experienced a longer time-to-worsen-
ing of quality of life scores.
In patients positive for an epidermal growth factor receptor
(EGFR) mutation, subgroup analysis of the INFORM study
showed an improvement in median overall survival from 21
months to 47 months and maintenance gefitinib reduced the risk
of death by 61% (Zhang 2012 INFORM). Maintenance gefitinib
also improved progression-free survival from 2.8 months to 16.6
months.
Several phase II and III studies compared gefitinib with chemo-
therapy. Eighteen randomised studies have examined the effec-
tiveness of gefitinib compared with recommended chemotherapy
regimes. Meta-analysis of four studies failed to demonstrate any
benefit for survival or response rate in a general population (mod-
erate quality of evidence). (Please refer to Summary of findings
for the main comparison and Summary of findings 2). Quality of
life was significantly better for patients on gefitinib than for those
having chemotherapy, and gefitinib was significantly less toxic and
generally well tolerated when compared with chemotherapy (high
quality of evidence), in keeping with results from other studies.
Skin rash, diarrhoea and increased liver transaminases were more
frequent in the gefitinib group, but other significant side effects
such as neutropenia, anaemia, leukopenia and febrile neutropenia
were less frequent. (Please refer to Summary of findings 3).
Fourteen trials included patients exclusively of Asian ethnicity,
with some additionally selecting by EGFRmutation status or clin-
ical criteria that are likely to have enriched EGFRmutations. Gefi-
tinib improved the overall response rate by 43% and progression-
free survival by 35%when compared with first-line chemotherapy,
but this did not translate into an improvement in overall survival.
Comparing gefitinib with second-line chemotherapy found that
progression-free survival was improved by 29%, but there was no
effect on overall survival or overall response rate. The effect of
Asian ethnicity is complicated, and may be confounded by higher
rates of EGFR mutation and the biologically plausible predictive
biomarker characteristic of EGFRmutations. Two trials compared
maintenance gefitinibwithmaintenance chemotherapy.Therewas
no difference in either progression-free survival or overall survival,
but gefitinib was able to improve the one-year survival rate by
21% and the disease control rate by 35%. Skin rash, diarrhoea and
elevated liver transaminases were more common in those treated
with gefitinib, however severe adverse side effects such as haemato-
logical derangements, neurotoxicity, nausea, anorexia, fatigue and
arthralgia were much more common in the chemotherapy group.
Eight studies either selected patients with tumours expressing
EGFR mutations for comparison or conducted subgroup analy-
ses in these patients. Use of gefitinib in the first-line setting im-
proved progression-free survival over platinum-doublet chemo-
therapy. Studies that selected patients with EGFR mutations ex-
clusively were able to show a 61% improvement in progression-
free survival over first-line chemotherapy. Two studies recruited
patients with clinical features likely to respond favourably to gefi-
tinib, and showed a 51% improvement in progression-free survival
after subgroup analysis of EGFRmutation positive patients. Gefi-
tinib also improved the overall response rate by 73% over first-line
chemotherapy. However, none were able to demonstrate an im-
provement in overall survival, arguably due to high rates of cross-
over.When comparing gefitinib with second-line chemotherapy, a
similar improvement in progression-free survival of 76%was seen.
There was no impact on overall survival or overall response rate.
Increasing the dose of gefitinib from 250 mg/day to 500 mg/day
yielded no additional benefit in survival or response rate in three
phase II trials. This increased dose, however, was associated with
greater toxicity.
Two phase II studies compared pemetrexed plus gefitinib with
gefitinib alone as first-line treatment. Progression-free survival was
improved by 31% with a median improvement from 12.6 months
to 18.3 months. There were, however, increased rates of raised
ALT in this treatment arm. All other toxicities were similar. The
two studies comparing gefitinib plus chemotherapy with gefitinib
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alone in the second-line setting showed improved one-year pro-
gression-free survival when chemotherapy was added to gefitinib.
Five studies showed that the addition of gefitinib to a chemother-
apy regimen compared to chemotherapy alone did not confer any
survival benefit. In patients of Asian ethnicity, two studies showed
that first-line gefitinib plus chemotherapy improved progression-
free survival by 31% compared to chemotherapy alone. One phase
III study compared gefitinib plus chemotherapy to chemotherapy
alone and found that survival was improved in favour of chemo-
therapy alone. All patients in this study were EGFRmutation pos-
itive, but had failed prior first-line therapy with gefitinib.
A summary of the efficacy results is presented in Table 2.
Overall completeness and applicability of
evidence
Much of the data analysed in this review has predated the routine
assessment of EGFR mutation status in NSCLC. This testing is
now done routinely in many countries before starting treatment,
and the status of EGFR mutation now guides the therapeutic op-
tions. Gefitinib has already been registered in occidental countries
for treatment of NSCLC with EGFR activating mutations. The
treatment options for patients with advanced NSCLC continue to
evolve rapidly and although some of the data in this review may
be considered historical, it still provides a foundation upon which
ongoing studies examining the relationship between the effective-
ness of gefitinib and the timing of its use with other treatment
modalities can be built.
The inclusion criteria for selecting patients for these studies may
have adversely affected their ability to provide statistically sig-
nificant results. For example, some studies selected patients with
highly refractory disease who may have been less likely to respond
to any additional therapy. Some studies selected chemotherapy-
naive patients for inclusion (Giaccone 2004 INTACT I; Herbst
2004 INTACT II), whereas others included patients who had re-
ceived at least one prior platinum-containing chemotherapy reg-
imen (Kris 2003 IDEAL II; Fukuoka 2003 IDEAL I). Thatcher
2005 ISEL selected patients who had recurrence or progressive
disease during treatment or within 90 days of the last dose of che-
motherapy.
In some studies, patients who progressed on a certain treatment
were allowed the opportunity to switch to the comparison arm.
This was reported in some studies (e.g. Mok 2009 IPASS) and
in some data were censored accordingly (e.g. Mitsudomi 2010
WJTOG3405). The impact of this cross-over is difficult to analyse
and may contribute to a lack of survival benefit seen in these large
phase III studies.
We analysed EGFRmutation positive patients in this review, find-
ing that gefitinib improved progression-free survival over first- and
second-line chemotherapy and over placebo in the maintenance
setting. However, patients with EGFR wild type NSCLC were
not formally included in this meta-analysis. Studies such as Zhou
2014 CTONG0806 were excluded from thismeta-analysis as they
selected only EGFR wild type NSCLC. This study showed that
second-line pemetrexed chemotherapy was superior to gefitinib in
terms of progression-free survival but a trend towards improved
overall survival was also seen. Thus, this highlights the impor-
tance of determining the EGFR mutation status in patients with
advanced NSCLC, as this result will guide further management
decisions.
Patients with progressive NSCLC who have failed to respond to
first-line chemotherapy have an extremely poor prognosis and of-
ten exhibit severe symptoms. One difficulty with meta-analyses
of quality of life data is that outcomes are not consistently re-
ported in the published papers, limiting the pooling of data. Some
studies reported changes in FACT-L and the lung cancer subscale
that reached the pre-defined criteria for clinical significance (Cella
2005; Kris 2003 IDEAL II), whereas others failed to show any im-
provement (Fukuoka 2003 IDEAL I; Thatcher 2005 ISEL). Cella
2005 reported a correlation between symptom improvement, ob-
jective response and survival, and found that 30% of patients
showed a quality of life improvement that was correlated with
tumour response. Kris 2003 IDEAL II reported that symptoms
improved in 96% of patients with partial radiographic responses.
Pre-planned subgroup analysis in Thatcher 2005 ISEL found that
gefitinib was associated with a significant improvement in symp-
tom score compared with placebo in never-smokers and patients
of Asian origin.
Quality of the evidence
The ’Risk of bias’ tables have enabled a methodical and thorough
assessment of the quality of evidence. We included a total of 35
randomised controlled trials (RCTs) randomising 12,089 patients
in this review. (Please refer to Figure 2). Trials included in this
meta-analysis generally had a low risk of selection and attrition
bias. Unfortunately, differences in reporting of outcomes, such
as survival times, and a lack of survival curves, meant that only
extractable data could be included in the analyses. The duration
of gefitinib treatment and duration of follow-up may also have
affected outcomes in these RCTs. Despite these limitations, the
included RCTs were generally consistent with their findings.
For studies that compared gefitinib with first-line chemotherapy,
we judged the quality of evidence as moderate. One study enrolled
elderly patients (over 70 years old) and thus we downgraded the
quality of evidence as this may be at serious risk of indirectness
(Crino 2008 INVITE). When comparing gefitinib with second-
line chemotherapy, we also judged the quality of evidence as mod-
erate as one studywas not statistically powered to detect differences
in any endpoint and was thus at serious risk of imprecision (Cufer
2006 SIGN). When considering toxicity outcomes, generally the
quality of data was high, except for fatigue, which we judged as
moderate quality of evidence. We downgraded this outcome one
level, as we judged one study as having a serious risk of indirect-
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ness for enrolling only patients over the age of 70 years old (Crino
2008 INVITE).
Agreements and disagreements with other
studies or reviews
Two published meta-analyses also examined the effect of gefitinib
in NSCLC. The first by Ibrahim 2010 reported on seven studies
that included chemotherapy-naive patients (Crino 2008 INVITE;
Giaccone 2004 INTACT I; Goss 2009 INSTEP; Herbst 2004
INTACT II; Kelly2008 SWOGS0023;Mok 2009 IPASS; Takeda
2010 WJTOG0203), analysing a total of 2545 and 1939 patients
in the gefitinib and control arms. The same seven studies also
fulfilled the inclusion criteria for this review; however our review
included a further 17 studies that analysed the use of gefitinib as
second- or third-line and maintenance therapy. The authors were
not able to showany benefit in objective response rate, progression-
free survival or overall survival in this general population. In a small
subset of patients with EGFR mutations, gefitinib was shown to
significantly improve the overall response rate (odds ratio (OR)
2.81, 95% CI 1.71 to 4.62, P < 0.0001). This benefit was not
associated with a progression-free or overall survival advantage in
that group. Only three of the included seven studies reported on
quality of life, showing a measurable and statistically significant
improvement as measured by FACT-L.
The second meta-analysis by Jiang 2011 compared gefitinib with
docetaxel as second-line therapy. Four studies were included, all of
which were also included in this review (Cufer 2006 SIGN; Kim
2008 INTEREST; Lee 2010 ISTANA; Maruyama 2008 V-15-
32). A total of 2247 patients received either gefitinib or docetaxel
as second-line therapy. Similar results were also found in this meta-
analysis. Therewas an improved overall response ratewith gefitinib
compared with docetaxel (risk ratio (RR) 1.58, 95% CI 1.02 to
2.45, P = 0.04) and quality of life as measured with the FACT-
L and TOI questionnaires (RR 1.55, 95% CI 1.27 to 1.88, P <
0.001; RR 1.86, 95% 1.43 to 2.42, P < 0.001, respectively). There
was no benefit in overall survival or progression-free survival.
Both of these systematic reviews reported results similar to those
of this meta-analysis.
Patients with tumours bearing EGFR mutations derive benefit
from gefitinib treatment. It has been shown that in patients of
Asian ethnicity with tumours with EGFRmutations, progression-
free survival and overall response rate were significantly improved
by the use of gefitinib as first-line therapy; however there was no
effect on overall survival, perhaps because of cross-over between
study interventions.
An interactionbetween ethnicity, EGFRmutation status andother
clinical features is likely to confound a straightforward analysis of
factors predictive of a gefitinib response. Patients of Asian descent,
who are non-smokers or with adenocarcinoma histology are also
more likely to have tumours harbouring EGFR mutations.
There is increasing evidence to justify the use of molecularmarkers
in clinical practice and the EGFR mutation status appears to be a
significant predictor of benefit in terms of progression-free survival
and response to gefitinib. Other markers of EGFR status such as
EGFR protein expression and EGFR gene copy number appear
to be related to EGFR mutations, but interpretation criteria still
need to be established. Further research into optimal sampling,
mutation testing methods and the precise spectrum of predictive
EGFR mutations is required.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
• In patients of Asian ethnicity or who are epidermal growth
factor receptor (EGFR) mutation positive, first-line gefitinib
significantly improves progression-free survival and overall
response rate but not overall survival when compared with
chemotherapy.
• Side effects such as skin rash, diarrhoea and increased
alanine aminotransferase (ALT) and aspartate transaminase
(AST) are more common with gefitinib. Side effects such as
nausea, vomiting, anorexia, fatigue, arthralgia, asthenia,
neurotoxicity, neutropenia, leukopenia, thrombocytopaenia and
anaemia are more common with chemotherapy.
• In patients of Asian ethnicity, first-line gefitinib plus
chemotherapy improves progression-free survival over either
gefitinib or chemotherapy alone.
• In the second-line setting, gefitinib is more effective than
placebo, with improvements in the one-year survival rate,
progression-free survival and overall response rate. There was no
improvement in overall survival.
• One study demonstrated an improvement in overall
survival, time to treatment failure and overall response rate when
comparing second-line gefitinib to placebo in patients of Asian
ethnicity. However, the prevalence of EGFR mutations in
cancers from Asian patients means that caution needs to be
exercised in interpreting these results.
• Second-line gefitinib plus chemotherapy is probably more
effective in improving progression-free survival than gefitinib
alone.
• One second-line study selected EGFR mutation positive
patients and showed that chemotherapy is more effective in
improving survival than gefitinib plus chemotherapy in patients
who have failed first-line gefitinib.
• Maintenance treatment with gefitinib was shown to be
more effective in improving overall survival and progression-free
survival than placebo in patients with EGFR mutation positive
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tumours. In unselected patients or those of Asian ethnicity,
gefitinib improves progression-free survival but not overall
survival or overall response rate over placebo.
• Increasing the dose of gefitinib from 250 mg/day to 500
mg/day results in significantly more adverse side effects, without
any impact on response rate, survival or reported quality of life.
• Quality of life is higher in patients who receive gefitinib
than those who either receive placebo or chemotherapy.
Implications for research
• Extended follow-up of existing trials and the inclusion of
other randomised trials will provide additional evidence on the
use of gefitinib in advanced non-small cell lung cancer.
• Gaining a clearer understanding of why most, but not all,
patients with tumours bearing EGFR mutations respond to
gefitinib, as well as identifying new predictive factors, and the
mechanisms and the management of drug resistance, are high-
priority research issues.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ahn 2012
Methods Design: parallel-group
Randomisation: yes, method stated
Blinding: open-label
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 86
Number enrolled: 73
Number in treatment group: 39
Number in control group: 31
Number of withdrawals (treatment/control): TP1 14/31; TPII 25/24
Number completing trial (treatment/control): 0/0
Age range: (treatment/control) 35 to 73 years/29 to 76 years
Sex: 15 M, 55 F
Ethnicity: East Asian
NSCLC diagnosis: histologic/cytologic diagnosis of NSCLC, stage IIIB to IV disease
Inclusion criteria: stage IIIB to IV NSCLC with at least one measurable lesion, ECOG
PS 0 or 1, EGFR mutation status unknown
Exclusion criteria: received treatment for NSCLC other than palliative radiotherapy,
smoker of more than 100 cigarettes in lifetime, life expectancy of < 12 weeks
Baseline characteristics of treatment/control groups: comparable
Interventions TP1
All patients received first-line chemotherapy:
Pemetrexed 500 mg/m2 + cisplatin 75 mg/m2
Intravenously on day 1 of 3-week cycle for 4 cycles
TPII
Received either:
Gefitinib 250 mg/day OR
Pemetrexed 500 mg/m2 with optional cisplatin 75 mg/m2 in first 2 cycles intravenously
Outcomes Progression-free survival
Overall survival
Tumour response - RECIST
Duration of response
ASEs - NCI-CTC
Haematology and biochemical parameters
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Ahn 2012 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Stratified random assignment
method, random allocation sequence gen-
erated by central computerised voice re-
sponse unit”
Comment: this was judged as a low risk of
bias
Allocation concealment (selection bias) Low risk Quote: “random allocation sequence gen-
erated by central computerised voice re-
sponse unit”
Comment: this was judged as adequate
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions and reasons forwithdrawals pre-
sented in Figure 1. Missing outcome data
balanced in numbers across interventional
groupswith similar reasons formissing data
across groups
Data analysed using intention-to-treat
analysis
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Unclear risk Funded by Eli Lilly and Company. Authors
have received honoraria from Eli Lilly and
some authors are current employees or pre-
vious employees of Eli Lilly
Comment: this was judged as an unclear
risk of bias
An 2016
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: double-blind
Withdrawals: not stated
Participants Setting: single-centre study, hospital outpatient department
Number eligible: 90
Number enrolled: 90
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An 2016 (Continued)
Number in treatment group: 45
Number in control group: 45
Number of withdrawals (treatment/control): not stated
Number completing trial (treatment/control): not stated
Age range: 57 to 83 years
Sex: 50 M, 40 F
Ethnicity: East Asian
NSCLC diagnosis: histologic/cytologic diagnosis of non-squamous NSCLC, stage IIIB
to IV disease. Presence of EGFR sensitive mutation
Inclusion criteria: at least one measurable lesion, an estimated life expectancy of at least
12 weeks, adequate major organ function
Exclusion criteria: any of the following: myocardial infarction within the previous 3
months, uncontrolled angina pectoris or arrhythmia, brain metastasis, uncontrolled hy-
pertension or diabetes, active infection, pulmonary fibrosis, pleural effusion or ascites
requiring drainage, or cerebrovascular disease
Baseline characteristics of treatment/control groups: comparable
Interventions Pemetrexed 500 mg/m2 on day 1
PLUS gefitinib 250 mg on day 2 to 16
Cycles repeated every 3 weeks until disease progression
Gefitinib 250 mg on day 2 to 16
PLUS placebo on day 1
Cycles repeated every 3 weeks until disease progression
Outcomes Tumour response - RECIST
ASEs - NCI-CTC
Progression-free survival
Overall survival
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly divided..”
but no further information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “All investigators and patients were
masked to treatment allocation”
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An 2016 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Unclear risk There were no declarations of potential
conflicts of interest or indication of fund-
ing or support
Comment: there was insufficient informa-
tion to permit a clear judgement of the risk
of bias
Chen 2007
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: nil
Withdrawals: stated
Participants Setting: single-centre study, hospital outpatient department
Number eligible: 48
Number enrolled: 48
Number in treatment group: 21
Number in control group: 27
Number of withdrawals (treatment/control): 6/0
Number completing trial (treatment/control): 15/27
Age range: treatment 39 to 80; control 35 to 85
Sex: 25 M, 23 F
Ethnicity: Ethnic Chinese
NSCLC diagnosis: histologic or cytologic diagnosis of stage IV adenocarcinoma
Inclusion criteria: failed previous chemotherapy with ?2 regimens (including taxanes
and platinum-based chemotherapy); clinically measurable disease; no previous radio-
therapy directed at lesions; adequate bone marrow reserve with WBC count < 4000/mm
3; platelets < 100,000/mm3 ; haemoglobin < 10 g/dL; life expectancy of > 2 months
Exclusion criteria: inadequate liver function (total bilirubin > 1.5 times upper limit of
normal and alanine and aspartate aminotransferase levels > 3 times upper limit of normal)
or inadequate renal function with creatinine levels > 2 mg/dL
Baseline characteristics of treatment/control groups: no difference between groups
Interventions 250 mg gefitinib daily
Vinorelbine (15 mg/m2) on day 1, 250 mg gefitinib daily on days 2 to 14 every 2 weeks
Outcomes Overall survival
Time to progression, 1-year progression-free survival
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Tumour response - RECIST
ASEs - NCI-CTC
EGFR FISH examination
LCS of FACT-L
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Eligible patients were randomized.
..” but no further information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
High risk No information provided
Comment: this was judged as a high risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Unclear risk There were no declarations of potential
conflicts of interest or indication of fund-
ing or support
Comment: there was insufficient informa-
tion to permit a clear judgement of the risk
of bias
49Gefitinib for advanced non-small cell lung cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Chen 2011
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: open-label
Withdrawals: stated
Jadad score: 2
Participants Setting: single-centre study, hospital outpatient department
Number eligible: 115
Number enrolled: 115
Number in treatment group: 58
Number in control group: 57
Number of withdrawals (treatment/control): 0/0
Number completing trial (treatment/control): 58/57
Age range (treatment/control): 37 to 87 years/30 to 85 years
Sex: 69 M, 45 F
Ethnicity: Taiwanese
NSCLC diagnosis: histological and cytological diagnosis of adenocarcinoma of the lung
Inclusion criteria: stage IIIB or IV adenocarcinoma of the lung, age 18 years or older,
failed previous chemotherapy, WHO PS of 0 to 3, clinically measurable disease, no
previous radiotherapy directed at themeasurable lesion(s), adequate bonemarrow reserve
with a white blood count > 4000/mm3
Exclusion criteria: previous treatment with 5FU-related chemotherapeutic agent, inter-
stitial lung disease, with inadequate liver function (total bilirubin > 1.5 times and alanine
aminotransferase/aspartate transaminase > 3 times the upper limit normal) or inadequate
renal function with creatinine > 2.0 mg/dl
Baseline characteristics of treatment/control groups: comparable
Interventions Gefitinib 250 mg/day
Gefitinib (250 mg/day) + UFT (tegafur 100 mg + uracil 224 mg)
Outcomes Progression-free survival
Overall survival
Tumour response - RECIST
ASEs - NCI-CTC
Haematology and biochemical parameters
Quality of life (LCS)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised but no details provided
Comment: there was insufficient detail re-
ported about the method used to generate
the allocation sequence to allow a clear as-
sessment ofwhether it would produce com-
parable groups
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Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
High risk No information provided
Comment: this was judged as a high risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Low risk Grants from National Science Council of
the Republic of China and Taipei Veterans
General Hospital
Cheng 2016
Methods Design: parallel-group
Randomisation: yes, method stated
Blinding: open-label
Withdrawals: not stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 232
Number enrolled: 195
Number in treatment group: 129
Number in control group: 66
Number of withdrawals (treatment/control): 106/59
Number completing trial (treatment/control): 23/7
Age range: (treatment/control) 33 to 84 years/41 to 80 years
Sex: 68 M, 123 F
Ethnicity: East Asian
NSCLC diagnosis: histologic/cytologic diagnosis of non-squamous NSCLC, stage IV or
recurrent disease. Presence of activating EGFR mutation
Inclusion criteria: age≥ 18 years, ECOG 0 or 1, measurable disease documented by CT
or MRI as defined by RECIST criteria
Exclusion criteria: prior systemic chemotherapy, immunotherapy or biologic therapy,
including targeted therapy (e.g. EGFR-TKI) for stage IV or recurrentNSCLC.Receipt of
adjuvant or neoadjuvant treatmentwith pemetrexed or anEGFR-TKI, thoracic radiation
therapy within 28 days before enrolment or could not take folic acid, vitamin B12 and
dexamethasone
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Baseline characteristics of treatment/control groups: comparable
Interventions Pemetrexed 500 mg/m2 on day 1
PLUS gefitinib 250 mg daily
Cycles repeated every 3 weeks
Gefitinib 250 mg daily
Outcomes Progression-free survival
Overall survival
Time to progressive disease (TtPD)
Tumour response - RECIST
Duration of response
ASEs - NCI-CTC
Quality of life
Biomarker analysis
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “random assignment was conducted
using a computer-generated random se-
quence and an interactive voice-response
system.”
Comment: this was judged as a low risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions and reasons for withdrawals
presented in Figure 1. Missing outcomes
balanced in numbers across intervention
groupswith similar reasons formissing data
across groups
Data analysed using intention-to-treat
analysis
Comment: this was judged as low risk of
bias
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Selective reporting (reporting bias) Low risk All prespecified outcomes were reported,
except for overall survival
Quote: “At time of PFS analysis, OS data
were immature, and therefore, are not pre-
sented”
Comment: this was judged as a low risk of
bias
Other bias Unclear risk Authors report consultative roles within in-
dustry, and other potential financial con-
flicts of interest
Comment: this was judged as an unclear
risk of bias
Crino 2008 INVITE
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: open-label
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 205
Number enrolled: 196
Number in treatment group: 97
Number in control group: 99
Number of withdrawals (treatment/control): 20/38
Number completing trial (treatment/control): 77/61
Age range: treatment 70 to 89, control 70 to 86
Sex: M 148, F 48
Ethnicity: white 162, Asian 31, other 3
NSCLC diagnosis: histologically confirmed stage IIIB or stage IV NSCLC
Inclusion criteria: age > 70 years, at least 1 measurable lesion according to RECIST
criteria, histological biopsy and paraffin block from the original tumour or metastatic
site, no prior chemotherapy, biologic or immunologic therapy,WHOperformance status
of 0 to 2, life expectancy of at least 12 weeks
Exclusion criteria: newly diagnosed central nervous system metastases that had not yet
been treated, any evidence of clinically active interstitial lung disease, other coexisting
malignancies or malignancies discovered within the last 5 years other than basal cell
carcinoma or cervical cancer in situ, prior treatment with EGFR inhibitors, treatment
with an investigational drug within 30 days
Baseline characteristics of treatment/control groups: comparable
Interventions Gefitinib 250 mg/day
Vinorelbine 30 mg/m2 infusion on days 1 and 8 of a 21-day cycle
Outcomes Overall survival
Progression-free survival (PFS)
53Gefitinib for advanced non-small cell lung cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Crino 2008 INVITE (Continued)
Tumour response - RECIST
ASEs - NCI-CTC
Quality of life - LCS/FACT-L
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomly assigned in 1:1manner”
Comment: this was judged as a low risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions and reasons for withdrawals
presented in Figure 1. Missing outcomes
balanced in numbers across intervention
groupswith similar reasons formissing data
across groups
Data analysed using intention-to-treat
analysis
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Unclear risk Authors report consultative roles within in-
dustry and other potential financial con-
flicts of interest
Comment: this was judged as an unclear
risk of bias
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Methods Design: parallel-group
Randomisation: yes, method stated
Blinding: open-label
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 141
Number enrolled: 141
Number in treatment 1 group: 68
Number in treatment 2 group: 73
Number of withdrawals (treatment 1/treatment 2): 0/0
Number completing trial (treatment 1/treatment 2): 68/73
Age range: treatment 1 34 to 85 years; treatment 2 29 to 83 years
Sex: 98 M, 43 F
Ethnicity: 42.6% Caucasian; 44.0% Hispanic; 5.0% Oriental; 1.5% Black; 7.1% other
NSCLC diagnosis: histologically or cytologically confirmed advanced (stage IIIb or IV)
NSCLC that had progressed on or after 1 previous chemotherapy regimen. Also 1 or
more measurable lesion according to RECIST
Inclusion criteria: WHO PS 0 to 2; life expectancy > 12 weeks, age > 18 years, symp-
tomatic (LCS score < 24), capable of understanding the FACT-L questionnaire
Exclusion criteria: previous taxane treatment, treatment with any chemotherapeutic
within 30 days prior to study, radiotherapy within 3 weeks prior to study, known cere-
bral metastasis, any evidence of ongoing interstitial lung disease (ILD), coexisting ma-
lignancies, malignancies diagnosed within the last 5 years, with exception of basal cell
carcinoma or cervical carcinoma in situ, any unresolved chronic toxicity above grade 2
NCI-CTC from previous anti-cancer therapy, laboratory values outside requested limits,
psychiatric disorders that may affect completion of FACT-L questionnaire
Baseline characteristics of treatment/control groups: comparable
Interventions Treatment 1: gefitinib 250 mg/day
Treatment 2: docetaxel 75 mg/m2 IV every 3 weeks
Outcomes LCS component of FACT-L
Tumour response - RECIST
Overall survival, progression-free survival
ASEs - NCI-CTC
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “sealed randomisation envelopes
which were allocated sequentially to pa-
tients”
Comment: this was judged as low risk of
bias
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Allocation concealment (selection bias) Low risk Quote: “sealed randomisation envelopes
which were allocated sequentially to pa-
tients”
Comment: this was judged as low risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcomes balanced in numbers
across intervention groups with similar rea-
sons for missing data across groups. 139/
141 completed the trial
Comment: this was judged as low risk of
bias
Selective reporting (reporting bias) Unclear risk All prespecified outcomes were reported.
Progression-free survival was not a pre-
specified outcome but included in results.
Quote: “Progression-free survival was not
defined as a study variable in the protocol,
but as tumour assessments were performed
consistently for both treatment arms, it was
also estimated.”
Comment: this was judged as an unclear
risk of bias
Other bias Unclear risk There were no declarations of potential
conflicts of interest or indication of fund-
ing or support
Comment: there was insufficient informa-
tion to permit a clear judgement of the risk
of bias
Dai 2013
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: open-label
Withdrawals: stated
Participants Setting: single-centre study, hospital outpatient department
Number eligible: 46
Number enrolled: 46
Number in treatment group: 23
Number in control group: 23
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Number of withdrawals (treatment/control): 0/0
Number completing trial (treatment/control): 23/23
Age range: (treatment/control): 41 to 74years/47 to 72 years
Sex: 29 M, 17 F
Ethnicity: East Asian
NSCLC diagnosis: histologic or pathologically proven diagnosis of nonsquamous
NSCLC, stage IIIB to IV disease
Inclusion criteria: age 18 to 75 years, Received prior platinum-based chemotherapy of 4
to 6 cycles and has had progressive disease,at least 1 target lesion, ECOG0 to 2, adequate
bone marrow and organ function
Exclusion criteria: not stated
Baseline characteristics of treatment/control groups: comparable
Interventions Gefitinib 250 mg/day
Pemetrexed 500 mg/m2 intravenously, every 4 weeks until disease progression or unac-
ceptable toxicity
Outcomes Tumour response - RECIST
Progression-free survival
Overall survival
Toxicity - CTCAE
Quality of life - FACT-L
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized” but random se-
quence generation not discussed
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Comment: this was judged as low risk of
bias
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Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as low risk of
bias
Other bias Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Fukuoka 2003 IDEAL I
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: double-blind
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 210
Number enrolled: 209
Number in treatment group 1: 103
Number in treatment group 2: 106
Number of withdrawals (treatment 1/treatment 2): 1/0
Number completing trial (treatment 1/treatment 2): 103/105
Age range: treatment 1 28 to 85 years; treatment 2 37 to 78 years
Sex: 148 M, 62 F
Ethnicity: 50% Caucasian, 50% Japanese
NSCLC diagnosis: histologic or cytologic confirmation of advanced or metastatic
NSCLC; stage III or IV not curable with surgery or radiotherapy at study entry
Inclusion criteria: recurrent or refractory disease following 1 or 2 previous chemotherapy
regimens (at least 1 containing platinum); at least 1 bi-dimensionally measurable or
radiographically assessable lesion, age 18 or older, WHO PS 0 to 2, life expectancy of
12 weeks or longer
Exclusion criteria: more than 2 previous chemotherapy regimens, systemic anticancer
therapywithin 21 days, radiotherapy within 14 days before start of treatment; unresolved
chronic toxicity higher than in NCI-CTC grade 2; ALT or AST levels greater than 2.5
times upper limit of reference range; serum creatinine levels greater than 1.5 times the
upper limit of reference range; neutrophils less than 1.5 x 109/L or platelets less than 75
x 109/L
Baseline characteristics of treatment/control groups: comparable except for sex. Some
demographic imbalances between Japanese and non-Japanese populations
Interventions Treatment 1: gefitinib 250 mg/day
Treatment 2: gefitinib 500 mg/day
Outcomes Objective tumour response rate - RECIST
Disease control rate (response + stable disease)
Progression-free survival
Overall survival
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FACT-L questionnaire
LCS of FACT-L
ASEs - NCI-CTC
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized” but no further infor-
mation provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “double-blind”, “blinded treatment
supplies”
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “1 patient excluded due to protocol
violation”, otherwise no missing data
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Unclear risk Co-authors are recipients of research grants
and honoraria from Astra Zeneca
Comment: this was judged as an unclear
risk of bias
Gaafar 2011 EORTC08021
Methods Design: parallel-group
Randomisation: yes, method stated
Blinding: double-blind, double-dummy
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 173
Number enrolled: 173
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Number in treatment group: 86
Number in control group: 87
Number of withdrawals (treatment/control): 15/9
Number completing trial (treatment/control): 71/78
Age range: 28 to 80 years
Sex: M 133, F 40
Ethnicity: not stated
NSCLC diagnosis: histologically or cytologically confirmed stage IIIB or IV NSCLC
(UICC 6th ed)
Inclusion criteria: not amenable to local therapy, non-progressing after prior platinum-
based chemotherapy (2 to 6 cycles) and without unacceptable toxicity. Age older than 18
years, WHO PS 2 or less, adequate renal, hepatic and haematological function. Patients
with brain metastasis were eligible, provided asymptomatic after cranial irradiation
Exclusion criteria: previous EGFR therapy, symptomatic brain metastasis, other malig-
nancies, pregnancy or breastfeeding and interstitial pulmonary disease
Baseline characteristics of treatment/control groups: comparable
Interventions Treatment: gefitinib 250 mg daily
Control: placebo
Outcomes Overall survival
Time to progression
Tumour response - RECIST
ASEs - NCI-CTC
Haematology and biochemical parameters
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “centralised double blind random
assignment using minimisation technique”
Comment: this was judged as a low risk of
bias
Allocation concealment (selection bias) Low risk Quote: “centralised double blind random
assignment using minimisation technique”
Comment: this was judged as a low risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind. Quote: “matched daily
placebo tablet”
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions and reasons for withdrawals
presented in Figure 1. Missing outcomes
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balanced in numbers across intervention
groupswith similar reasons formissing data
across groups (24/173 lost to follow-up/
censored)
Intention-to-treat analysis
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Low risk Funding from EORTC, ILCP, National
Cancer Institute, Fonda Cancer (FOCA)
Belgium
Comment: this was judged as a low risk of
bias
Giaccone 2004 INTACT I
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: double-blind
Withdrawals: not stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 1093
Number enrolled: 1093
Number in treatment 1 group: 365
Number in treatment 2 group: 365
Number in control group: 363
Number of withdrawals (treatment 1/treatment 2/control): 3/7/8
Number completing trial (treatment 1/treatment 2/control): 362/358/355
Age range: median age 60 years
Sex: 805 M, 288 F
Ethnicity: 998 white (90.4%)
NSCLC diagnosis: histologically or cytologically confirmed NSCLC
Inclusion criteria: NSCLC locally advanced stage II disease not curable with surgery or
radiotherapy or stage IV disease; aged < 18 years; WHO PS 0 to 2
Exclusion criteria: previously received chemotherapy (prior radiotherapy or surgery al-
lowed); hypersensitive to mannitol, corticosteroids, H2-antagonists, antihistamines or
agents formulated with polyoxyethylated castor oil; had received radiotherapy within
the last 2 weeks; had unresolved toxicity from previous radiation therapy or incomplete
healing from previous surgery; had pre-existing motor or sensory neurotoxicity (NCI-
CTC < grade 2); showed evidence of severe or uncontrolled systemic disease; had recent
conditions requiring medication or uncontrolled significant active infections; had ab-
solute neutrophils count < 2000/mm3 ; WBC < 4000/mm3 ; platelets < 100000/mm3 ;
serum bilirubin greater than 1.25 times normal upper limit; ALT or AST greater than 2.
5 times normal upper limit; creatinine clearance < 60 mL/min; were pregnant or breast-
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feeding; other coexisting malignancies or malignancies diagnosed within the last 5 years
with the exception of basal cell carcinoma or cervical cancer in situ; had mixed NSCLC
plus small cell lung cancer
Baseline characteristics of treatment/control groups: comparable
Interventions Regime A: 3-week cycle of IV gemcitabine 1250 mg/m2 for 30 min of day 1 and day 8;
IV Cisplatin 80 mg/m2 after gemcitabine administration on day 1 only
Treatment 1: gefitinib 250 mg/day + 6 cycles of regime A
Treatment 2: gefitinib 500 mg/day + 6 cycles of regime A
Control: placebo + 6 cycles of regime A
Outcomes Overall survival
Time to progression
Tumour response - RECIST
ASE - NCI-CTC
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomly assigned to one of three
groups.. further stratification by dynamic
randomisation...”
Comment: this was judged as a low risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “double-blind manner”
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
High risk No information provided
Comment: this was judged as a high risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Low risk Financial conflicts of interest declared
Comment: this was judged as a low risk of
bias
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Goss 2009 INSTEP
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: double-blind, double-dummy
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 220
Number enrolled: 201
Number in treatment group: 100
Number in control group: 101
Number of withdrawals (treatment/control): 26/19
Number completing trial (treatment/control): 100/101
Age range: treatment 43 to 89, control 42 to 90
Sex: M 122, F 79
Ethnicity: white 193
NSCLC diagnosis: histologically or cytologically confirmed locally advanced or
metastatic NSCLC not amenable to curative surgery or radiotherapy
Inclusion criteria: age > 18 years, chemotherapy-naive, WHO performance of 2 or 3,
measurable disease (RECIST), no prior EGFR inhibitor therapy
Exclusion criteria: untreated, newly diagnosed metastases in the CNS; other coexisting
malignancies or malignancies diagnosed within the last 5 years other than basal cell
carcinoma or cervical cancer in situ; fewer than 4 weeks since completion of wide-
field radiotherapy or persistence of any radiotherapy-related toxicity; unresolved chronic
toxicity greater than National Cancer Institute Common Toxicity Criteria for Adverse
Events grade 2 from previous anticancer therapy (except alopecia); evidence of clinically
active interstitial lung disease; prior treatment with epidermal growth factor receptor
inhibitors, biologic or immunological therapy; and treatment with an investigational
drug within the prior 30 days.
Baseline characteristics of treatment/control groups: comparable
Interventions Gefitinib 250 mg/day plus best supportive care
Placebo plus best supportive care
Outcomes Overall survival
Progression-free survival (PFS)
Tumour response - RECIST
ASEs - NCI-CTC
Haematology and biochemical parameters
Quality of life
Pulmonary symptom improvement (PSI)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomly assigned 1:1 according
to a randomisation scheme prepared by
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biostatics group, AstraZeneca”
Comment: this was judged as a low risk of
bias
Allocation concealment (selection bias) Low risk Central allocation
Comment: this was judged as a low risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “double-blind”, “gefitinib and
placebo tablets physically identical and pre-
sented in identical packaging”
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition presented in Figure 1. Missing
outcomes balanced in numbers across in-
tervention groups with similar reasons for
missing data across groups
Intention-to-treat analysis performed
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Unclear risk Co-authors are recipients of research grants
and honoraria from industry
Comment: this was judged as an unclear
risk of bias
Han 2012 First SIGNAL
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: open-label
Withdrawals: stated
Jadad score: 2
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 316
Number enrolled: 313
Number in treatment group: 159
Number in control group: 154
Number of withdrawals (treatment/control): 0/4
Number completing trial (treatment/control): 159/150
Age range: (treatment/control): 32 to 74 years/19 to 74 years
Sex: 35 M, 174 F
Ethnicity: Asian
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NSCLCdiagnosis: stage IIIB (ineligible for curative radiotherapy) or IV adenocarcinoma
of the lung with measurable or non-measurable disease
Inclusion criteria: stage IIIB or IV adenocarcinoma of the lung. ECOG PS 0 to 2,
adequate bone marrow, liver and renal function
Exclusion criteria: known severe hypersensitivity to gefitinib or any constituents of this
product, any evidence of clinically active interstitial lung disease; severe or uncontrolled
systemic disease; concomitant use of phenytoin, carbamazepine, rifampin, barbiturate
or St John’s Wort; non-stable brain metastasis
Baseline characteristics of treatment/control groups: comparable
Interventions Gefitinib 250 mg/day
Gemcitabine (1250 mg/m2) on days 1 and 8 plus cisplatin (75 mg/m2) on day 1. Cycles
repeated every 3 weeks for up to a maximum of 9 cycles as tolerated
Outcomes Overall survival
Progression-free survival
Tumour response - RECIST
ASEs - NCI-CTC
Quality of life - EORTC Quality of Life Questionnaire C30 and LC13
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised but no further details pro-
vided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions and reasons forwithdrawals pre-
sented in Figure 1. Reasons formissing data
unlikely to be related to true outcome (4/
313 withdrawn, but all from the chemo-
therapy arm)
Intention-to-treat analysis performed
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Han 2012 First SIGNAL (Continued)
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Unclear risk Co-authors are recipients of research grants
and honoraria from industry
Comment: this was judged as an unclear
risk of bias
Herbst 2004 INTACT II
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: double-blind
Withdrawals: not stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 1037
Number enrolled: 1037
Number in treatment 1 group: 345
Number in treatment 2 group: 347
Number in control group: 345
Number of withdrawals (treatment 1/treatment 2/control): 3/5/4
Number completing trial (treatment 1/treatment 2/control): 342/342/341
Age range: treatment 1 median 62 years; treatment 2 median 61 years; control median
63 years
Sex: 619 M, 418 F
Ethnicity: treatment 1 88.5% white, 7.5% black, 4% other; treatment 2 90.4% white,
4.1% black, 5.5% other; control 91.9% white, 5.2% black, 2.9% other
NSCLC diagnosis: histologically or cytologically diagnosed NSCLC; unresectable stage
III or IV disease
Inclusion criteria: no prior chemotherapy; age < 18 years; WHO PS 0 to 2
Exclusion criteria: presence of mixed NSCLC or small cell lung cancer; brain metastases
that were newly diagnosed or had not been treated with surgery or radiation; previously
treated CNS metastases or spinal cord compression in presence of clinically stable dis-
ease; less than 2 weeks since radiotherapy; unresolved toxicity from prior radiotherapy or
incomplete healing from surgery; evidence of severe systemic disease; greater than trace
protein or blood on repeat urinalysis; absolute neutrophils count < 2000/µL; WBC <
4000/µL; platelets < 100,000/µL; serum bilirubin greater than 1.25 times normal upper
limit; ALT or AST greater than 2.5 times normal upper limit; serum creatinine greater 1.
5 times normal upper limit; pregnancy; breastfeeding; hypersensitive to mannitol, corti-
costeroids, H2-antagonists, antihistamines or agents formulated with polyoxyethylated
castor oil
Baseline characteristics of treatment/control groups: comparable
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Herbst 2004 INTACT II (Continued)
Interventions Regime A: IV Paclitaxel 225 mg/m3 over 3 hours on day 1 of 3 week cycle immediately
followed by IV carboplatin AUC of 6 mg/mL over 15 to 30 min on day 1
Treatment 1: gefitinib 250 mg/day + 6 cycles of regime A
Treatment 2: gefitinib 500 mg/day + 6 cycles of regime A
Control: placebo + 6 cycles of regime A
Outcomes Overall survival
Time to progression
Tumour response - RECIST
ASEs - NCI-CTC
Haematology and biochemical parameters
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized to receive...”
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double-blind” with use of placebo tablets
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information provided
Intention-to-treat analysis performed
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Low risk Financial conflicts of interest declared
Comment: this was judged as a low risk of
bias
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Kelly 2008 SWOG S0023
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: not stated
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 243
Number enrolled: 243
Number in treatment group: 118
Number in control group: 125
Number of withdrawals (treatment/control): 0/0
Number completing trial (treatment/control): 118/125
Age range: treatment: 24 to 79 years, control 37 to 81 years
Sex: M 153, F 90
Ethnicity: White 221, Black 18, Asian 2, other 2
NSCLC diagnosis: pathologically confirmed and inoperable stage IIIA or IIIB NSCLC
Inclusion criteria: ECOG0or 1,measurable or non-measurable disease, noprior systemic
therapy, radiation therapy or complete surgical resection, adequate organ function, FEV1
of less then 2.0 L if also have a minimum FEV1 of 800 mL in contralateral lung
Exclusion criteria: pleural or pericardial effusions, patients with multiple tumours within
the lung
Baseline characteristics of treatment/control groups: comparable
Interventions All patients received concurrent cisplatin and etoposide with thoracic radiation according
to SWOG 9504
Treatment 1: gefitinib 250 mg/day
Treatment 2: placebo
Outcomes Overall survival
Progression-free survival (PFS)
ASEs - NCI-CTC
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomised” but no further in-
formation given
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
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Kelly 2008 SWOG S0023 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions and attrition stated in text.
Missing outcomes balanced in numbers
across intervention groups with similar rea-
sons for missing data across groups. 115/
571 (20%) eligible patients dropped out
before random assignment due to progres-
sive disease and 27 (5%) dropped out as a
result of death from cancer, treatment or
other causes
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Unclear risk Co-authors are recipients of research grants
and honoraria from industry
Quote: “Study closed early as unplanned
interim analysis rejected alternative hy-
pothesis of improved survival...”
Comment: this was judged as an unclear
risk of bias
Kim 2008 INTEREST
Methods Design: parallel-group
Randomisation: yes, method stated
Blinding: open-label
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 1607
Number enrolled: 1466
Number in treatment group: 733
Number in control group: 733
Number of withdrawals (treatment/control): 701/711
Number completing trial (treatment/control): 116/107
Age range: treatment 27 to 84 years, control 20 to 84 years
Sex: M 954, F 512
Ethnicity: White 1090, Asian 323, Black 22, other 31
NSCLC diagnosis: histologically or cytologically confirmed locally advanced or
metastatic NSCLC
69Gefitinib for advanced non-small cell lung cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kim 2008 INTEREST (Continued)
Inclusion criteria: 18 years or older, NSCLC that progressed or recurred after at least
1 previous platinum-based chemotherapy regimen (up to 2 regimens allowed), WHO
performance status 0 to 2, measurable or non-measurable disease by Response Evaluation
Criteria in Solid Tumours (RECIST), had no previous therapy with EGFR tyrosine
kinase inhibitor, absolute neutrophil count < 1.5 x 109/L, adequate hepatic function
Exclusion criteria: not stated
Baseline characteristics of treatment/control groups: comparable
Interventions Treatment: gefitinib (250 mg/day)
Control: docetaxel (75 mg/m2 in a 1-hour infusion every 3 weeks) with standard pre-
medication
Outcomes Overall survival
Progression-free survival (PFS)
Tumour response - RECIST
ASEs - NCI-CTC
FACT-L, TOI, LCS
EGFR gene copy number
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Use of a centralised registration
and randomisation centre, contacted by
telephone, to assign patients to a specific
treatment group”
Comment: this was judged as a low risk of
bias
Allocation concealment (selection bias) Low risk Quote: “Use of a centralised registration
and randomisation centre, contacted by
telephone, to assign patients to a specific
treatment group”
Comment: this was judged as a low risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions and attritionpresented inFigure
1. Missing outcome data balanced in num-
bers across intervention groups with simi-
lar reasons for missing data across groups
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Kim 2008 INTEREST (Continued)
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Low risk Co-authors are recipients of research grants
and honoraria from industry. Study was
supported by Astra Zeneca, but principal
investigators had unrestricted access to the
study data and gave assurance for the accu-
racy and completeness of the reported anal-
yses
Comment: this was judged as a low risk of
bias
Kim 2016
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: open-label
Withdrawals: stated
Participants Setting: single-centre study, hospital outpatient department
Number eligible: 95
Number enrolled: 95
Number in treatment group: 48
Number in control group: 47
Number of withdrawals (treatment/control): not stated
Number completing trial (treatment/control): 0/2
Age range: (treatment/control) 42 to 82 years/31 to 81 years
Sex: 68 M, 27 F
Ethnicity: East Asian
NSCLC diagnosis: histologically or cytologically proven advanced (stage IIIB or IV)
or recurrent NSCLC; disease progression after first-line or second-line chemotherapy;
age ≥ 18 years; ECOG PS ≤ 2; at least one measurable lesion; adequate bone marrow
(absolute neutrophil count ≥ 1500/mL and platelet count ≥ 100,000/mL), normal
hepatic (bilirubin ≥ 1.5 ULN and hepatic transaminase ≤ 2.5 ULN) and renal (serum
creatinine < 1.5 mg/dL) functions; and an estimated life expectancy of at least 3 months
Patients with brain metastases were eligible if treated with radiotherapy and clinically
stable
Exclusion criteria: patients with chronic diarrhoea of any grade, inflammatory bowel
disease, uncontrolled comorbid illness or other malignancies
Baseline characteristics of treatment/control groups: comparable
Interventions Pemetrexed 500 mg/m2 intravenously on day 1 of 21-day cycle
Gefitinib 250 mg/day oral 1 cycle for 21 days
Cycles to continue until disease progression, unacceptable toxicity or until patient de-
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Kim 2016 (Continued)
clined further treatment
Outcomes Progression-free survival rate at 6 months
Progression-free survival
Tumour response - RECIST
ASEs - NCI-CTC
Overall survival
Notes Study closed early due to poor accrual
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomized..” but
no further information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk Open-label but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawals not stated
Comment: this was judged as a high risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Unclear risk No specific funding was disclosed and au-
thors made no disclosure of conflicts of in-
terest
Comment: this was judged as an unclear
risk of bias
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Kris 2003 IDEAL II
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: double-blind, double-dummy
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 261
Number enrolled: 221
Number in treatment 1 group: 106
Number in treatment 2 group: 115
Number of withdrawals (treatment 1/treatment 2): 4/1
Number completing trial (treatment 1/treatment 2): 102/114
Age range: treatment 1 34 to 84 years; treatment 2 30 to 80 years
Sex: 128 M, 93 F
Ethnicity: not stated
NSCLC diagnosis: pathological diagnosis of NSCLC, stage IIIB or IV disease extent
Inclusion criteria: treatment with 2 or more regimens containing cisplatin or carboplatin
and docetaxel, given either concurrently or as separate regimens; disease progression or
unacceptable toxicity with last chemotherapy regimen; symptomatic NSCLC as deter-
mined by score of 24 of 28 on LCS of FACT-L; measurable or evaluable indicator lesions,
WHO PS 0 to 2
Exclusion criteria: received chemotherapy or irradiation within 14 days; unresolved toxi-
city greater than grade 2 from prior chemotherapy; neutrophil count less than 1.5 x 109/
L; platelet count less than 75 x 109/L; bilirubin level more than 1.25 times the upper
limit of normal; creatinine clearance less than 30 mL/min
Baseline characteristics of treatment/control groups: comparable
Interventions Treatment 1: gefitinib 250 mg/day (1 x 250 mg tablet + 1 placebo tablet)
Treatment 2: gefitinib 500 mg/day (2 x 250 mg tablets)
Outcomes FACT-L
- Time to symptom improvement as measured by FACT-L
- Duration of improvement as measured by FACT-L
Radiographic assessments (PR - 50% decrease in lesion size)
- Duration of radiographic response
- Radiographic response rates
ASEs - NCI-CTC
Overall survival by dose, frequency, severity of ASE
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomized..” but
no further information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
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Kris 2003 IDEAL II (Continued)
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1/261 “lost to follow-up”
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Unclear risk Research support received from Astra
Zeneca
Comment: this was judged as an unclear
risk of bias
Lee 2010 ISTANA
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: double-blind
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 163
Number enrolled: 161
Number in treatment group: 82
Number in control group: 79
Number of withdrawals (treatment/control): 8/12
Number completing trial (treatment/control): 82/79
Age range: treatment 21 to 74 years, control 20 to 73 years
Sex: M 100, F 61
Ethnicity: Korean
NSCLC diagnosis: histologically or cytologically confirmed NSCLC with stage IIB or
IV
Inclusion criteria: patients with NSCLC who received only 1 previous platinum-doublet
chemotherapy regimen, and who were considered candidates for further chemotherapy.
Age 18 years or older,WHOperformance status of 0 to 2, progressive or recurrent disease
following previous chemotherapy (adjuvant chemotherapy was allowed if full cytotoxic
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Lee 2010 ISTANA (Continued)
doses of platinum-based doublet therapy was given in patients with early disease having
progressed), measurable disease by RECIST, adequate bone marrow, renal and hepatic
function
Exclusion criteria: previous docetaxel or any other EGFR-targeted treatment, any evi-
dence of clinically active interstitial lung disease, newly diagnosed central nervous system
metastases, or any unresolved chronic toxicity greater than NCI-CTCAE grade 2 from
previous anti-cancer therapy
Baseline characteristics of treatment/control groups: comparable
Interventions Gefitinib 250 mg/day
Docetaxel 75 mg/m2 as a 1-hour intravenous infusion on day 1 every 3 weeks
Outcomes Overall survival
Progression-free survival (PFS)
Tumour response - RECIST
ASEs - NCI-CTC
Quality of life - LCS of FACT-L, the Trial Outcome Index
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly assigned .. after stratifi-
cation...” but no further information pro-
vided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition presented in Figure 1. Missing
outcome data balanced in numbers across
intervention groupswith similar reasons for
missing data across groups
Comment: this was judged as a low risk of
bias
75Gefitinib for advanced non-small cell lung cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lee 2010 ISTANA (Continued)
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Low risk Quote: “No potential conflicts of interest
were disclosed.”
Comment: this was judged as a low risk of
bias
Li 2010
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: open-label
Withdrawals: stated
Participants Setting: single-centre study, hospital outpatient department
Number eligible: 98
Number enrolled: 98
Number in treatment group: 50
Number in control group: 48
Number of withdrawals (treatment/control): 1/0
Number completing trial (treatment/control): 49/48
Age range: (treatment/control): 42 to 69 years
Sex: 59 M, 39 F
Ethnicity: East Asian
NSCLC diagnosis: pathologically proven diagnosis of NSCLC, stage IIIB to IV disease
Inclusion criteria: age ≥ 18 years, Karnofsky score of≥ 70, life expectancy≥ 3 months,
Received at least 1 cycles of prior chemotherapy (Navelbine, Gemzar or cisplatin), Have
at least 1 target lesion, adequate organ function, normal ECG
Exclusion criteria: not stated
Baseline characteristics of treatment/control groups: comparable
Interventions Gefitinib 250 mg/day
Docetaxel 75 mg/m2 intravenously, every 3 weeks for 2 to 4 cycles or until disease
progression or unacceptable toxicity
Outcomes Tumour response - RECIST
Survival
Toxicity - CTCAE
Quality of life - WHO criteria
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Li 2010 (Continued)
Random sequence generation (selection
bias)
Unclear risk “Randomized” but no further information
provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Comment: this was judged as low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Lou 2014
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: open-label
Withdrawals: stated
Participants Setting: single-centre study, hospital outpatient department
Number eligible: 51
Number enrolled: 51
Number in treatment group: 25
Number in control group: 26
Number of withdrawals (treatment/control): 0/0
Number completing trial (treatment/control): 25/26
Age range: (treatment/control): 34 to 73years/36 to 76 years
Sex: 9 M, 42 F
Ethnicity: East Asian
NSCLC diagnosis: histologic or pathologically proven diagnosis of NSCLC, stage IIIB
to IV disease
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Lou 2014 (Continued)
Inclusion criteria: age ≥ 18 years, non-smoker (< 100 cigarettes consumed in lifetime)
or former light smoker (< 10 pack-year history), received no prior chemotherapy of
biological/immunological anti-cancer therapy
Exclusion criteria: not stated
Baseline characteristics of treatment/control groups: comparable
Interventions Gefitinib 250 mg/day
Paclitaxel 200 mg/m2 with carboplatin AUC5 intravenously for 6 cycles or until disease
progression
Outcomes Progression-free survival
Overall survival
Tumour response - RECIST
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized” but no further information
provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
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Maemondo 2010 NEJ002
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: not blinded
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 230
Number enrolled: 230
Number in treatment group: 115
Number in control group: 115
Number of withdrawals (treatment/control): 1/5
Number completing trial (treatment/control): 114/110
Age range: treatment: 43 to 75 years, control: 35 to 75 years
Sex: 48 M, 145 F
Ethnicity: not stated - Japanese
NSCLC diagnosis: advanced NSCLC
Inclusion criteria: harbouring sensitive EGFR mutations, absence of resistant EGFR
mutation T790M, no history of chemotherapy, age 75 or younger
Exclusion criteria: presence of resistant EGFR mutation
Baseline characteristics of treatment/control groups: comparable
Interventions Treatment 1: gefitinib 250 mg/day
Treatment 2: Paclitaxel (at least dose of 200 mg/m2 of body-surface area, given intra-
venously over 3-hour period) and carboplatin (at a dose equivalent to an area under the
concentration-time curve of 6, given intravenously over a 1-hour period), both admin-
istered on the first day of every 3-week cycle
Outcomes Overall survival - date of randomisation to date of death
Progression-free survival (PFS)
Tumour response - RECIST
ASEs - NCI-CTC
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized” but no further information
provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
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Maemondo 2010 NEJ002 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions presented in Figure 1, attrition
stated in text. Reasons for missing data un-
likely to be related to true outcome. 224/
230 patients included in PFS population,
227/230 patients included in safety popu-
lation
Intention-to-treat analysis performed
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Low risk Quote: “In the planned interim analysis of
data, PFS was significantly longer in the
gefitinib group than in standard-chemo-
therapy group resulting in early termina-
tion of the study”
Funded by Japan Society for Promotion
and Science and Japanese Foundation for
Multidisciplinary Treatment of Cancer and
Tokyo Cooperative Oncology Group
Comment: this was judged as an unclear
risk of bias
Maruyama 2008 V-15-32
Methods Design: parallel-group
Randomisation: yes, method stated
Blinding: open-label
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 511
Number enrolled: 489
Number in treatment group: 245
Number in control group: 244
Number of withdrawals (treatment/control): 233/241
Number completing trial (treatment/control): 12/3
Age range: < 64 years = 275, > 65 years = 216
Sex: M 302, F 187
Ethnicity: Japanese
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Maruyama 2008 V-15-32 (Continued)
NSCLC diagnosis: histologically or cytologically confirmed NSCLC (stage IIIB/IV)
Inclusion criteria: age 20 years or older, pretreated locally advanced/metastatic (stage
IIIB/IV) NSCLC, or recurrent NSCLC, NSCLC not amenable to curative surgery or
radiotherapy or postoperative recurrent NSCLC, failure of prior treatment with 1 or 2
chemotherapy regimens (> 1 platinum based regimen), life expectancy of 3 months or
greater, WHO PS score 0 to 2, measurable disease by RECIST, WBC count of 4.0 to 12.
0 x 109 cells/L, neutrophil count < 2.0 x 109 cells/L, platelet count > 100 x 109 cells/L,
serum bilirubin < 1.5 x 109 cells/L, ALT or AST < 2.5 x upper limit of reference range,
serum creatinine < 1.5 mg/dL, arterial oxygen tension > 70 torr
Exclusion criteria: received last chemotherapy within 4 weeks before enrolment, received
prior treatment with a docetaxel-containing regimen or any anti-EGFR therapy, an al-
lergy or suspected allergy to gefitinib or docetaxel, other coexisting malignancies diag-
nosed within the last 5 years, with exceptions, any unresolved chronic toxicity greater
than NCI-CTC grade 2 from previous anticancer therapy, any evidence of severe or
uncontrolled systemic disease, as judged by investigator, current status of pregnancy or
breastfeeding, treatment with a non-approved or investigational drug within 30 drugs
before enrolment, intracerebral metastases, significant malabsorption syndrome, past
history of or concurrent interstitial lung disease, idiopathic pulmonary fibrosis or pneu-
moconiosis, or radiation pneumonia or drug-induced pneumonia, that required corti-
costeroids, fever with suspected infection or treatment with systemic corticosteroids for
> 4 weeks
Baseline characteristics of treatment/control groups: comparable
Interventions Gefitinib 250 mg/day
Docetaxel every 3 weeks as a 1-hour intravenous infusion of 60 mg/m2
Outcomes Overall survival
Progression-free survival (PFS)
Tumour response - RECIST
ASEs - NCI-CTC
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomly assigned by using strat-
ification...”
Comment: this was judged as a low risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
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Maruyama 2008 V-15-32 (Continued)
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition and exclusions presented in Fig-
ure 1. Missing outcome data balanced in
numbers across intervention groups with
similar reasons for missing data across
groups. 483/489 patients analysed for sa-
fety, 387/489 (79%) analysed for response
(balanced between treatment arms)
Intention-to-treat analysis performed
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Low risk Co-authors have received honoraria from
industry
Comment: this was judged as a low risk of
bias
Mitsudomi 2010 WJTOG3405
Methods Design: parallel-group
Randomisation: yes, method stated
Blinding: open-label
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 177
Number enrolled: 177
Number in treatment group: 88
Number in control group: 89
Number of withdrawals (treatment/control): 50/30
Number completing trial (treatment/control): 30/59
Age range: treatment: 34 to 73 years, control: 41 to 75 years
Sex: M 53, F 119
Ethnicity: Japanese
NSCLC diagnosis: histologically or cytologically confirmed NSCLC (stage IIIB/IV)
harbouring an activating mutation of EGFR gene (either exon 19 deletion or L858R in
exon 21)
Inclusion criteria: aged 75 or younger, WHO performance status 0 to 1, had measurable
or non-measurable disease according to RECIST, adequate organ function. Patients
with postoperative recurrence, treated with adjuvant therapy other than cisplatin plus
docetaxel, were included when interval between end of adjuvant chemotherapy and
registration exceeded 6 months for platinum-doublet therapy and more than 1 month
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for oral tegafur plus uracil therapy
Exclusion criteria: received previous drug therapy that had targeted the EGFR, a history
of interstitial lung disease, severe drug allergy, active infection or other serious disease
condition, symptomatic brain metastases, poorly controlled pleural effusion, pericardial
effusion or ascites necessitating drainage, active double cancer, or severe hypersensitivity
to drugs containing poly solvate 80, pregnancy or lactation
Baseline characteristics of treatment/control groups: comparable
Interventions Gefitinib 250 mg/day
Docetaxel 60 mg/m2, administered intravenously over a 1-hour period, followed by
cisplatin 80 mg/m2, administered intravenously over a 90-min period with adequate
hydration, in cycles of once every 21 days for 3 to 6 cycles
Outcomes Progression-free survival (PFS)
Overall survival
Tumour response - RECIST
Disease control rate
ASEs - NCI-CTC
Mutation-type-specific survival
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomly assigned in 1:1 ratio”
Comment: this was judged as a low risk of
bias
Allocation concealment (selection bias) Low risk Quote: “Patients were allocated at the
WJOGdata centre to each treatment group
using a desktop computer programmed for
the minimisation method.”
Comment: this was judged as a low risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions and attritionpresented inFigure
1. Reasons for missing data unlikely to be
related to true outcome. 5/177 withdrawn
Comment: this was judged as a low risk of
bias
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Selective reporting (reporting bias) Low risk All prespecified outcomes were reported,
except for overall survival
Quote: “data for overall survival were im-
mature, with follow-up still ongoing”
Comment: this was judged as a low risk of
bias
Other bias Low risk Trial designed and conducted indepen-
dently of any pharmaceutical company
Author conflicts of interest declared
Trial closed early as results of contemporary
studies showing improved PFS in EGFR
mutationpositiveNSCLC. Further trial ac-
crual was felt to be futile and unethical
Comment: this was judged as low risk of
bias
Mok 2009 IPASS
Methods Design: parallel-group
Randomisation: yes, method stated
Blinding: not blinded
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 1329
Number enrolled: 1217
Number in treatment group: 609
Number in control group: 608
Number of withdrawals (treatment/control): 12/28
Number completing trial (treatment/control): 597/580
Age range: treatment: 24 to 84 years, control: 25 to 84 years
Sex: M 252, F 965
Ethnicity: Chinese 618, Japanese 233, other East Asian 363, other 3
NSCLC diagnosis: histologically or cytologically confirmed stage IIIB or IV NSCLC
with histological features of adenocarcinoma
Inclusion criteria: 18 years or older, non-smoker or former light smokers (those who
had stopped smoking at least 15 years previously and had a total of ?10 pack-years of
smoking), no previous chemotherapy or biologic or immunologic therapy, WHO PS 0
to 2, measurable disease according to RECIST criteria with at least 1 measurable lesion,
not previously irradiated, adjuvant chemotherapy permitted if not platinum-based and
completed > 6 months previously, absolute neutrophil count > 2.0 x 109 and adequate
hepatic function
Exclusion criteria: not stated
Baseline characteristics of treatment/control groups: comparable
Interventions Treatment: gefitinib 250 mg/day
Control: Paclitaxel (200 mg/m2 of body-surface area, administered intravenously over
a 3-hour period on the first day of the cycle) followed immediately by carboplatin (at
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a dose calculated to produce an area under the curve of 5.0 to 6.0 per mL per min,
administered intravenously over a period of 15 to 60 min)
Outcomes Overall survival
Progression-free survival (PFS)
Tumour response - RECIST
ASEs - NCI-CTC
Quality of life - FACT-L, TOI, LCS score of FACT-L
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomisation was performed
with the use of dynamic balancing...”
Comment: this was judged as a low risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions and attritionpresented inFigure
1. Missing outcome data balanced in num-
bers across intervention groups with simi-
lar reasons for missing data across groups.
1159/1217 (95%) included in analysis
Intention-to-treat analysis performed
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Unclear risk Funding from the Chinese Lung Cancer
Research Foundation. Co-authors received
consulting fees and grant support from in-
dustry
Comment: this was judged as an unclear
risk of bias
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Methods Design: parallel-group
Randomisation: yes, method stated
Blinding: double-blind
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 128
Number enrolled: 85
Number in treatment group: 43
Number in control group: 42
Number of withdrawals (treatment/control): 43/41
Number completing trial (treatment/control): 0/0
Age range: treatment 45 to 79 years, control 30 to 79 years
Sex: M 71, F 14
Ethnicity: not stated
NSCLC diagnosis: stage IIIb/IV NSCLC
Inclusion criteria: age 18 to 80, NSCLC with measurable disease, ECOG PS 2 or 3,
adequate organ function
Exclusion criteria: prior chemotherapy, prior EGFR therapy or prior thoracic radiother-
apy
Baseline characteristics of treatment/control groups: comparable
Interventions Gefitinib 250 mg daily
Docetaxel 75 mg/m2 day 1 every 3 weeks
Outcomes Overall survival
Time to progression
Tumour response - RECIST
ASEs - NCI-CTC
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “random assignment was block
stratified...”
Comment: this was judged as a low risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
86Gefitinib for advanced non-small cell lung cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Morere 2010 IFCT-0301 (Continued)
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions and attritionpresented inFigure
1. Missing outcome data balanced in num-
bers across intervention groups with simi-
lar reasons for missing data across groups
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Low risk Co-authors have received honoraria from
industry
Comment: this was judged as a low risk of
bias
Soria 2015 IMPRESS
Methods Design: parallel-group
Randomisation: yes, method stated
Blinding: placebo-controlled
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 287
Number enrolled: 265
Number in treatment group: 133
Number in control group: 132
Number of withdrawals (treatment/control): 1/0
Number completing trial (treatment/control): 23/18
Age range: (treatment/control) 33 to 79 years/35 to 79 years
Sex: 94 M, 171 F
Ethnicity: East Asian 78%; Spanish/French/German/Italian/Russia 22%
NSCLC diagnosis: histologic/cytologic diagnosis of NSCLC, stage IIIB to IV disease,
chemotherapy-naive
Inclusion criteria: age ≥ 18 years; chemotherapy-naive advanced NSCLC and an acti-
vating EGFR mutation as confirmed by local testing, who had achieved a complete or
partial response for longer than 4 months, or durable stable disease for at least 6 months
on first-line gefitinib and had subsequently developed radiological disease progression.
Life expectancy of > 12 months, and a WHO PS of 0 or 1
Exclusion criteria: NSCLC of predominately squamous cell histology, a history of inter-
stitial lung disease, any other coexisting malignancies diagnosed within the past 5 years
(excluding basal cell carcinoma, cervical cancer in situ, or completely resected intramu-
cosal gastric cancer) or treatment with another investigational drug 4 weeks of less before
random allocation
Baseline characteristics of treatment/control groups: comparable
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Interventions Gefitinib 250 mg daily PLUS cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 on day
1 of cycle
Placebo PLUS cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 on day 1 of cycle
Outcomes Progression-free survival
Tumour response - RECIST
Overall survival
ASEs - NCI-CTC
Health-related quality of life - FACT-L, LCS, TOI
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Use of “central block randomisation to al-
locate patients (1:1)...”
Comment: this was judged as a low risk of
bias
Allocation concealment (selection bias) Low risk Patients were assigned a unique enrolment
number using an interactive web response
system
Comment: this was judged as a low risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk Placebo-controlled with identical packag-
ing
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals stated in Figure 1
Missing outcome data balanced in num-
bers across intervention groups with simi-
lar reasons for missing data across groups
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Unclear risk Authors have received honoraria, consul-
tant and advisor fees from industry
Study funded by Astra Zeneca, who co-or-
dinated the trial, managed the database and
undertook analyses
Comment: this was judged as an unclear
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risk of bias
Sun 2012 KCSG-LU08-01
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: open-label
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 147
Number enrolled: 141
Number in treatment group: 71
Number in control group: 70
Number of withdrawals (treatment/control): 3/3
Number completing trial (treatment/control): 68/67
Age range: (treatment/control): 40 to 77 years/30 to 78 years
Sex: 20 M, 115 F
Ethnicity: Asian
NSCLC diagnosis: histologically or cytologically confirmed pulmonary adenocarcinoma
Inclusion criteria: histologically or cytologically confirmed pulmonary adenocarcinoma
that progressed after just 1 previous platinum-based chemotherapy regimen for advanced
disease, never-smoker, 18 years or older, ECOG PS 0 to 2, measurable or evaluable
disease, adequate bone marrow, renal and hepatic function
Exclusion criteria: prior EGFR TKI or pemetrexed treatment and symptomatic or un-
controlled brain metastases
Baseline characteristics of treatment/control groups: comparable
Interventions Gefitinib 250 mg/day
Pemetrexed 500 mg/m2 on day 1 of a 21-day cycle
Cycles repeated until disease progression, unacceptable toxicity, or until patient or in-
vestigator requested therapy discontinuation
Outcomes Tumour response - RECIST
Overall survival
Progression-free survival
ASEs - NCI-CTC
Haematology and biochemical parameters
Quality of life - EORTC Quality of Life Questionnaire C30 (EORTC QLQ-C30)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “consecutively assigned to either
arm according to a predefined computer-
generated randomisation scheme devel-
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oped by statisticians”
Comment: this was judged as a low risk of
bias
Allocation concealment (selection bias) Low risk Quote: “consecutively assigned to either
arm according to a predefined computer-
generated randomisation scheme devel-
oped by statisticians”
Comment: this was judged as a low risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions and attritionpresented inFigure
1. Missing outcome data balanced in num-
bers across intervention groups with simi-
lar reasons for missing data across groups.
135/141 patients analysed for efficacy
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Unclear risk No specific funding was disclosed and au-
thors made no disclosure of conflicts of in-
terest
Comment: this was judged as an unclear
risk of bias
Takeda 2010 WJTOG0203
Methods Design: parallel-group
Randomisation: yes, method stated
Blinding: double-blind
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 604
Number enrolled: 603
Number in treatment group: 302
Number in control group: 301
Number of withdrawals (treatment/control): 4/4
Number completing trial (treatment/control): 298/297
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Age range: treatment 25 to 74 years; control 35 to 74 years
Sex: M 383, F 215
Ethnicity: Japanese
NSCLC diagnosis: histologically or cytologically confirmed stage IIIB (with malignant
pleural effusion or contralateral hilar lymph node metastases) or stage IV NSCLC
Inclusion criteria: NSCLC who had not previously received any chemotherapy, patients
who had recurrence after complete surgical resection were permitted, ECOG perfor-
mance status 0 to 1, adequate organ function as indicated as WBC count > 4000/µL,
absolute neutrophil count > 2000/µL, haemoglobin > 9.5 g/dL, AST/ALT < 2.5 times
the upper limit of normal, total bilirubin < 1.5 mg/dL, serum creatinine < 1.2 mg/
dL, PaO2 in arterial blood > 70 mmHg. Asymptomatic brain metastases were allowed
provided they had been irradiated and were clinically and radiologically stable
Exclusion criteria: patients treated with either adjuvant or neoadjuvant chemotherapy.
Radiologically or clinically apparent interstitial pneumonitis or pulmonary fibrosis
Baseline characteristics of treatment/control groups: comparable
Interventions Arm A: platinum doublet chemotherapy - up to 6 cycles
Arm B: 3 cycles of chemotherapy followed by gefitinib 250g/day orally until disease
progression
Outcomes Overall survival
Progression-free survival (PFS)
Tumour response - RECIST
Quality of life - FACT-L
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised” but no further information
provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions presented in Figure 1; with-
drawals were stated in text. Missing out-
come data balanced in numbers across in-
tervention groups with similar reasons for
missing data across groups. 595/604 in-
cluded in analysis
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Low risk Co-authors have received honoraria from
industry
Comment: this was judged as a low risk of
bias
Thatcher 2005 ISEL
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: double-blind, double-dummy
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 1836
Number enrolled: 1692
Number in treatment group: 1126
Number in control group: 562
Number of withdrawals (treatment/control): 818/451
Number completing trial (treatment/control): 308/111
Age range: treatment 28 to 90 years, control 31 to 87 years
Sex: 1139 M, 553 F
Ethnicity: 1274 Caucasian; 342 Asian; 14 Black; 62 other
NSCLC diagnosis: histologically or cytologically proven NSCLC
Inclusion criteria: NSCLC not curable with surgery or radiotherapy; previously received
1 or 2 chemotherapy regimens; refractory to (recurrent or progressive disease within 90
days of chemotherapy) or intolerant of latest chemotherapy regimen; younger than 70
years; received at least 1 previous platinum-based chemotherapy regimen; WHO PS 0
to 2; life expectancy of at least 8 weeks
Exclusion criteria: presence of small cell lung cancer alone or with NSCLC; administra-
tion of last dose of single-agent chemotherapy within the previous 21 days; untreated
or clinically unstable newly diagnosed metastasis in central nervous system; less than
1 week since completion of previous radiotherapy or persistence of any radiotherapy-
related toxic effects; unresolved chronic toxic effects from previous anticancer therapy;
known severe hypersensitivity to gefitinib or any tablet excipients; inability to swallow
tablets; other coexisting malignant disease (apart from basal cell carcinoma); absolute
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neutrophils count less than 1.0 x 109/L; platelet count less than 100 x 109/L; serum
bilirubin concentration more than 3 times upper limit of normal; AST or AST con-
centration more than 5x upper limit of normal; more than 2 previous chemotherapy
regimens for NSCLC; previous treatment with an experimental agent of which the main
mechanism of action is inhibition of epidermal growth receptor or its associated tyrosine
kinase; concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, St John’s
wort; severe or uncontrolled systemic disease; clinically active interstitial lung disease
(except uncomplicated lymphangitic carcinomatosis); pregnancy; breastfeeding
Baseline characteristics of treatment/control groups: comparable
Interventions Gefitinib 250 mg/day
Placebo
Outcomes Overall survival
Time to treatment failure
Tumour progression - RECIST
FACT-L
LCS of FACT-L
ASEs - NCI-CTC
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomisation done by a minimi-
sation method”
Comment: this was judged as a low risk of
bias
Allocation concealment (selection bias) Low risk Quote: “central registration and randomi-
sation centre”
Comment: this was judged as a low risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “double-blind”, “physically identi-
cal tablets and packaging”
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “818/1126 in treatment group and
451/562 in placebo group discontinued”.
Missing outcomes balanced in numbers
across intervention groups with similar rea-
sons for missing data across groups
Comment: this was judged as a low risk of
bias
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Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Low risk Co-authors have received honoraria from
industry
Comment: this was judged as a low risk of
bias
Xu 2015
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: open-label
Withdrawals: not stated
Participants Setting: single-centre study, hospital outpatient department
Number eligible: 188
Number enrolled: 188
Number in treatment group: 94
Number in control group: 94
Number of withdrawals (treatment/control): not stated
Number completing trial (treatment/control): not stated
Age range: (treatment/control): 60 to 82 years
Sex: 98 M, 90 F
Ethnicity: East Asian
NSCLC diagnosis: histologic/cytologic diagnosis of NSCLC, stage IIIB to IV disease
Inclusion criteria: stage IIIB to IVNSCLC, inoperable due tomedical reasons or rejecting
surgery, or the patients accepting 4 to 8 cycles of first-line chemotherapy and achieving
complete remission, partial response or stability. KPS ≥ 60, no other disease interfering
patients to complete the treatment; no brain metastases, with good compliance
Exclusion criteria: not stated
Baseline characteristics of treatment/control groups: comparable
Interventions Pemetrexed 500 mg/m2 day 1 to 3
Gefitinib 250 mg/daily
Outcomes Tumour response - RECIST
ASEs - NCI-CTC
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...randomized”
Comment: there was insufficient informa-
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tion to permit a clear judgement of risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk Open-label but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawals not stated
Comment: this was judged as a high risk of
bias
Selective reporting (reporting bias) High risk “survival time” was a prespecified outcome
but not reported inmethods; reason for this
is unclear
Comment: this was judged as a high risk of
bias
Other bias Low risk Disclosed no conflicts of interest
Comment: this was judged as a low risk of
bias
Xue 2015
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: open-label
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 155
Number enrolled: 100
Number in treatment group: 48
Number in control group: 48
Number of withdrawals (treatment/control): 2/2
Number completing trial (treatment/control): 8/10
Age range: (treatment/control) 33 to 83 years/32 to 83 years
Sex: 43 M, 53 F
Ethnicity: East Asian
NSCLC diagnosis: histologic/cytologic diagnosis of NSCLC, stage IIIB to IV disease
Inclusion criteria: advanced, refractory or recurrent NSCLC after at least 1 previous
regimen; achievement of stable disease after 1 month of gefitinib 250 mg daily therapy;
measurable lesions by RECIST criteria; ECOG PS 0 to 2; satisfactory renal, haemato-
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logical and cardiac function. Stable brain metastases were allowed
Exclusion criteria: previous EGFR TKI therapy, pregnancy, breastfeeding, or unable to
take oral medications
Baseline characteristics of treatment/control groups: comparable
Interventions Gefitinib 500 mg/day
Gefitinib 250 mg/day
Outcomes Tumour response - RECIST
Progression-free survival
Overall survival
ASEs - NCI-CTC
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...randomized ”
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk Open-label but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals stated with reasons such as
“consent not given” provided
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Low risk Study supported by Wu Jieping Medi-
cal Foundation Project grant and National
funding programmes. One author has de-
clared having received research support
from industry
Comment: this was judged as a low risk of
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bias
Yang 2014
Methods Design: parallel-group
Randomisation: yes, method stated
Blinding: open-label
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 253
Number enrolled: 236
Number in treatment group: 118
Number in control group: 118
Number of withdrawals (treatment/control): 4/0
Number completing trial (treatment/control): 12/46
Age range: treatment 24 to 81 years; control 31 to 79 years
Sex: 59 M, 177 F
Ethnicity: East Asian
NSCLC diagnosis: histologic/cytologic diagnosis of non-squamous NSCLC, stage IIIB
to IV disease
Inclusion criteria: chemotherapy-naive patients of East Asian ethnicity and unknown
EGFR mutation status. Stage IIIB to IV non-squamous NSCLC. Age≥ 18 years, “light
ex smokers” or “never smokers” measurable disease by RECIST version 1.0, ECOG PS
0 or 1
Exclusion criteria: known EGFR status before study entry, documented brain metastasis
(previously treated stable brain metastases were allowed), clinically significant third space
fluid collections, inability to interrupt aspirin or other non-steroidal anti-inflammatory
agents (except aspirin at a dose of 1300 mg daily for a 5-day period) and concomitant
use of CYP3A4 inducers
Baseline characteristics of treatment/control groups: comparable
Interventions PC/Gefitinib arm
Pemetrexed (500 mg/m2) + cisplatin (75 mg/m2) on day 1 of 21-day cycle. Maximum
of 6 cycles.
Then non-progressing patients received gefitinib 250 mg daily as maintenance
Gefitinib arm
Gefitinib 250 mg daily as maintenance
Outcomes Progression-free survival
Overall survival
Tumour response - RECIST
Time to progressive disease (TtPD)
Duration of response (DoR)
ASEs - NCI-CTC
Association between EGFR mutation status and clinical outcomes
Notes -
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “... randomisation was controlled by a cen-
trally located computerised voice response
unit using a computer-generated random
sequence and an interactive voice response
system...”
Comment: this was judged as a low risk of
bias
Allocation concealment (selection bias) Low risk External computer generated random se-
quence
Comment: this was judged as a low risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk Open-label but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals presented in Figure 1. 58 pa-
tients completed the study, with balanced
numbers between both arms
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Unclear risk Authors have declared paid consultancies,
honorarium and research funding from in-
dustry
Comment: this was judged as an unclear
risk of bias
Yu 2014
Methods Design: parallel-group
Randomisation: yes, method not stated
Blinding: open-label
Withdrawals: stated
Participants Setting: single-centre study, hospital outpatient department
Number eligible: 120
Number enrolled: 117
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Number in treatment group: 58
Number in control group: 59
Number of withdrawals (treatment/control): 6/2
Number completing trial (treatment/control): 27/27
Age range: treatmnet 36 to 72 years;control 33 to 70 years
Sex: 58 M, 59 F
Ethnicity: East Asian
NSCLC diagnosis: histologic/cytologic diagnosis of advanced or recurrent non-squa-
mous NSCLC, stage IIIB to IV disease
Inclusion criteria: ≥ 18 years, stage IIIB to IV non-squamous NSCLC ECOG PS 0 to
1; measurable disease according to RECIST, adequate haematological hepatic and renal
functions, life expectancy of > 12 weeks
Exclusion criteria: received previous systemic anticancer treatment or had severe drug
allergy, or another serious disease or condition, uncontrolled brain metastases, uncon-
trolled pleural effusion and/or pericardial effusion, or second malignancy, pregnancy or
lactation. Baseline characteristics of treatment/control groups: comparable
Interventions PC/G
Pemetrexed 500 mg/m2 + either cisplatin (75 mg/m2) or carboplatin (AUC5)
Intravenously on day 1 of a 3-week cycle
Gefitinib 250 mg orally on day 3 to 16 of a 21-day cycle
PC
Pemetrexed 500 mg/m2 + either cisplatin (75 mg/m2) or carboplatin (AUC5)
Intravenously on day 1 of a 3-week cycle
Continued until disease progression
Outcomes Non-progression rate (NPR)
Tumour response - RECIST
Progression-free survival
Overall survival
ASEs - NCI-CTC
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...randomized in 1:1 ratio” and stratified
by smoking status, EGFR genotype
Comment: this was judged as an unclear
risk of bias
Allocation concealment (selection bias) Unclear risk No information provided
Comment: there was insufficient informa-
tion to permit a clear judgement of risk of
bias
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Yu 2014 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but review authors judge that
outcome is not likely to be influenced by
lack of blinding
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals stated in text
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Low risk Authors declared no competing conflicts of
interest
Zhang 2012 INFORM
Methods Design: parallel-group
Randomisation: yes, method stated
Blinding: double-blind
Withdrawals: stated
Participants Setting: multicentre study, hospital outpatient department
Number eligible: 298
Number enrolled: 296
Number in treatment group: 148
Number in control group: 148
Number of withdrawals (treatment/control): 81/95
Number completing trial (treatment/control): 67/53
Age range: treatment 31 to 79 years; control 20 to 75 years
Sex: 175 M, 121 F
Ethnicity: East Asian (Chinese)
NSCLC diagnosis: histologically or cytologically confirmed stage IIIB or IV NSCLC
Inclusion criteria: stage IIIB or IV NSCLC, 18 years or older, life expectancy of > 12
weeks,WHO PS 0 to 2, completed 4 cycles of first-line platinum doublet chemotherapy
without disease progression and acceptable toxic effects
Exclusion criteria: patients with known EGFR status to avoid selection bias. Prior expo-
sure to monoclonal antibodies or small molecule inhibitors against EGFR receptors (e.g.
gefitinib, erlotinib, C225). Participation in another clinical study or received treatment
with a non-approved agent within 42 days before Day 1 of study treatment. Serum
bilirubin > 3 x ULRR, Aspartate aminotransferase (AST/SGOT) or alanine aminotrans-
ferase (ALT/SGPT) ≥ 2.5 x ULN if no demonstrable liver metastases (or > 5 x in pres-
ence of liver metastases). Any unresolved chronic toxicity greater than common toxicity
criteria (CTCAE) grade 2 from previous anticancer therapy excluding peripheral neu-
ropathy. Patients with previously diagnosed and treated CNS metastases or spinal cord
compression may be considered if they are clinically stable and have been discontinued
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Zhang 2012 INFORM (Continued)
from steroid therapy for at least 4 weeks prior to first dose of study medication. Any
evidence of clinically active interstitial lung disease (patients with chronic, stable, radio-
graphic changes who are asymptomatic need not be excluded). Pre-existing idiopathic
pulmonary fibrosis evidence by CT scan at baseline. Patients who have undergone com-
plete tumour resection after responding to platinum-based chemotherapy. As judged by
the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable
or uncompensated respiratory, cardiac, hepatic or renal disease). Treatment with any
systemic anticancer therapies other than the prescribed protocol chemotherapy regimen
(refer to Inclusion criterion). Exception: palliative radiotherapy for symptom relief of
lesions present at diagnosis will be allowed; however, palliative wide field radiotherapy
to the lung must be completed at least 4 weeks before day 1 with no persistence of any
radiotherapy-related toxicity. Other co-existing malignancies or malignancies diagnosed
within the last 5 years with the exception of basal cell carcinoma or cervical cancer in
situ. Pregnancy or breastfeeding (women of child bearing potential). Concomitant use
of phenytoin, carbamazepine, rifampicin, barbiturates or St. John’s wort. Previous bone
marrow transplant. Whole blood transfusion within 120 days of the date of genetic
sample collection. Known biomarker status of one or more of the following: tumour
EGFR gene copy number, tumour EGFR gene mutation status, tumour EGFR protein
expression
Baseline characteristics of treatment/control groups: comparable
Interventions Gefitinib 250 mg/day
Placebo (oral)
Outcomes Progression-free survival
Overall survival
Time to progression
Tumour response - RECIST
ASEs - NCI-CTC
Haematology and biochemical parameters
Quality of life (FACT-L)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomisation was done centrally
by a third-party randomisation centre that
had no other role in the study”, “Random-
ization was performed using dynamic bal-
ancing...”
Comment: this was judged as a low risk of
bias
Allocation concealment (selection bias) Low risk Quote: “randomisation was done centrally
by a third-party randomisation centre that
had no other role in the study”
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Zhang 2012 INFORM (Continued)
Comment: this was judged as a low risk of
bias
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “active and placebo drugs were
identical in form and packaging to ensure
blinding”
Comment: this was judged as a low risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions and attrition presented in Fig-
ure 1. Missing outcomes balanced in num-
bers across intervention groups with simi-
lar reasons for missing data across groups.
All 296 patients were available for analysis
Comment: this was judged as a low risk of
bias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Comment: this was judged as a low risk of
bias
Other bias Unclear risk Funding for study from Astra Zeneca.
Co-authors have received research support
from industry
Comment: this was judged as an unclear
risk of bias
ALT: alanine transaminase
ASE: adverse side effects
AST: aspartate transaminase
AUC: area under curve
CNS: central nervous system
CT: computerised tomography
CTCAE: Common Toxicity Criteria for Adverse Events
ECG: electrocardiogram
ECOG: Eastern Cooperative Oncology Group
ECOG PS: ECOG Performance Status
EGFR: epidermal growth factor receptor
EORTC: European Organisation for Research and Treatment of Cancer
F: female
FACT-L: Functional Assessment of Cancer Therapy-Lung
FEV1: forced expiratory volume in one second
ILCP: Italian Lung Cancer Project
IV: intravenous
KPS: Karnofsky Performance Status
LCS: lung cancer subscale
M: male
MRI: magnetic resonance imaging
NCI-CTC: National Cancer Institute Common Toxicity Criteria
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NSCLC: non-small cell lung cancer
PFS: progression-free survival
PR: partial response
RECIST: Response Evaluation Criteria in Solid Tumours
SGOT: serum glutamic-oxaloacetic transaminase
SGPT: serum glutamic-pyruvic transaminase
TKI: tyrosine kinase inhibitor
TOI: Trial Outcome Index
UFT: tegafur + uracil
UICC: Union for International Cancer Control
ULN: upper limit of normal
ULRR: upper limit of the reference range
WBC: white blood cell
WHO: World Health Organization
WHO PS: WHO Performance Status
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Choi 2015 Recruited only EGFR-mutation negative patients
Kim 2012 Gefitinib versus other EGFR TKI
Lee 2009 Open-label, non-randomised study
Manegold 2005 No direct comparison arm
Natale 2009 Cross-over study
Shi 2013 ICOGEN Gefitinib versus other EGFR TKI
Sugawara 2015 Gefitinib + chemotherapy (sequential) versus gefitinib + chemotherapy (alternating)
Urata 2016 Gefitinib versus other EGFR TKI
Zhou 2014 CTONG 0806 Recruited only EGFR-mutation negative patients
EGFR: epidermal growth factor receptor
TKI: tyrosine kinase inhibitor
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Characteristics of ongoing studies [ordered by study ID]
Bhatnagar 2012
Trial name or title Docetaxel versus gefitinib in patients with locally advanced or metastatic NSCLC pretreated with platinum-
based chemotherapy
Methods Randomised
Participants 30 patients with locally advanced or metastatic NSCLC previously treated with cisplatin-based chemotherapy,
who had progressive or recurrent disease and ECOG performance score 0 to 2
Interventions Gefitinib 250 mg/day versus docetaxel 75 mg/m2 every 3 weeks
Outcomes Tumour response
Adverse events
Starting date Not known
Contact information Not known
Notes -
Gaafar 2010
Trial name or title A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts)
with advancedNSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC08021-ILCP
01/03)
Methods Randomised
Participants Advanced NSCLC
Interventions Gefitinib 250 mg daily versus placebo
Outcomes Overall survival
Progression-free survival
Toxicity
Starting date Not known
Contact information Not known
Notes -
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Hong 2010
Trial name or title Randomized phase II study of pemetrexed versus gefitinib for patients with previously treated non-small cell
lung cancer
Methods Randomised
Participants Patients with histologically or cytologically confirmed advanced (stage IIIB or IV) or recurrent NSCLC
were eligible if they were; age > 18 years, with measurable lesion, previously treated, an Eastern Cooperative
Oncology Group (ECOG) Performance Status (PS) 0 to 2, and with adequate organ function
Interventions 500 mg/m2 of pemetrexed intravenously every 3 weeks with vitamin supplementation versus gefitinib 250
mg/day until disease progression, intolerable toxicity or withdrawal of consent
Outcomes Tumour response
PFS
OS
Toxicity
Starting date Not known
Contact information Not known
Notes -
Laurie 2000
Trial name or title Pilot trial of ZD1839 (Iressa-TM-), an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine
kinase, in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small
cell lung cancer
Methods Not known
Participants Not known
Interventions Not known
Outcomes Not known
Starting date Not known
Contact information Not known
Notes -
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Lee 2013
Trial name or title Randomized phase II study comparing paclitaxel/carboplatin intercalated with gefitinib to paclitaxel/carbo-
platin alone for chemotherapy-naive non-small cell lung cancer patients either with history of smoking or
with wild-type EGFR
Methods Randomised
Participants Chemotherapy-naive advanced NSCLC patients with good ECOG PS of 0 or 1
Interventions PCG arm: P 175 mg/m2 and C AUC 5 intravenously on day 1 intercalated with G 250 mg orally on days 2
through 15 every 3 weeks for 4 cycles followed by G 250 mg orally until progressive disease
PC arm: P 175 mg/m2 and C AUC 5 on day 1 every 3 weeks for 4 cycles only without maintenance therapy
Outcomes Tumour response
PFS
OS
Toxicity
Starting date Not known
Contact information Not known
Notes -
Liang 2010
Trial name or title First-line treatment (txt) with pemetrexed-cisplatin (PC), followed sequentially by gefitinib (G) or pemetrexed,
in Asian, never-smoker (n/smkr) patients (pts) with advanced NSCLC: an open-label, randomized phase II
trial
Methods Randomised
Participants Advanced NSCLC
Asian, chemotherapy-naive, non-smoker
Interventions First-line PC + TXT followed by gefitinib 250 mg daily versus placebo
Outcomes Progression-free survival
Response rate
Toxicities
Starting date February 2007
Contact information Not known
Notes -
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Nokihara 2006
Trial name or title A randomized phase II study of sequential carboplatin/paclitaxel (CP) and gefitinib (G) in chemotherapy-
naive patients with advanced non-small-cell lung cancer (NSCLC): preliminary results
Methods Not known
Participants Not known
Interventions Not known
Outcomes Not known
Starting date Not known
Contact information Not known
Notes -
Puri 2013
Trial name or title A randomized phase 2 trial of pemetrexed (P) and gefitinib (G) versus G as first-line treatment for patients
with stage IV non-squamous (NS) non-small cell lung cancer (NSCLC) with activating epidermal growth
factor receptor (EGFR) mutations
Methods Randomised
Participants Stage IV NS NSCLC, an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1
and an activating EGFR mutation
Interventions Gefitinib versus pemetrexed
Outcomes PFS
Time to progressive disease
OS
ORR
DCR
Adverse events
Starting date Not known
Contact information Not known
Notes -
AUC: Area under curve
C: carboplatin
DCR: disease control rate
ECOG: Eastern Cooperative Oncology Group
ECOG PS: ECOG Performance Status
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EGFR: epidermal growth factor receptor
G: gefitinib
NSCLC: non-small cell lung cancer
ORR: overall response rate
OS: overall survival
P: paclitaxel
PC: pemetrexed-cisplatin
PFS: progression-free survival
TXT: first-line treatment
108Gefitinib for advanced non-small cell lung cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Gefitinib versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HR Overall survival 4 Hazard Ratio (Random, 95% CI) Subtotals only
1.1 G(250) vs P = 1st line 1 Hazard Ratio (Random, 95% CI) 0.84 [0.62, 1.14]
1.2 G(250) vs P = 2nd line 1 Hazard Ratio (Random, 95% CI) 0.89 [0.79, 1.01]
1.3 G(500) vs P =
Maintenance
2 Hazard Ratio (Random, 95% CI) 1.14 [0.61, 2.14]
2 HR Progression-free survival 4 Hazard Ratio (Random, 95% CI) Subtotals only
2.1 G(250) vs P = 1st line 1 Hazard Ratio (Random, 95% CI) 0.82 [0.60, 1.12]
2.2 G(250) vs P = 2nd line 1 Hazard Ratio (Random, 95% CI) 0.82 [0.75, 0.90]
2.3 G(500) vs P =
Maintenance
2 Hazard Ratio (Random, 95% CI) 0.70 [0.53, 0.91]
3 1-year survival rate 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 G(250) vs P = 2nd line 1 1439 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [1.05, 1.57]
3.2 G(500) vs P =
Maintenance
1 243 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.78, 1.04]
4 Skin rash 3 2060 Risk Ratio (M-H, Fixed, 95% CI) 7.92 [1.46, 43.03]
4.1 G(250) vs P = 1st line 1 201 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 G(250) vs P = 2nd line 1 1688 Risk Ratio (M-H, Fixed, 95% CI) 8.98 [1.20, 67.13]
4.3 G(250) vs P =
Maintenance
1 171 Risk Ratio (M-H, Fixed, 95% CI) 5.06 [0.25, 103.82]
5 Pruritus 2 1889 Risk Ratio (M-H, Fixed, 95% CI) 2.00 [0.22, 17.82]
5.1 G(250) vs P = 1st line 1 201 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 G(250) vs P = 2nd line 1 1688 Risk Ratio (M-H, Fixed, 95% CI) 2.00 [0.22, 17.82]
6 Diarrhoea 3 2060 Risk Ratio (M-H, Fixed, 95% CI) 2.48 [1.15, 5.35]
6.1 G(250) vs P = 1st line 1 201 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.21, 4.89]
6.2 G(250) vs P = 2nd line 1 1688 Risk Ratio (M-H, Fixed, 95% CI) 3.09 [1.21, 7.91]
6.3 G(250) vs P =
Maintenance
1 171 Risk Ratio (M-H, Fixed, 95% CI) 3.03 [0.13, 73.47]
7 Constipation 1 201 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.06, 15.93]
7.1 G(250) vs P = 1st line 1 201 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.06, 15.93]
8 Nausea 2 1889 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.03, 12.44]
8.1 G(250) vs P = 1st line 1 201 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.01, 2.06]
8.2 G(250) vs P = 2nd line 1 1688 Risk Ratio (M-H, Random, 95% CI) 2.25 [0.49, 10.36]
9 Vomiting 2 1859 Risk Ratio (M-H, Fixed, 95% CI) 3.21 [0.83, 12.38]
9.1 G(250) vs P = 2nd line 1 1688 Risk Ratio (M-H, Fixed, 95% CI) 3.24 [0.73, 14.33]
9.2 G(250) vs P =
Maintenance
1 171 Risk Ratio (M-H, Fixed, 95% CI) 3.03 [0.13, 73.47]
10 Anorexia 3 2060 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.64, 2.33]
10.1 G(250) vs P = 1st line 1 201 Risk Ratio (M-H, Fixed, 95% CI) 5.05 [0.25, 103.87]
10.2 G(250) vs P = 2nd line 1 1688 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.59, 2.37]
10.3 G(250) vs P =
Maintenance
1 171 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.01, 8.16]
11 Fatigue 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 G(250) vs P = 1st line 1 201 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.27, 2.10]
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11.2 G(250) vs P =
Maintenance
1 171 Risk Ratio (M-H, Fixed, 95% CI) 4.05 [0.46, 35.47]
12 Asthenia 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 G(250) vs P = 2nd line 1 1688 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.66, 2.17]
13 Respiratory tract infection 2 1889 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.07, 3.83]
13.1 G(250) vs P = 1st line 1 201 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.01, 2.06]
13.2 G(250) vs P = 2nd line 1 1688 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.54, 1.84]
14 Dyspnoea 3 2060 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.59, 1.63]
14.1 G(250) vs P = 1st line 1 201 Risk Ratio (M-H, Random, 95% CI) 1.85 [0.71, 4.81]
14.2 G(250) vs P = 2nd line 1 1688 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.49, 1.42]
14.3 G(250) vs P =
Maintenance
1 171 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.20, 2.31]
15 Anaemia 1 201 Risk Ratio (M-H, Fixed, 95% CI) 7.07 [0.37, 135.12]
15.1 G(250) vs P = 1st line 1 201 Risk Ratio (M-H, Fixed, 95% CI) 7.07 [0.37, 135.12]
16 Abdominal pain 1 201 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.05, 5.48]
16.1 G(250) vs P = 1st line 1 201 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.05, 5.48]
17 Increased ALT 1 171 Risk Ratio (M-H, Fixed, 95% CI) 9.11 [1.18, 70.32]
17.1 G(250) vs P =
Maintenance
1 171 Risk Ratio (M-H, Fixed, 95% CI) 9.11 [1.18, 70.32]
18 Increased AST 1 171 Risk Ratio (M-H, Fixed, 95% CI) 7.08 [0.89, 56.34]
18.1 G(250) vs P =
Maintenance
1 171 Risk Ratio (M-H, Fixed, 95% CI) 7.08 [0.89, 56.34]
19 Neutropenia 1 171 Risk Ratio (M-H, Fixed, 95% CI) 3.03 [0.13, 73.47]
19.1 G(250) vs P =
Maintenance
1 171 Risk Ratio (M-H, Fixed, 95% CI) 3.03 [0.13, 73.47]
20 Anaemia 1 171 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.15]
20.1 G(250) vs P =
Maintenance
1 171 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.15]
21 Thrombocytopaenia 1 171 Risk Ratio (M-H, Fixed, 95% CI) 3.03 [0.13, 73.47]
21.1 G(250) vs P =
Maintenance
1 171 Risk Ratio (M-H, Fixed, 95% CI) 3.03 [0.13, 73.47]
22 Overall response rate 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
22.1 G(250) vs P = 1st line 1 201 Risk Ratio (M-H, Fixed, 95% CI) 6.06 [0.74, 49.43]
22.2 G(250) vs P= 2nd line 1 1439 Risk Ratio (M-H, Fixed, 95% CI) 6.42 [2.82, 14.64]
22.3 G(250) vs P =
Maintenance
1 173 Risk Ratio (M-H, Fixed, 95% CI) 10.12 [1.32, 77.33]
23 Disease control rate 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
23.1 G(250) vs P = 1st line 1 201 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.86, 2.16]
23.2 G(250) vs P = 2nd line 1 1439 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [1.06, 1.44]
23.3 G(250) vs P =
Maintenance
1 173 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [1.00, 1.46]
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Comparison 2. Gefitinib versus placebo (Asian subgroup)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HR Overall survival 2 Hazard Ratio (Fixed, 95% CI) Subtotals only
1.1 G(250) vs P = 2nd line 1 Hazard Ratio (Fixed, 95% CI) 0.66 [0.48, 0.91]
1.2 G(250) vs P =
Maintenance
1 Hazard Ratio (Fixed, 95% CI) 0.88 [0.68, 1.14]
2 HR Progression-free survival 2 Hazard Ratio (Fixed, 95% CI) Subtotals only
2.1 G(250) vs P = 2nd line 1 Hazard Ratio (Fixed, 95% CI) 0.69 [0.52, 0.91]
2.2 G(250) vs P =
Maintenance
1 Hazard Ratio (Fixed, 95% CI) 0.42 [0.33, 0.54]
3 1-year survival rate 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 G(250) vs P = 2nd line 1 342 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [1.20, 2.55]
4 Overall response rate 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 G(250) vs P = 2nd line 1 306 Risk Ratio (M-H, Random, 95% CI) 6.03 [1.46, 24.91]
4.2 G(250) vs P =
Maintenance
1 296 Risk Ratio (M-H, Random, 95% CI) 35.00 [4.86, 252.15]
Comparison 3. Gefitinib versus placebo (biomarker subgroup)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HR Overall survival 1 Hazard Ratio (Fixed, 95% CI) Subtotals only
1.1 G(250) vs P =
Maintenance
1 Hazard Ratio (Fixed, 95% CI) 0.39 [0.15, 0.98]
2 HR Progression-free survival 1 Hazard Ratio (Fixed, 95% CI) Subtotals only
2.1 G(250) vs P =
Maintenance
1 Hazard Ratio (Fixed, 95% CI) 0.17 [0.07, 0.41]
Comparison 4. Gefitinib versus chemotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HR Overall survival 2 Hazard Ratio (Fixed, 95% CI) Subtotals only
1.1 G vs vinorelbine = 1st line 1 Hazard Ratio (Fixed, 95% CI) 0.98 [0.66, 1.46]
1.2 G vs docetaxel = 2nd line 1 Hazard Ratio (Fixed, 95% CI) 1.02 [0.91, 1.15]
2 HR Progression-free survival 2 Hazard Ratio (Fixed, 95% CI) Subtotals only
2.1 G vs vinorelbine = 1st line 1 Hazard Ratio (Fixed, 95% CI) 1.19 [0.86, 1.65]
2.2 G vs docetaxel = 2nd line 1 Hazard Ratio (Fixed, 95% CI) 1.04 [0.92, 1.17]
3 1-year survival rate 3 1741 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.82, 1.08]
3.1 G vs vinorelbine = 1st line 1 190 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.69, 1.52]
3.2 G vs docetaxel = 1st line 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.08, 1.90]
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3.3 G vs docetaxel = 2nd line 1 1466 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.82, 1.09]
4 Skin rash 4 1858 Risk Ratio (M-H, Fixed, 95% CI) 2.40 [1.08, 5.31]
4.1 G vs vinorelbine = 1st line 1 190 Risk Ratio (M-H, Fixed, 95% CI) 5.11 [0.25, 104.94]
4.2 G vs docetaxel = 1st line 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.05, 5.19]
4.3 G vs docetaxel = 2nd line 2 1583 Risk Ratio (M-H, Fixed, 95% CI) 2.82 [1.11, 7.13]
5 Constipation 3 1719 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.17, 0.97]
5.1 G vs vinorelbine = 1st line 1 190 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.20]
5.2 G vs docetaxel = 1st line 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.78]
5.3 G vs docetaxel = 2nd line 1 1444 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.17, 1.18]
6 Fatigue 2 275 Risk Ratio (M-H, Fixed, 95% CI) 0.16 [0.03, 0.88]
6.1 G vs vinorelbine = 1st line 1 190 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.00, 1.18]
6.2 G vs docetaxel = 1st line 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.05, 5.19]
7 Asthenia 3 1773 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.35, 0.75]
7.1 G vs vinorelbine = 1st line 1 190 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.01, 2.79]
7.2 G vs docetaxel = 2nd line 2 1583 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.36, 0.78]
8 Neurotoxicity 2 1529 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.01, 0.34]
8.1 G vs docetaxel = 1st line 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 1.56]
8.2 G vs docetaxel = 2nd line 1 1444 Risk Ratio (M-H, Fixed, 95% CI) 0.06 [0.01, 0.43]
9 Neutropenia 4 1857 Risk Ratio (M-H, Fixed, 95% CI) 0.04 [0.02, 0.06]
9.1 G vs vinorelbine = 1st line 1 190 Risk Ratio (M-H, Fixed, 95% CI) 0.03 [0.00, 0.43]
9.2 G vs docetaxel = 1st line 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.04, 0.63]
9.3 G vs docetaxel = 2nd line 2 1582 Risk Ratio (M-H, Fixed, 95% CI) 0.04 [0.02, 0.06]
10 Leukopenia 2 324 Risk Ratio (M-H, Fixed, 95% CI) 0.03 [0.00, 0.22]
10.1 G vs vinorelbine = 1st
line
1 190 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.00, 1.18]
10.2 G vs docetaxel = 2nd line 1 134 Risk Ratio (M-H, Fixed, 95% CI) 0.02 [0.00, 0.32]
11 Febrile neutropenia 3 1768 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.06, 0.23]
11.1 G vs vinorelbine = 1st
line
1 190 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.00, 1.18]
11.2 G vs docetaxel = 2nd line 2 1578 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.06, 0.24]
12 Pruritus 1 139 Risk Ratio (M-H, Fixed, 95% CI) 5.22 [0.26, 106.74]
12.1 G vs docetaxel = 2nd line 1 139 Risk Ratio (M-H, Fixed, 95% CI) 5.22 [0.26, 106.74]
13 Diarrhoea 4 1858 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.48, 1.34]
13.1 G vs vinorelbine = 1st
line
1 190 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.26, 3.96]
13.2 G vs docetaxel = 1st line 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.14, 6.62]
13.3 G vs docetaxel = 2nd line 2 1583 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.43, 1.35]
14 Vomiting 2 1583 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.19, 1.63]
14.1 G vs docetaxel = 2nd line 2 1583 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.19, 1.63]
15 Anorexia 3 1719 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [0.61, 3.32]
15.1 G vs vinorelbine = 1st
line
1 190 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.15, 7.10]
15.2 G vs docetaxel = 1st line 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.3 G vs docetaxel = 2nd line 1 1444 Risk Ratio (M-H, Fixed, 95% CI) 1.54 [0.60, 3.95]
16 Stomatitis 1 1444 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.71]
16.1 G vs docetaxel = 2nd line 1 1444 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.71]
17 Arthralgia/myalgia 2 1529 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 2.19]
17.1 G vs docetaxel = 1st line 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.2 G vs docetaxel = 2nd line 1 1444 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 2.19]
18 Peripheral oedema 2 1634 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.00, 1.61]
18.1 G vs vinorelbine = 1st
line
1 190 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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18.2 G vs docetaxel = 2nd line 1 1444 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.00, 1.61]
19 Respiratory tract infection 1 1444 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.52, 1.57]
19.1 G vs docetaxel = 2nd line 1 1444 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.52, 1.57]
20 Dyspnoea 3 1773 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.57, 1.16]
20.1 G vs vinorelbine = 1st
line
1 190 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.03, 2.24]
20.2 G vs docetaxel = 2nd line 2 1583 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.59, 1.22]
21 Cough 2 1583 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.36, 3.84]
21.1 G vs docetaxel = 2nd line 2 1583 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.36, 3.84]
22 Anaemia 4 1853 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.36, 1.36]
22.1 G vs vinorelbine = 1st
line
1 190 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.01, 8.25]
22.2 G vs docetaxel = 1st line 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.62]
22.3 G vs docetaxel = 2nd line 2 1578 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.42, 1.75]
23 Thrombocytopenia 2 219 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.12, 72.35]
23.1 G vs docetaxel = 1st line 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
23.2 G vs docetaxel = 2nd line 1 134 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.12, 72.35]
24 Hypokalaemia 1 190 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.06, 16.09]
24.1 G vs vinorelbine = 1st
line
1 190 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.06, 16.09]
25 Pyrexia 3 1773 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.14, 2.47]
25.1 G vs vinorelbine = 1st
line
1 190 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.06, 16.09]
25.2 G vs docetaxel = 2nd line 2 1583 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.09, 2.67]
26 Overall response rate 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
26.1 G vs docetaxel = 2nd line 2 1607 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.85, 1.59]
27 Disease control rate 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
27.1 G vs docetaxel = 1st line 1 190 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.61, 1.10]
27.2 G vs docetaxel = 2nd line 1 141 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.82, 1.40]
28 FACT-L QOL improvement
rate
2 1656 Mean Difference (IV, Fixed, 95% CI) 10.50 [9.55, 11.45]
28.1 G vs vinorelbine = 1st
line
1 190 Mean Difference (IV, Fixed, 95% CI) 13.4 [8.25, 18.55]
28.2 G vs docetaxel = 2nd line 1 1466 Mean Difference (IV, Fixed, 95% CI) 10.40 [9.43, 11.37]
29 LCS QOL improvement rate 2 1656 Mean Difference (IV, Fixed, 95% CI) 3.63 [3.08, 4.19]
29.1 G vs vinorelbine = 1st
line
1 190 Mean Difference (IV, Fixed, 95% CI) 3.80 [2.42, 5.18]
29.2 G vs docetaxel = 2nd line 1 1466 Mean Difference (IV, Fixed, 95% CI) 3.60 [2.99, 4.21]
30 TOI QOL improvement rate 2 1656 Mean Difference (IV, Random, 95% CI) 9.87 [1.26, 18.48]
30.1 G vs vinorelbine = 1st
line
1 190 Mean Difference (IV, Random, 95% CI) 16.60 [4.61, 28.59]
30.2 G vs docetaxel = 2nd line 1 1466 Mean Difference (IV, Random, 95% CI) 7.0 [5.97, 8.03]
31 PSI QOL improvement rate 1 190 Mean Difference (IV, Fixed, 95% CI) 5.60 [3.55, 7.65]
31.1 G vs vinorelbine = 1st
line
1 190 Mean Difference (IV, Fixed, 95% CI) 5.60 [3.55, 7.65]
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Comparison 5. Gefitinib versus chemotherapy (Asian subgroup)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HR Overall survival = 1st line 4 Hazard Ratio (Random, 95% CI) 0.94 [0.82, 1.06]
1.1 G vs carboplatin +
paclitaxel
2 Hazard Ratio (Random, 95% CI) 1.09 [0.64, 1.84]
1.2 G vs gemcitabine +
cisplatin
1 Hazard Ratio (Random, 95% CI) 0.93 [0.72, 1.21]
1.3 G vs pemetrexed +
cisplatin
1 Hazard Ratio (Random, 95% CI) 0.94 [0.68, 1.30]
2 HR Overall survival = 2nd line 3 Hazard Ratio (Random, 95% CI) 0.94 [0.79, 1.12]
2.1 G vs docetaxel 2 Hazard Ratio (Random, 95% CI) 0.97 [0.80, 1.17]
2.2 G vs pemetrexed 1 Hazard Ratio (Random, 95% CI) 0.80 [0.50, 1.28]
3 HR Overall survival =
Maintenance
1 Hazard Ratio (Random, 95% CI) 2.15 [0.83, 5.55]
3.1 G vs pemetrexed 1 Hazard Ratio (Random, 95% CI) 2.15 [0.83, 5.55]
4 HR Progression-free survival =
1st line
5 Hazard Ratio (Random, 95% CI) 0.65 [0.43, 0.98]
4.1 G vs carboplatin +
paclitaxel
2 Hazard Ratio (Random, 95% CI) 0.48 [0.20, 1.15]
4.2 G vs cisplatin + docetaxel 1 Hazard Ratio (Random, 95% CI) 0.49 [0.34, 0.71]
4.3 G vs gemcitabine +
cisplatin
1 Hazard Ratio (Random, 95% CI) 1.20 [0.95, 1.52]
4.4 G vs pemetrexed +
cisplatin
1 Hazard Ratio (Random, 95% CI) 0.85 [0.64, 1.14]
5 HR Progression-free survival =
2nd line
3 Hazard Ratio (Random, 95% CI) 0.71 [0.57, 0.88]
5.1 G vs docetaxel 2 Hazard Ratio (Random, 95% CI) 0.78 [0.65, 0.94]
5.2 G vs pemetrexed 1 Hazard Ratio (Random, 95% CI) 0.54 [0.37, 0.79]
6 HR Progression-free survival =
Maintenance
1 Hazard Ratio (Random, 95% CI) 0.53 [0.27, 1.04]
6.1 G vs pemetrexed 1 Hazard Ratio (Random, 95% CI) 0.53 [0.27, 1.04]
7 1-year survival rate 7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 1st line 3 1754 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.97, 1.09]
7.2 2nd line 3 681 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.81, 1.11]
7.3 Maintenance 1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.65, 0.98]
8 Nausea 10 2898 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.17, 0.64]
8.1 1st line 4 1912 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.06, 0.54]
8.2 2nd line 5 916 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.22, 1.60]
8.3 Maintenance 1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.09, 2.98]
9 Vomiting 6 2447 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.05, 0.77]
9.1 1st line 3 1737 Risk Ratio (M-H, Random, 95% CI) 0.08 [0.02, 0.29]
9.2 2nd line 2 640 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.30, 5.77]
9.3 Maintenance 1 70 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.02, 1.69]
10 Anorexia 10 2950 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.27, 0.49]
10.1 1st line 4 1964 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.23, 0.45]
10.2 2nd line 5 916 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.27, 1.02]
10.3 Maintenance 1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.05, 12.20]
11 Fatigue 10 1960 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.22, 0.46]
114Gefitinib for advanced non-small cell lung cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
11.1 1st line 4 943 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.17, 0.40]
11.2 2nd line 4 759 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.06, 1.03]
11.3 Maintenance 2 258 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.41, 2.89]
12 Arthralgia/myalgia 4 2063 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.03, 0.61]
12.1 1st line 2 1423 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.03, 0.61]
12.2 2nd line 2 640 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Asthenia 4 1755 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.08, 0.58]
13.1 1st line 3 1598 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.07, 0.61]
13.2 2nd line 1 157 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.03, 2.94]
14 Neurotoxicity 4 1797 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.02, 0.24]
14.1 1st line 2 1505 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.02, 0.24]
14.2 2nd line 2 292 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Neutropenia 10 3061 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.05, 0.27]
15.1 1st line 5 2139 Risk Ratio (M-H, Random, 95% CI) 0.05 [0.03, 0.07]
15.2 2nd line 3 664 Risk Ratio (M-H, Random, 95% CI) 0.12 [0.08, 0.18]
15.3 Maintenance 2 258 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.49, 2.96]
16 Anaemia 9 2538 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.12, 0.29]
16.1 1st line 5 2139 Risk Ratio (M-H, Fixed, 95% CI) 0.16 [0.10, 0.26]
16.2 2nd line 2 141 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.02, 1.61]
16.3 Maintenance 2 258 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.24, 7.87]
17 Leukopenia 4 2086 Risk Ratio (M-H, Random, 95% CI) 0.07 [0.02, 0.23]
17.1 1st line 3 1603 Risk Ratio (M-H, Random, 95% CI) 0.04 [0.02, 0.08]
17.2 2nd line 1 483 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.09, 0.26]
18 Thrombocytopenia 7 1070 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.14, 0.72]
18.1 1st line 2 536 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.04, 0.51]
18.2 2nd line 3 276 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 2.15]
18.3 Maintenance 2 258 Risk Ratio (M-H, Fixed, 95% CI) 3.63 [0.42, 31.44]
19 Febrile neutropenia 2 1679 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.03, 0.28]
19.1 1st line 1 1196 Risk Ratio (M-H, Fixed, 95% CI) 0.06 [0.01, 0.43]
19.2 2nd line 1 483 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.03, 0.49]
20 Skin rash 10 3174 Risk Ratio (M-H, Random, 95% CI) 3.11 [1.28, 7.55]
20.1 1st line 5 2141 Risk Ratio (M-H, Random, 95% CI) 5.09 [2.21, 11.72]
20.2 2nd line 3 775 Risk Ratio (M-H, Random, 95% CI) 2.54 [0.46, 13.95]
20.3 Maintenance 2 258 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.24, 3.44]
21 Diarrhoea 10 3055 Risk Ratio (M-H, Fixed, 95% CI) 2.79 [1.57, 4.94]
21.1 1st line 5 2139 Risk Ratio (M-H, Fixed, 95% CI) 2.74 [1.43, 5.27]
21.2 2nd line 5 916 Risk Ratio (M-H, Fixed, 95% CI) 2.93 [0.88, 9.73]
22 Increased ALT 7 1542 Risk Ratio (M-H, Fixed, 95% CI) 10.03 [5.23, 19.26]
22.1 1st line 4 943 Risk Ratio (M-H, Fixed, 95% CI) 11.66 [5.13, 26.49]
22.2 2nd line 2 529 Risk Ratio (M-H, Fixed, 95% CI) 13.22 [3.18, 54.99]
22.3 Maintenance 1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.01, 6.33]
23 Increased AST 4 762 Risk Ratio (M-H, Fixed, 95% CI) 7.73 [2.78, 21.46]
23.1 1st line 3 716 Risk Ratio (M-H, Fixed, 95% CI) 7.73 [2.78, 21.46]
23.2 2nd line 1 46 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
24 Overall response rate 14 Risk Ratio (M-H, Random, 95% CI) Subtotals only
24.1 1st line 6 2158 Risk Ratio (M-H, Random, 95% CI) 1.43 [1.13, 1.82]
24.2 2nd line 6 921 Risk Ratio (M-H, Random, 95% CI) 1.43 [0.92, 2.22]
24.3 Maintenance 2 258 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.41, 1.87]
25 Stable disease 9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
25.1 1st line 5 941 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.34, 0.64]
25.2 2nd line 2 143 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.64, 1.82]
25.3 Maintenance 2 258 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.44, 0.93]
26 Disease control rate 9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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26.1 1st line 5 1848 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.86, 1.13]
26.2 2nd line 3 528 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.78, 1.25]
26.3 Maintenance 1 188 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.49, 0.85]
27 FACT-L QOL improvement
rate
3 1670 Mean Difference (IV, Fixed, 95% CI) 9.50 [7.95, 11.05]
27.1 1st line 1 1151 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
27.2 2nd line 2 519 Mean Difference (IV, Fixed, 95% CI) 9.50 [7.95, 11.05]
28 LCS QOL improvement rate 3 1748 Mean Difference (IV, Fixed, 95% CI) 2.30 [1.53, 3.07]
28.1 1st line 1 1151 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
28.2 2nd line 2 597 Mean Difference (IV, Fixed, 95% CI) 2.30 [1.53, 3.07]
29 TOI QOL improvement rate 3 1670 Mean Difference (IV, Fixed, 95% CI) 11.8 [9.17, 14.43]
29.1 1st line 1 1151 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
29.2 2nd line 2 519 Mean Difference (IV, Fixed, 95% CI) 11.8 [9.17, 14.43]
Comparison 6. Gefitinib versus chemotherapy (EGFR mutation)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HR Overall survival = 1st line 5 Hazard Ratio (Fixed, 95% CI) 0.97 [0.77, 1.21]
1.1 Biomarker driven selection 2 Hazard Ratio (Fixed, 95% CI) 0.98 [0.72, 1.33]
1.2 Clinical feature driven
selection
3 Hazard Ratio (Fixed, 95% CI) 0.95 [0.68, 1.33]
2 HR Overall survival = 2nd line 1 Hazard Ratio (Fixed, 95% CI) 0.83 [0.41, 1.66]
2.1 G vs docetaxel 1 Hazard Ratio (Fixed, 95% CI) 0.83 [0.41, 1.66]
3 HR Progression-free survival =
1st line
5 Hazard Ratio (Random, 95% CI) 0.47 [0.36, 0.61]
3.1 Biomarker driven selection 2 Hazard Ratio (Random, 95% CI) 0.39 [0.26, 0.59]
3.2 Clinical feature driven
selection
3 Hazard Ratio (Random, 95% CI) 0.53 [0.41, 0.70]
4 HR Progression-free survival =
2nd line
2 Hazard Ratio (Fixed, 95% CI) 0.24 [0.12, 0.47]
4.1 G vs docetaxel 1 Hazard Ratio (Fixed, 95% CI) 0.16 [0.05, 0.50]
4.2 G vs pemetrexed 1 Hazard Ratio (Fixed, 95% CI) 0.30 [0.13, 0.70]
5 Overall response rate 7 758 Risk Ratio (M-H, Random, 95% CI) 1.71 [1.34, 2.19]
5.1 First-line biomarker
driven selection
2 347 Risk Ratio (M-H, Random, 95% CI) 2.23 [1.75, 2.85]
5.2 First-line, clinical feature
driven selection
3 353 Risk Ratio (M-H, Random, 95% CI) 1.45 [1.05, 1.99]
5.3 2nd line 2 58 Risk Ratio (M-H, Random, 95% CI) 1.65 [0.88, 3.09]
6 Stable disease 3 397 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.28, 0.97]
6.1 First-line, biomarker
driven selection
2 347 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.22, 0.98]
6.2 First-line, clinical feature
driven selection
1 50 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.26, 2.85]
7 Disease control rate 5 2001 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.93, 1.19]
7.1 First-line, biomarker
driven selection
2 347 Risk Ratio (M-H, Random, 95% CI) 1.15 [1.05, 1.26]
116Gefitinib for advanced non-small cell lung cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
7.2 First-line, clinical feature
driven selection
2 1267 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.87, 0.99]
7.3 Second-line 1 387 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.77, 1.36]
Comparison 7. Gefitinib 250 mg versus gefitinib 500 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 1-year survival rate 2 424 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.61, 1.11]
1.1 2nd line 2 424 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.61, 1.11]
2 Skin rash 2 290 Risk Ratio (M-H, Fixed, 95% CI) 8.13 [1.51, 43.72]
2.1 2nd line 1 209 Risk Ratio (M-H, Fixed, 95% CI) 6.80 [0.85, 54.32]
2.2 Maintenance 1 81 Risk Ratio (M-H, Fixed, 95% CI) 10.41 [0.61, 176.21]
3 Acne 1 209 Risk Ratio (M-H, Fixed, 95% CI) 4.86 [0.24, 100.02]
3.1 2nd line 1 209 Risk Ratio (M-H, Fixed, 95% CI) 4.86 [0.24, 100.02]
4 Pruritus 1 209 Risk Ratio (M-H, Fixed, 95% CI) 2.92 [0.12, 70.77]
4.1 2nd line 1 209 Risk Ratio (M-H, Fixed, 95% CI) 2.92 [0.12, 70.77]
5 Diarrhoea 3 521 Risk Ratio (M-H, Fixed, 95% CI) 8.36 [1.58, 44.34]
5.1 2nd line 3 521 Risk Ratio (M-H, Fixed, 95% CI) 8.36 [1.58, 44.34]
6 Nausea 1 209 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.06, 15.33]
6.1 2nd line 1 209 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.06, 15.33]
7 Vomiting 1 209 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.1 2nd line 1 209 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Anorexia 1 209 Risk Ratio (M-H, Fixed, 95% CI) 2.92 [0.12, 70.77]
8.1 2nd line 1 209 Risk Ratio (M-H, Fixed, 95% CI) 2.92 [0.12, 70.77]
9 Asthenia 1 209 Risk Ratio (M-H, Fixed, 95% CI) 2.92 [0.12, 70.77]
9.1 2nd line 1 209 Risk Ratio (M-H, Fixed, 95% CI) 2.92 [0.12, 70.77]
10 Overall response rate 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 2nd line 2 424 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.58, 1.46]
10.2 Maintenance 1 96 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.35, 2.88]
11 Partial response 1 216 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.34, 1.65]
11.1 2nd line 1 216 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.34, 1.65]
12 FACT-L Symptom
improvement rate
2 356 Mean Difference (IV, Fixed, 95% CI) 3.70 [-7.28, 14.69]
12.1 2nd line 2 356 Mean Difference (IV, Fixed, 95% CI) 3.70 [-7.28, 14.69]
13 TOI QOL improvement rate 2 424 Mean Difference (IV, Fixed, 95% CI) 7.38 [-2.30, 17.05]
13.1 2nd line 2 424 Mean Difference (IV, Fixed, 95% CI) 7.38 [-2.30, 17.05]
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Comparison 8. Gefitinib versus gefitinib + chemotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HR Progression-free survival 2 Hazard Ratio (Random, 95% CI) Subtotals only
1.1 1st line 1 Hazard Ratio (Random, 95% CI) 0.69 [0.49, 0.96]
1.2 2nd line 1 Hazard Ratio (Random, 95% CI) 0.65 [0.43, 0.97]
2 1-year survival rate 2 163 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.92, 1.43]
2.1 2nd line 2 163 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.92, 1.43]
3 1-year progression-free survival 2 163 Risk Ratio (M-H, Fixed, 95% CI) 2.29 [1.38, 3.80]
3.1 2nd line 2 163 Risk Ratio (M-H, Fixed, 95% CI) 2.29 [1.38, 3.80]
4 Skin rash 3 329 Risk Ratio (M-H, Fixed, 95% CI) 1.34 [0.39, 4.57]
4.1 1st line 2 281 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.23, 4.51]
4.2 2nd line 1 48 Risk Ratio (M-H, Fixed, 95% CI) 2.57 [0.25, 26.47]
5 Diarrhoea 3 329 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.21, 6.34]
5.1 1st line 2 281 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.21, 6.34]
5.2 2nd line 1 48 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Constipation 1 48 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.02, 9.92]
6.1 2nd line 1 48 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.02, 9.92]
7 Fatigue 3 329 Risk Ratio (M-H, Fixed, 95% CI) 2.68 [0.60, 11.90]
7.1 1st line 2 281 Risk Ratio (M-H, Fixed, 95% CI) 2.68 [0.60, 11.90]
7.2 2nd line 1 48 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Leukopenia 2 138 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.48, 4.70]
8.1 1st line 1 90 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.36, 4.35]
8.2 2nd line 1 48 Risk Ratio (M-H, Fixed, 95% CI) 3.82 [0.16, 89.24]
9 Anaemia 3 329 Risk Ratio (M-H, Fixed, 95% CI) 3.22 [0.66, 15.72]
9.1 1st line 2 281 Risk Ratio (M-H, Fixed, 95% CI) 3.06 [0.49, 19.15]
9.2 2nd line 1 48 Risk Ratio (M-H, Fixed, 95% CI) 3.82 [0.16, 89.24]
10 Thrombocytopenia 2 138 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.1 1st line 1 90 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 2nd line 1 48 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Neutropenia 3 329 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [0.71, 3.02]
11.1 1st line 2 281 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.65, 2.88]
11.2 2nd line 1 48 Risk Ratio (M-H, Fixed, 95% CI) 3.82 [0.16, 89.24]
12 Increased ALT 2 281 Risk Ratio (M-H, Fixed, 95% CI) 2.57 [1.09, 6.04]
12.1 1st line 2 281 Risk Ratio (M-H, Fixed, 95% CI) 2.57 [1.09, 6.04]
13 Increased AST 2 281 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [0.56, 3.88]
13.1 1st line 2 281 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [0.56, 3.88]
14 Vomiting 1 191 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.06, 37.74]
14.1 1st line 1 191 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.06, 37.74]
15 Nausea 1 191 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.06, 37.74]
15.1 1st line 1 191 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.06, 37.74]
16 Overall response rate 2 281 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.89, 1.17]
16.1 1st line 2 281 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.89, 1.17]
17 Partial response 4 444 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.88, 1.16]
17.1 1st line 2 281 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.88, 1.16]
17.2 2nd line 2 163 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.71, 1.47]
18 Stable disease 4 444 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.69, 1.37]
18.1 1st line 2 281 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.39, 1.16]
18.2 2nd line 2 163 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.84, 2.03]
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Comparison 9. Gefitinib + chemotherapy versus chemotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HR Overall survival 3 Hazard Ratio (Fixed, 95% CI) Subtotals only
1.1 1st line [Asian] 2 Hazard Ratio (Fixed, 95% CI) 0.86 [0.72, 1.02]
1.2 2nd line [EGFRm] 1 Hazard Ratio (Fixed, 95% CI) 1.62 [1.05, 2.50]
2 HR Progression-free survival 3 Hazard Ratio (Fixed, 95% CI) Subtotals only
2.1 1st line [Asian] 2 Hazard Ratio (Fixed, 95% CI) 0.69 [0.62, 0.77]
2.2 2nd line [EGFRm] 1 Hazard Ratio (Fixed, 95% CI) 0.86 [0.65, 1.13]
3 1-year survival rate 2 1411 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.84, 1.08]
3.1 1st line 2 1411 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.84, 1.08]
4 Skin rash 5 2379 Risk Ratio (M-H, Fixed, 95% CI) 2.98 [1.54, 5.77]
4.1 1st line 2 1400 Risk Ratio (M-H, Fixed, 95% CI) 2.64 [1.23, 5.63]
4.2 1st line [Asian] 2 715 Risk Ratio (M-H, Fixed, 95% CI) 4.23 [1.08, 16.54]
4.3 2nd line [EGFRm] 1 264 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Acne 3 1664 Risk Ratio (M-H, Fixed, 95% CI) 4.95 [1.09, 22.51]
5.1 1st line 2 1400 Risk Ratio (M-H, Fixed, 95% CI) 5.59 [0.99, 31.60]
5.2 2nd line [EGFRm] 1 264 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.12, 72.98]
6 Diarrhoea 5 2379 Risk Ratio (M-H, Random, 95% CI) 2.04 [1.17, 3.58]
6.1 1st line 2 1400 Risk Ratio (M-H, Random, 95% CI) 2.44 [1.17, 5.09]
6.2 1st line [Asian] 2 715 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.32, 2.92]
6.3 2nd line [EGFRm] 1 264 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.32, 28.47]
7 Pruritus 2 1400 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [0.18, 21.89]
7.1 1st line 2 1400 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [0.18, 21.89]
8 Vomiting 5 2379 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.81, 1.89]
8.1 1st line 2 1400 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.53, 2.06]
8.2 1st line [Asian] 2 715 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.70, 2.32]
8.3 2nd line [EGFRm] 1 264 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.51, 7.83]
9 Nausea 5 2379 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.58, 1.17]
9.1 1st line 2 1400 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.51, 2.18]
9.2 1st line [Asian] 2 715 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.48, 1.14]
9.3 2nd line [EGFRm] 1 264 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.26, 2.66]
10 Anorexia 5 2379 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.55, 1.20]
10.1 1st line 2 1400 Risk Ratio (M-H, Fixed, 95% CI) 1.98 [0.36, 10.76]
10.2 1st line [Asian] 2 715 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.53, 1.20]
10.3 2nd line [EGFRm] 1 264 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 3.16]
11 Asthenia 3 1664 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.21, 2.99]
11.1 1st line 2 1400 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.10, 7.76]
11.2 2nd line [EGFRm] 1 264 Risk Ratio (M-H, Random, 95% CI) 0.5 [0.09, 2.68]
12 Dyspnoea 2 947 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.25, 3.96]
12.1 1st line 1 683 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [0.18, 21.89]
12.2 2nd line [EGFRm] 1 264 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.11, 3.93]
13 Anaemia 3 979 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.53, 1.03]
13.1 1st line [Asian] 2 715 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.44, 0.90]
13.2 2nd line [EGFRm] 1 264 Risk Ratio (M-H, Fixed, 95% CI) 2.2 [0.79, 6.16]
14 Neutropenia 5 2379 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.87, 1.08]
14.1 1st line 2 1400 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.77, 1.80]
14.2 1st line [Asian] 2 715 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.84, 1.03]
14.3 2nd line [EGFRm] 1 264 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.49, 3.35]
15 Leukopenia 4 2262 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.89, 1.31]
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15.1 1st line 2 1400 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.61, 2.26]
15.2 1st line [Asian] 1 598 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.87, 1.30]
15.3 2nd line [EGFRm] 1 264 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.21, 4.86]
16 Overall response rate 5 2314 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.97, 1.20]
16.1 1st line 2 1343 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.94, 1.22]
16.2 1st line [Asian] 2 706 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.93, 1.40]
16.3 2nd line [EGFRm] 1 265 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.66, 1.31]
Analysis 1.1. Comparison 1 Gefitinib versus placebo, Outcome 1 HR Overall survival.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 1 HR Overall survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 G(250) vs P = 1st line
Goss 2009 INSTEP -0.17435339 (0.1576) 100.0 % 0.84 [ 0.62, 1.14 ]
Subtotal (95% CI) 100.0 % 0.84 [ 0.62, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
2 G(250) vs P = 2nd line
Thatcher 2005 ISEL -0.1165338 (0.0620386) 100.0 % 0.89 [ 0.79, 1.01 ]
Subtotal (95% CI) 100.0 % 0.89 [ 0.79, 1.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.060)
3 G(500) vs P = Maintenance
Gaafar 2011 EORTC08021 -0.1863296 (0.16429) 50.8 % 0.83 [ 0.60, 1.15 ]
Kelly 2008 SWOG S0023 0.4572849 (0.1835025) 49.2 % 1.58 [ 1.10, 2.26 ]
Subtotal (95% CI) 100.0 % 1.14 [ 0.61, 2.14 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 6.83, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Chi2 = 0.72, df = 2 (P = 0.70), I2 =0.0%
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Analysis 1.2. Comparison 1 Gefitinib versus placebo, Outcome 2 HR Progression-free survival.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 2 HR Progression-free survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 G(250) vs P = 1st line
Goss 2009 INSTEP -0.1984509 (0.1576147) 100.0 % 0.82 [ 0.60, 1.12 ]
Subtotal (95% CI) 100.0 % 0.82 [ 0.60, 1.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
2 G(250) vs P = 2nd line
Thatcher 2005 ISEL -0.19845 (0.04847) 100.0 % 0.82 [ 0.75, 0.90 ]
Subtotal (95% CI) 100.0 % 0.82 [ 0.75, 0.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.09 (P = 0.000042)
3 G(500) vs P = Maintenance
Gaafar 2011 EORTC08021 -0.4942963 (0.1545904) 51.5 % 0.61 [ 0.45, 0.83 ]
Kelly 2008 SWOG S0023 -0.2231436 (0.1616256) 48.5 % 0.80 [ 0.58, 1.10 ]
Subtotal (95% CI) 100.0 % 0.70 [ 0.53, 0.91 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.47, df = 1 (P = 0.23); I2 =32%
Test for overall effect: Z = 2.68 (P = 0.0074)
Test for subgroup differences: Chi2 = 1.32, df = 2 (P = 0.52), I2 =0.0%
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Analysis 1.3. Comparison 1 Gefitinib versus placebo, Outcome 3 1-year survival rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 3 1-year survival rate
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = 2nd line
Thatcher 2005 ISEL 259/959 101/480 100.0 % 1.28 [ 1.05, 1.57 ]
Subtotal (95% CI) 959 480 100.0 % 1.28 [ 1.05, 1.57 ]
Total events: 259 (Gefitinib), 101 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.016)
2 G(500) vs P = Maintenance
Kelly 2008 SWOG S0023 86/118 101/125 100.0 % 0.90 [ 0.78, 1.04 ]
Subtotal (95% CI) 118 125 100.0 % 0.90 [ 0.78, 1.04 ]
Total events: 86 (Gefitinib), 101 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
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Analysis 1.4. Comparison 1 Gefitinib versus placebo, Outcome 4 Skin rash.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 4 Skin rash
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = 1st line
Goss 2009 INSTEP 0/100 0/101 Not estimable
Subtotal (95% CI) 100 101 Not estimable
Total events: 0 (Gefitinib), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 G(250) vs P = 2nd line
Thatcher 2005 ISEL 18/1126 1/562 72.9 % 8.98 [ 1.20, 67.13 ]
Subtotal (95% CI) 1126 562 72.9 % 8.98 [ 1.20, 67.13 ]
Total events: 18 (Gefitinib), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
3 G(250) vs P = Maintenance
Gaafar 2011 EORTC08021 2/85 0/86 27.1 % 5.06 [ 0.25, 103.82 ]
Subtotal (95% CI) 85 86 27.1 % 5.06 [ 0.25, 103.82 ]
Total events: 2 (Gefitinib), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Total (95% CI) 1311 749 100.0 % 7.92 [ 1.46, 43.03 ]
Total events: 20 (Gefitinib), 1 (Placebo)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.40 (P = 0.017)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.76), I2 =0.0%
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Analysis 1.5. Comparison 1 Gefitinib versus placebo, Outcome 5 Pruritus.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 5 Pruritus
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = 1st line
Goss 2009 INSTEP 0/100 0/101 Not estimable
Subtotal (95% CI) 100 101 Not estimable
Total events: 0 (Gefitinib), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 G(250) vs P = 2nd line
Thatcher 2005 ISEL 4/1126 1/562 100.0 % 2.00 [ 0.22, 17.82 ]
Subtotal (95% CI) 1126 562 100.0 % 2.00 [ 0.22, 17.82 ]
Total events: 4 (Gefitinib), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
Total (95% CI) 1226 663 100.0 % 2.00 [ 0.22, 17.82 ]
Total events: 4 (Gefitinib), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Gefitinib versus placebo, Outcome 6 Diarrhoea.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 6 Diarrhoea
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = 1st line
Goss 2009 INSTEP 3/100 3/101 29.4 % 1.01 [ 0.21, 4.89 ]
Subtotal (95% CI) 100 101 29.4 % 1.01 [ 0.21, 4.89 ]
Total events: 3 (Gefitinib), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
2 G(250) vs P = 2nd line
Thatcher 2005 ISEL 31/1126 5/562 65.7 % 3.09 [ 1.21, 7.91 ]
Subtotal (95% CI) 1126 562 65.7 % 3.09 [ 1.21, 7.91 ]
Total events: 31 (Gefitinib), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.36 (P = 0.018)
3 G(250) vs P = Maintenance
Gaafar 2011 EORTC08021 1/85 0/86 4.9 % 3.03 [ 0.13, 73.47 ]
Subtotal (95% CI) 85 86 4.9 % 3.03 [ 0.13, 73.47 ]
Total events: 1 (Gefitinib), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
Total (95% CI) 1311 749 100.0 % 2.48 [ 1.15, 5.35 ]
Total events: 35 (Gefitinib), 8 (Placebo)
Heterogeneity: Chi2 = 1.48, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.31 (P = 0.021)
Test for subgroup differences: Chi2 = 1.46, df = 2 (P = 0.48), I2 =0.0%
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Analysis 1.7. Comparison 1 Gefitinib versus placebo, Outcome 7 Constipation.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 7 Constipation
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = 1st line
Goss 2009 INSTEP 1/100 1/101 100.0 % 1.01 [ 0.06, 15.93 ]
Total (95% CI) 100 101 100.0 % 1.01 [ 0.06, 15.93 ]
Total events: 1 (Gefitinib), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Gefitinib versus placebo, Outcome 8 Nausea.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 8 Nausea
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G(250) vs P = 1st line
Goss 2009 INSTEP 0/100 4/101 41.5 % 0.11 [ 0.01, 2.06 ]
Subtotal (95% CI) 100 101 41.5 % 0.11 [ 0.01, 2.06 ]
Total events: 0 (Gefitinib), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
2 G(250) vs P = 2nd line
Thatcher 2005 ISEL 9/1126 2/562 58.5 % 2.25 [ 0.49, 10.36 ]
Subtotal (95% CI) 1126 562 58.5 % 2.25 [ 0.49, 10.36 ]
Total events: 9 (Gefitinib), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Total (95% CI) 1226 663 100.0 % 0.65 [ 0.03, 12.44 ]
Total events: 9 (Gefitinib), 6 (Placebo)
Heterogeneity: Tau2 = 3.28; Chi2 = 3.33, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Chi2 = 3.19, df = 1 (P = 0.07), I2 =69%
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Analysis 1.9. Comparison 1 Gefitinib versus placebo, Outcome 9 Vomiting.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 9 Vomiting
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = 2nd line
Thatcher 2005 ISEL 13/1126 2/562 84.3 % 3.24 [ 0.73, 14.33 ]
Subtotal (95% CI) 1126 562 84.3 % 3.24 [ 0.73, 14.33 ]
Total events: 13 (Gefitinib), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
2 G(250) vs P = Maintenance
Gaafar 2011 EORTC08021 1/85 0/86 15.7 % 3.03 [ 0.13, 73.47 ]
Subtotal (95% CI) 85 86 15.7 % 3.03 [ 0.13, 73.47 ]
Total events: 1 (Gefitinib), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
Total (95% CI) 1211 648 100.0 % 3.21 [ 0.83, 12.38 ]
Total events: 14 (Gefitinib), 2 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.090)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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Analysis 1.10. Comparison 1 Gefitinib versus placebo, Outcome 10 Anorexia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 10 Anorexia
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = 1st line
Goss 2009 INSTEP 2/100 0/101 3.0 % 5.05 [ 0.25, 103.87 ]
Subtotal (95% CI) 100 101 3.0 % 5.05 [ 0.25, 103.87 ]
Total events: 2 (Gefitinib), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
2 G(250) vs P = 2nd line
Thatcher 2005 ISEL 26/1126 11/562 88.1 % 1.18 [ 0.59, 2.37 ]
Subtotal (95% CI) 1126 562 88.1 % 1.18 [ 0.59, 2.37 ]
Total events: 26 (Gefitinib), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
3 G(250) vs P = Maintenance
Gaafar 2011 EORTC08021 0/85 1/86 8.9 % 0.34 [ 0.01, 8.16 ]
Subtotal (95% CI) 85 86 8.9 % 0.34 [ 0.01, 8.16 ]
Total events: 0 (Gefitinib), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Total (95% CI) 1311 749 100.0 % 1.22 [ 0.64, 2.33 ]
Total events: 28 (Gefitinib), 12 (Placebo)
Heterogeneity: Chi2 = 1.48, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Chi2 = 1.48, df = 2 (P = 0.48), I2 =0.0%
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Analysis 1.11. Comparison 1 Gefitinib versus placebo, Outcome 11 Fatigue.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 11 Fatigue
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = 1st line
Goss 2009 INSTEP 6/100 8/101 100.0 % 0.76 [ 0.27, 2.10 ]
Subtotal (95% CI) 100 101 100.0 % 0.76 [ 0.27, 2.10 ]
Total events: 6 (Gefitinib), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
2 G(250) vs P = Maintenance
Gaafar 2011 EORTC08021 4/85 1/86 100.0 % 4.05 [ 0.46, 35.47 ]
Subtotal (95% CI) 85 86 100.0 % 4.05 [ 0.46, 35.47 ]
Total events: 4 (Gefitinib), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 1.87, df = 1 (P = 0.17), I2 =47%
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Analysis 1.12. Comparison 1 Gefitinib versus placebo, Outcome 12 Asthenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 12 Asthenia
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = 2nd line
Thatcher 2005 ISEL 36/1126 15/562 100.0 % 1.20 [ 0.66, 2.17 ]
Subtotal (95% CI) 1126 562 100.0 % 1.20 [ 0.66, 2.17 ]
Total events: 36 (Gefitinib), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Gefitinib versus placebo, Outcome 13 Respiratory tract infection.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 13 Respiratory tract infection
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G(250) vs P = 1st line
Goss 2009 INSTEP 0/100 4/101 28.7 % 0.11 [ 0.01, 2.06 ]
Subtotal (95% CI) 100 101 28.7 % 0.11 [ 0.01, 2.06 ]
Total events: 0 (Gefitinib), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
2 G(250) vs P = 2nd line
Thatcher 2005 ISEL 30/1126 15/562 71.3 % 1.00 [ 0.54, 1.84 ]
Subtotal (95% CI) 1126 562 71.3 % 1.00 [ 0.54, 1.84 ]
Total events: 30 (Gefitinib), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 1.0)
Total (95% CI) 1226 663 100.0 % 0.53 [ 0.07, 3.83 ]
Total events: 30 (Gefitinib), 19 (Placebo)
Heterogeneity: Tau2 = 1.33; Chi2 = 2.15, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Chi2 = 2.08, df = 1 (P = 0.15), I2 =52%
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Analysis 1.14. Comparison 1 Gefitinib versus placebo, Outcome 14 Dyspnoea.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 14 Dyspnoea
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G(250) vs P = 1st line
Goss 2009 INSTEP 11/100 6/101 24.5 % 1.85 [ 0.71, 4.81 ]
Subtotal (95% CI) 100 101 24.5 % 1.85 [ 0.71, 4.81 ]
Total events: 11 (Gefitinib), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
2 G(250) vs P = 2nd line
Thatcher 2005 ISEL 35/1126 21/562 59.7 % 0.83 [ 0.49, 1.42 ]
Subtotal (95% CI) 1126 562 59.7 % 0.83 [ 0.49, 1.42 ]
Total events: 35 (Gefitinib), 21 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
3 G(250) vs P = Maintenance
Gaafar 2011 EORTC08021 4/85 6/86 15.7 % 0.67 [ 0.20, 2.31 ]
Subtotal (95% CI) 85 86 15.7 % 0.67 [ 0.20, 2.31 ]
Total events: 4 (Gefitinib), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Total (95% CI) 1311 749 100.0 % 0.98 [ 0.59, 1.63 ]
Total events: 50 (Gefitinib), 33 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.41, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi2 = 2.41, df = 2 (P = 0.30), I2 =17%
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Analysis 1.15. Comparison 1 Gefitinib versus placebo, Outcome 15 Anaemia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 15 Anaemia
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = 1st line
Goss 2009 INSTEP 3/100 0/101 100.0 % 7.07 [ 0.37, 135.12 ]
Total (95% CI) 100 101 100.0 % 7.07 [ 0.37, 135.12 ]
Total events: 3 (Gefitinib), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Gefitinib versus placebo, Outcome 16 Abdominal pain.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 16 Abdominal pain
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = 1st line
Goss 2009 INSTEP 1/100 2/101 100.0 % 0.51 [ 0.05, 5.48 ]
Total (95% CI) 100 101 100.0 % 0.51 [ 0.05, 5.48 ]
Total events: 1 (Gefitinib), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Gefitinib versus placebo, Outcome 17 Increased ALT.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 17 Increased ALT
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = Maintenance
Gaafar 2011 EORTC08021 9/85 1/86 100.0 % 9.11 [ 1.18, 70.32 ]
Total (95% CI) 85 86 100.0 % 9.11 [ 1.18, 70.32 ]
Total events: 9 (Gefitinib), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Gefitinib versus placebo, Outcome 18 Increased AST.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 18 Increased AST
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = Maintenance
Gaafar 2011 EORTC08021 7/85 1/86 100.0 % 7.08 [ 0.89, 56.34 ]
Total (95% CI) 85 86 100.0 % 7.08 [ 0.89, 56.34 ]
Total events: 7 (Gefitinib), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.064)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Gefitinib versus placebo, Outcome 19 Neutropenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 19 Neutropenia
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = Maintenance
Gaafar 2011 EORTC08021 1/85 0/86 100.0 % 3.03 [ 0.13, 73.47 ]
Total (95% CI) 85 86 100.0 % 3.03 [ 0.13, 73.47 ]
Total events: 1 (Gefitinib), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Gefitinib versus placebo, Outcome 20 Anaemia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 20 Anaemia
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = Maintenance
Gaafar 2011 EORTC08021 0/85 2/86 100.0 % 0.20 [ 0.01, 4.15 ]
Total (95% CI) 85 86 100.0 % 0.20 [ 0.01, 4.15 ]
Total events: 0 (Gefitinib), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 Gefitinib versus placebo, Outcome 21 Thrombocytopaenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 21 Thrombocytopaenia
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = Maintenance
Gaafar 2011 EORTC08021 1/85 0/86 100.0 % 3.03 [ 0.13, 73.47 ]
Total (95% CI) 85 86 100.0 % 3.03 [ 0.13, 73.47 ]
Total events: 1 (Gefitinib), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 Gefitinib versus placebo, Outcome 22 Overall response rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 22 Overall response rate
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = 1st line
Goss 2009 INSTEP 6/100 1/101 100.0 % 6.06 [ 0.74, 49.43 ]
Subtotal (95% CI) 100 101 100.0 % 6.06 [ 0.74, 49.43 ]
Total events: 6 (Gefitinib), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.092)
2 G(250) vs P= 2nd line
Thatcher 2005 ISEL 77/959 6/480 100.0 % 6.42 [ 2.82, 14.64 ]
Subtotal (95% CI) 959 480 100.0 % 6.42 [ 2.82, 14.64 ]
Total events: 77 (Gefitinib), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.43 (P < 0.00001)
3 G(250) vs P = Maintenance
Gaafar 2011 EORTC08021 10/86 1/87 100.0 % 10.12 [ 1.32, 77.33 ]
Subtotal (95% CI) 86 87 100.0 % 10.12 [ 1.32, 77.33 ]
Total events: 10 (Gefitinib), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.23 (P = 0.026)
Test for subgroup differences: Chi2 = 0.18, df = 2 (P = 0.92), I2 =0.0%
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Analysis 1.23. Comparison 1 Gefitinib versus placebo, Outcome 23 Disease control rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 1 Gefitinib versus placebo
Outcome: 23 Disease control rate
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = 1st line
Goss 2009 INSTEP 31/100 23/101 100.0 % 1.36 [ 0.86, 2.16 ]
Subtotal (95% CI) 100 101 100.0 % 1.36 [ 0.86, 2.16 ]
Total events: 31 (Gefitinib), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
2 G(250) vs P = 2nd line
Thatcher 2005 ISEL 381/959 154/480 100.0 % 1.24 [ 1.06, 1.44 ]
Subtotal (95% CI) 959 480 100.0 % 1.24 [ 1.06, 1.44 ]
Total events: 381 (Gefitinib), 154 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.76 (P = 0.0058)
3 G(250) vs P = Maintenance
Gaafar 2011 EORTC08021 68/86 57/87 100.0 % 1.21 [ 1.00, 1.46 ]
Subtotal (95% CI) 86 87 100.0 % 1.21 [ 1.00, 1.46 ]
Total events: 68 (Gefitinib), 57 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.049)
Test for subgroup differences: Chi2 = 0.23, df = 2 (P = 0.89), I2 =0.0%
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Analysis 2.1. Comparison 2 Gefitinib versus placebo (Asian subgroup), Outcome 1 HR Overall survival.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 2 Gefitinib versus placebo (Asian subgroup)
Outcome: 1 HR Overall survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 G(250) vs P = 2nd line
Thatcher 2005 ISEL -0.4155154 (0.1615299) 100.0 % 0.66 [ 0.48, 0.91 ]
Subtotal (95% CI) 100.0 % 0.66 [ 0.48, 0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.57 (P = 0.010)
2 G(250) vs P = Maintenance
Zhang 2012 INFORM -0.127833 (0.130477) 100.0 % 0.88 [ 0.68, 1.14 ]
Subtotal (95% CI) 100.0 % 0.88 [ 0.68, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Chi2 = 1.92, df = 1 (P = 0.17), I2 =48%
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Analysis 2.2. Comparison 2 Gefitinib versus placebo (Asian subgroup), Outcome 2 HR Progression-free
survival.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 2 Gefitinib versus placebo (Asian subgroup)
Outcome: 2 HR Progression-free survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 G(250) vs P = 2nd line
Thatcher 2005 ISEL -0.3710637 (0.1413171) 100.0 % 0.69 [ 0.52, 0.91 ]
Subtotal (95% CI) 100.0 % 0.69 [ 0.52, 0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.63 (P = 0.0086)
2 G(250) vs P = Maintenance
Zhang 2012 INFORM -0.8675006 (0.1289964) 100.0 % 0.42 [ 0.33, 0.54 ]
Subtotal (95% CI) 100.0 % 0.42 [ 0.33, 0.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.72 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.73, df = 1 (P = 0.01), I2 =85%
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Analysis 2.3. Comparison 2 Gefitinib versus placebo (Asian subgroup), Outcome 3 1-year survival rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 2 Gefitinib versus placebo (Asian subgroup)
Outcome: 3 1-year survival rate
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G(250) vs P = 2nd line
Thatcher 2005 ISEL 96/235 25/107 100.0 % 1.75 [ 1.20, 2.55 ]
Subtotal (95% CI) 235 107 100.0 % 1.75 [ 1.20, 2.55 ]
Total events: 96 (Gefitinib), 25 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.91 (P = 0.0036)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Gefitinib versus placebo (Asian subgroup), Outcome 4 Overall response rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 2 Gefitinib versus placebo (Asian subgroup)
Outcome: 4 Overall response rate
Study or subgroup Gefitinib Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G(250) vs P = 2nd line
Thatcher 2005 ISEL 26/209 2/97 100.0 % 6.03 [ 1.46, 24.91 ]
Subtotal (95% CI) 209 97 100.0 % 6.03 [ 1.46, 24.91 ]
Total events: 26 (Gefitinib), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.013)
2 G(250) vs P = Maintenance
Zhang 2012 INFORM 35/148 1/148 100.0 % 35.00 [ 4.86, 252.15 ]
Subtotal (95% CI) 148 148 100.0 % 35.00 [ 4.86, 252.15 ]
Total events: 35 (Gefitinib), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.53 (P = 0.00042)
Test for subgroup differences: Chi2 = 2.01, df = 1 (P = 0.16), I2 =50%
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Analysis 3.1. Comparison 3 Gefitinib versus placebo (biomarker subgroup), Outcome 1 HR Overall survival.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 3 Gefitinib versus placebo (biomarker subgroup)
Outcome: 1 HR Overall survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 G(250) vs P = Maintenance
Zhang 2012 INFORM -0.941609 (0.471379) 100.0 % 0.39 [ 0.15, 0.98 ]
Subtotal (95% CI) 100.0 % 0.39 [ 0.15, 0.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.046)
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Analysis 3.2. Comparison 3 Gefitinib versus placebo (biomarker subgroup), Outcome 2 HR Progression-
free survival.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 3 Gefitinib versus placebo (biomarker subgroup)
Outcome: 2 HR Progression-free survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 G(250) vs P = Maintenance
Zhang 2012 INFORM -1.7719568 (0.4524645) 100.0 % 0.17 [ 0.07, 0.41 ]
Subtotal (95% CI) 100.0 % 0.17 [ 0.07, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.92 (P = 0.000090)
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Analysis 4.1. Comparison 4 Gefitinib versus chemotherapy, Outcome 1 HR Overall survival.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 1 HR Overall survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE -0.0202027 (0.2022166) 100.0 % 0.98 [ 0.66, 1.46 ]
Subtotal (95% CI) 100.0 % 0.98 [ 0.66, 1.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
2 G vs docetaxel = 2nd line
Kim 2008 INTEREST 0.0198026 (0.0605006) 100.0 % 1.02 [ 0.91, 1.15 ]
Subtotal (95% CI) 100.0 % 1.02 [ 0.91, 1.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.85), I2 =0.0%
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Analysis 4.2. Comparison 4 Gefitinib versus chemotherapy, Outcome 2 HR Progression-free survival.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 2 HR Progression-free survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 0.1739533 (0.1674985) 100.0 % 1.19 [ 0.86, 1.65 ]
Subtotal (95% CI) 100.0 % 1.19 [ 0.86, 1.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
2 G vs docetaxel = 2nd line
Kim 2008 INTEREST 0.0392207 (0.0601225) 100.0 % 1.04 [ 0.92, 1.17 ]
Subtotal (95% CI) 100.0 % 1.04 [ 0.92, 1.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Chi2 = 0.57, df = 1 (P = 0.45), I2 =0.0%
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Analysis 4.3. Comparison 4 Gefitinib versus chemotherapy, Outcome 3 1-year survival rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 3 1-year survival rate
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 32/94 32/96 11.1 % 1.02 [ 0.69, 1.52 ]
Subtotal (95% CI) 94 96 11.1 % 1.02 [ 0.69, 1.52 ]
Total events: 32 (Gefitinib), 32 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
2 G vs docetaxel = 1st line
Morere 2010 IFCT-0301 2/43 5/42 1.8 % 0.39 [ 0.08, 1.90 ]
Subtotal (95% CI) 43 42 1.8 % 0.39 [ 0.08, 1.90 ]
Total events: 2 (Gefitinib), 5 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.24)
3 G vs docetaxel = 2nd line
Kim 2008 INTEREST 235/733 249/733 87.1 % 0.94 [ 0.82, 1.09 ]
Subtotal (95% CI) 733 733 87.1 % 0.94 [ 0.82, 1.09 ]
Total events: 235 (Gefitinib), 249 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Total (95% CI) 870 871 100.0 % 0.94 [ 0.82, 1.08 ]
Total events: 269 (Gefitinib), 286 (Chemo)
Heterogeneity: Chi2 = 1.34, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Chi2 = 1.34, df = 2 (P = 0.51), I2 =0.0%
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Analysis 4.4. Comparison 4 Gefitinib versus chemotherapy, Outcome 4 Skin rash.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 4 Skin rash
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 2/94 0/96 5.8 % 5.11 [ 0.25, 104.94 ]
Subtotal (95% CI) 94 96 5.8 % 5.11 [ 0.25, 104.94 ]
Total events: 2 (Gefitinib), 0 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
2 G vs docetaxel = 1st line
Morere 2010 IFCT-0301 1/43 2/42 23.8 % 0.49 [ 0.05, 5.19 ]
Subtotal (95% CI) 43 42 23.8 % 0.49 [ 0.05, 5.19 ]
Total events: 1 (Gefitinib), 2 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
3 G vs docetaxel = 2nd line
Cufer 2006 SIGN 2/68 2/71 23.0 % 1.04 [ 0.15, 7.20 ]
Kim 2008 INTEREST 15/729 4/715 47.4 % 3.68 [ 1.23, 11.03 ]
Subtotal (95% CI) 797 786 70.4 % 2.82 [ 1.11, 7.13 ]
Total events: 17 (Gefitinib), 6 (Chemo)
Heterogeneity: Chi2 = 1.24, df = 1 (P = 0.27); I2 =19%
Test for overall effect: Z = 2.19 (P = 0.029)
Total (95% CI) 934 924 100.0 % 2.40 [ 1.08, 5.31 ]
Total events: 20 (Gefitinib), 8 (Chemo)
Heterogeneity: Chi2 = 3.28, df = 3 (P = 0.35); I2 =8%
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Chi2 = 2.10, df = 2 (P = 0.35), I2 =5%
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Analysis 4.5. Comparison 4 Gefitinib versus chemotherapy, Outcome 5 Constipation.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 5 Constipation
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 0/94 2/96 14.5 % 0.20 [ 0.01, 4.20 ]
Subtotal (95% CI) 94 96 14.5 % 0.20 [ 0.01, 4.20 ]
Total events: 0 (Gefitinib), 2 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
2 G vs docetaxel = 1st line
Morere 2010 IFCT-0301 0/43 1/42 8.9 % 0.33 [ 0.01, 7.78 ]
Subtotal (95% CI) 43 42 8.9 % 0.33 [ 0.01, 7.78 ]
Total events: 0 (Gefitinib), 1 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
3 G vs docetaxel = 2nd line
Kim 2008 INTEREST 6/729 13/715 76.7 % 0.45 [ 0.17, 1.18 ]
Subtotal (95% CI) 729 715 76.7 % 0.45 [ 0.17, 1.18 ]
Total events: 6 (Gefitinib), 13 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
Total (95% CI) 866 853 100.0 % 0.41 [ 0.17, 0.97 ]
Total events: 6 (Gefitinib), 16 (Chemo)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.043)
Test for subgroup differences: Chi2 = 0.26, df = 2 (P = 0.88), I2 =0.0%
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Analysis 4.6. Comparison 4 Gefitinib versus chemotherapy, Outcome 6 Fatigue.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 6 Fatigue
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 0/94 7/96 78.6 % 0.07 [ 0.00, 1.18 ]
Subtotal (95% CI) 94 96 78.6 % 0.07 [ 0.00, 1.18 ]
Total events: 0 (Gefitinib), 7 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.064)
2 G vs docetaxel = 1st line
Morere 2010 IFCT-0301 1/43 2/42 21.4 % 0.49 [ 0.05, 5.19 ]
Subtotal (95% CI) 43 42 21.4 % 0.49 [ 0.05, 5.19 ]
Total events: 1 (Gefitinib), 2 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
Total (95% CI) 137 138 100.0 % 0.16 [ 0.03, 0.88 ]
Total events: 1 (Gefitinib), 9 (Chemo)
Heterogeneity: Chi2 = 1.21, df = 1 (P = 0.27); I2 =17%
Test for overall effect: Z = 2.11 (P = 0.035)
Test for subgroup differences: Chi2 = 1.09, df = 1 (P = 0.30), I2 =8%
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Analysis 4.7. Comparison 4 Gefitinib versus chemotherapy, Outcome 7 Asthenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 7 Asthenia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 0/94 3/96 4.9 % 0.15 [ 0.01, 2.79 ]
Subtotal (95% CI) 94 96 4.9 % 0.15 [ 0.01, 2.79 ]
Total events: 0 (Gefitinib), 3 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
2 G vs docetaxel = 2nd line
Cufer 2006 SIGN 4/68 3/71 4.1 % 1.39 [ 0.32, 5.99 ]
Kim 2008 INTEREST 32/729 64/715 91.0 % 0.49 [ 0.32, 0.74 ]
Subtotal (95% CI) 797 786 95.1 % 0.53 [ 0.36, 0.78 ]
Total events: 36 (Gefitinib), 67 (Chemo)
Heterogeneity: Chi2 = 1.82, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 3.17 (P = 0.0015)
Total (95% CI) 891 882 100.0 % 0.51 [ 0.35, 0.75 ]
Total events: 36 (Gefitinib), 70 (Chemo)
Heterogeneity: Chi2 = 2.54, df = 2 (P = 0.28); I2 =21%
Test for overall effect: Z = 3.39 (P = 0.00069)
Test for subgroup differences: Chi2 = 0.72, df = 1 (P = 0.40), I2 =0.0%
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Analysis 4.8. Comparison 4 Gefitinib versus chemotherapy, Outcome 8 Neurotoxicity.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 8 Neurotoxicity
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs docetaxel = 1st line
Morere 2010 IFCT-0301 0/43 5/42 24.5 % 0.09 [ 0.01, 1.56 ]
Subtotal (95% CI) 43 42 24.5 % 0.09 [ 0.01, 1.56 ]
Total events: 0 (Gefitinib), 5 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.098)
2 G vs docetaxel = 2nd line
Kim 2008 INTEREST 1/729 17/715 75.5 % 0.06 [ 0.01, 0.43 ]
Subtotal (95% CI) 729 715 75.5 % 0.06 [ 0.01, 0.43 ]
Total events: 1 (Gefitinib), 17 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.78 (P = 0.0055)
Total (95% CI) 772 757 100.0 % 0.07 [ 0.01, 0.34 ]
Total events: 1 (Gefitinib), 22 (Chemo)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 3.25 (P = 0.0012)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
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Analysis 4.9. Comparison 4 Gefitinib versus chemotherapy, Outcome 9 Neutropenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 9 Neutropenia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 0/94 19/96 4.1 % 0.03 [ 0.00, 0.43 ]
Subtotal (95% CI) 94 96 4.1 % 0.03 [ 0.00, 0.43 ]
Total events: 0 (Gefitinib), 19 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.011)
2 G vs docetaxel = 1st line
Morere 2010 IFCT-0301 2/43 13/42 2.8 % 0.15 [ 0.04, 0.63 ]
Subtotal (95% CI) 43 42 2.8 % 0.15 [ 0.04, 0.63 ]
Total events: 2 (Gefitinib), 13 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0092)
3 G vs docetaxel = 2nd line
Cufer 2006 SIGN 1/67 29/67 6.2 % 0.03 [ 0.00, 0.25 ]
Kim 2008 INTEREST 15/729 406/719 86.9 % 0.04 [ 0.02, 0.06 ]
Subtotal (95% CI) 796 786 93.1 % 0.04 [ 0.02, 0.06 ]
Total events: 16 (Gefitinib), 435 (Chemo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 13.29 (P < 0.00001)
Total (95% CI) 933 924 100.0 % 0.04 [ 0.02, 0.06 ]
Total events: 18 (Gefitinib), 467 (Chemo)
Heterogeneity: Chi2 = 3.59, df = 3 (P = 0.31); I2 =16%
Test for overall effect: Z = 13.95 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.52, df = 2 (P = 0.17), I2 =43%
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Analysis 4.10. Comparison 4 Gefitinib versus chemotherapy, Outcome 10 Leukopenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 10 Leukopenia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 0/94 7/96 22.5 % 0.07 [ 0.00, 1.18 ]
Subtotal (95% CI) 94 96 22.5 % 0.07 [ 0.00, 1.18 ]
Total events: 0 (Gefitinib), 7 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.064)
2 G vs docetaxel = 2nd line
Cufer 2006 SIGN 0/67 25/67 77.5 % 0.02 [ 0.00, 0.32 ]
Subtotal (95% CI) 67 67 77.5 % 0.02 [ 0.00, 0.32 ]
Total events: 0 (Gefitinib), 25 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.77 (P = 0.0055)
Total (95% CI) 161 163 100.0 % 0.03 [ 0.00, 0.22 ]
Total events: 0 (Gefitinib), 32 (Chemo)
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 3.47 (P = 0.00053)
Test for subgroup differences: Chi2 = 0.38, df = 1 (P = 0.54), I2 =0.0%
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Analysis 4.11. Comparison 4 Gefitinib versus chemotherapy, Outcome 11 Febrile neutropenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 11 Febrile neutropenia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 0/94 7/96 9.0 % 0.07 [ 0.00, 1.18 ]
Subtotal (95% CI) 94 96 9.0 % 0.07 [ 0.00, 1.18 ]
Total events: 0 (Gefitinib), 7 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.064)
2 G vs docetaxel = 2nd line
Cufer 2006 SIGN 0/67 2/67 3.0 % 0.20 [ 0.01, 4.09 ]
Kim 2008 INTEREST 9/729 72/715 88.0 % 0.12 [ 0.06, 0.24 ]
Subtotal (95% CI) 796 782 91.0 % 0.13 [ 0.06, 0.24 ]
Total events: 9 (Gefitinib), 74 (Chemo)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 6.10 (P < 0.00001)
Total (95% CI) 890 878 100.0 % 0.12 [ 0.06, 0.23 ]
Total events: 9 (Gefitinib), 81 (Chemo)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 6.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
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Analysis 4.12. Comparison 4 Gefitinib versus chemotherapy, Outcome 12 Pruritus.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 12 Pruritus
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs docetaxel = 2nd line
Cufer 2006 SIGN 2/68 0/71 100.0 % 5.22 [ 0.26, 106.74 ]
Total (95% CI) 68 71 100.0 % 5.22 [ 0.26, 106.74 ]
Total events: 2 (Gefitinib), 0 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 4.13. Comparison 4 Gefitinib versus chemotherapy, Outcome 13 Diarrhoea.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 13 Diarrhoea
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 4/94 4/96 12.3 % 1.02 [ 0.26, 3.96 ]
Subtotal (95% CI) 94 96 12.3 % 1.02 [ 0.26, 3.96 ]
Total events: 4 (Gefitinib), 4 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
2 G vs docetaxel = 1st line
Morere 2010 IFCT-0301 2/43 2/42 6.3 % 0.98 [ 0.14, 6.62 ]
Subtotal (95% CI) 43 42 6.3 % 0.98 [ 0.14, 6.62 ]
Total events: 2 (Gefitinib), 2 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
3 G vs docetaxel = 2nd line
Cufer 2006 SIGN 2/68 4/71 12.2 % 0.52 [ 0.10, 2.76 ]
Kim 2008 INTEREST 18/729 22/715 69.2 % 0.80 [ 0.43, 1.48 ]
Subtotal (95% CI) 797 786 81.4 % 0.76 [ 0.43, 1.35 ]
Total events: 20 (Gefitinib), 26 (Chemo)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 934 924 100.0 % 0.81 [ 0.48, 1.34 ]
Total events: 26 (Gefitinib), 32 (Chemo)
Heterogeneity: Chi2 = 0.42, df = 3 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Chi2 = 0.20, df = 2 (P = 0.91), I2 =0.0%
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Analysis 4.14. Comparison 4 Gefitinib versus chemotherapy, Outcome 14 Vomiting.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 14 Vomiting
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs docetaxel = 2nd line
Cufer 2006 SIGN 1/68 1/71 10.8 % 1.04 [ 0.07, 16.36 ]
Kim 2008 INTEREST 4/729 8/715 89.2 % 0.49 [ 0.15, 1.62 ]
Total (95% CI) 797 786 100.0 % 0.55 [ 0.19, 1.63 ]
Total events: 5 (Gefitinib), 9 (Chemo)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 4.15. Comparison 4 Gefitinib versus chemotherapy, Outcome 15 Anorexia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 15 Anorexia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 2/94 2/96 21.9 % 1.02 [ 0.15, 7.10 ]
Subtotal (95% CI) 94 96 21.9 % 1.02 [ 0.15, 7.10 ]
Total events: 2 (Gefitinib), 2 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
2 G vs docetaxel = 1st line
Morere 2010 IFCT-0301 0/43 0/42 Not estimable
Subtotal (95% CI) 43 42 Not estimable
Total events: 0 (Gefitinib), 0 (Chemo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 G vs docetaxel = 2nd line
Kim 2008 INTEREST 11/729 7/715 78.1 % 1.54 [ 0.60, 3.95 ]
Subtotal (95% CI) 729 715 78.1 % 1.54 [ 0.60, 3.95 ]
Total events: 11 (Gefitinib), 7 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Total (95% CI) 866 853 100.0 % 1.43 [ 0.61, 3.32 ]
Total events: 13 (Gefitinib), 9 (Chemo)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 4.16. Comparison 4 Gefitinib versus chemotherapy, Outcome 16 Stomatitis.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 16 Stomatitis
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs docetaxel = 2nd line
Kim 2008 INTEREST 0/729 3/715 100.0 % 0.14 [ 0.01, 2.71 ]
Total (95% CI) 729 715 100.0 % 0.14 [ 0.01, 2.71 ]
Total events: 0 (Gefitinib), 3 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 4.17. Comparison 4 Gefitinib versus chemotherapy, Outcome 17 Arthralgia/myalgia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 17 Arthralgia/myalgia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs docetaxel = 1st line
Morere 2010 IFCT-0301 0/43 0/42 Not estimable
Subtotal (95% CI) 43 42 Not estimable
Total events: 0 (Gefitinib), 0 (Chemo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 G vs docetaxel = 2nd line
Kim 2008 INTEREST 1/729 4/715 100.0 % 0.25 [ 0.03, 2.19 ]
Subtotal (95% CI) 729 715 100.0 % 0.25 [ 0.03, 2.19 ]
Total events: 1 (Gefitinib), 4 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
Total (95% CI) 772 757 100.0 % 0.25 [ 0.03, 2.19 ]
Total events: 1 (Gefitinib), 4 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 4.18. Comparison 4 Gefitinib versus chemotherapy, Outcome 18 Peripheral oedema.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 18 Peripheral oedema
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 0/94 0/96 Not estimable
Subtotal (95% CI) 94 96 Not estimable
Total events: 0 (Gefitinib), 0 (Chemo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 G vs docetaxel = 2nd line
Kim 2008 INTEREST 0/729 5/715 100.0 % 0.09 [ 0.00, 1.61 ]
Subtotal (95% CI) 729 715 100.0 % 0.09 [ 0.00, 1.61 ]
Total events: 0 (Gefitinib), 5 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
Total (95% CI) 823 811 100.0 % 0.09 [ 0.00, 1.61 ]
Total events: 0 (Gefitinib), 5 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 4.19. Comparison 4 Gefitinib versus chemotherapy, Outcome 19 Respiratory tract infection.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 19 Respiratory tract infection
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs docetaxel = 2nd line
Kim 2008 INTEREST 23/729 25/715 100.0 % 0.90 [ 0.52, 1.57 ]
Total (95% CI) 729 715 100.0 % 0.90 [ 0.52, 1.57 ]
Total events: 23 (Gefitinib), 25 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 4.20. Comparison 4 Gefitinib versus chemotherapy, Outcome 20 Dyspnoea.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 20 Dyspnoea
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 1/94 4/96 6.2 % 0.26 [ 0.03, 2.24 ]
Subtotal (95% CI) 94 96 6.2 % 0.26 [ 0.03, 2.24 ]
Total events: 1 (Gefitinib), 4 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
2 G vs docetaxel = 2nd line
Cufer 2006 SIGN 6/68 4/71 6.2 % 1.57 [ 0.46, 5.31 ]
Kim 2008 INTEREST 45/729 55/715 87.6 % 0.80 [ 0.55, 1.17 ]
Subtotal (95% CI) 797 786 93.8 % 0.85 [ 0.59, 1.22 ]
Total events: 51 (Gefitinib), 59 (Chemo)
Heterogeneity: Chi2 = 1.05, df = 1 (P = 0.31); I2 =5%
Test for overall effect: Z = 0.86 (P = 0.39)
Total (95% CI) 891 882 100.0 % 0.82 [ 0.57, 1.16 ]
Total events: 52 (Gefitinib), 63 (Chemo)
Heterogeneity: Chi2 = 2.20, df = 2 (P = 0.33); I2 =9%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Chi2 = 1.15, df = 1 (P = 0.28), I2 =13%
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Analysis 4.21. Comparison 4 Gefitinib versus chemotherapy, Outcome 21 Cough.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 21 Cough
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs docetaxel = 2nd line
Cufer 2006 SIGN 0/68 0/71 Not estimable
Kim 2008 INTEREST 6/729 5/715 100.0 % 1.18 [ 0.36, 3.84 ]
Total (95% CI) 797 786 100.0 % 1.18 [ 0.36, 3.84 ]
Total events: 6 (Gefitinib), 5 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 4.22. Comparison 4 Gefitinib versus chemotherapy, Outcome 22 Anaemia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 22 Anaemia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 0/94 1/96 7.0 % 0.34 [ 0.01, 8.25 ]
Subtotal (95% CI) 94 96 7.0 % 0.34 [ 0.01, 8.25 ]
Total events: 0 (Gefitinib), 1 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 G vs docetaxel = 1st line
Morere 2010 IFCT-0301 0/43 3/42 16.7 % 0.14 [ 0.01, 2.62 ]
Subtotal (95% CI) 43 42 16.7 % 0.14 [ 0.01, 2.62 ]
Total events: 0 (Gefitinib), 3 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
3 G vs docetaxel = 2nd line
Cufer 2006 SIGN 3/67 1/67 4.7 % 3.00 [ 0.32, 28.12 ]
Kim 2008 INTEREST 11/729 15/715 71.5 % 0.72 [ 0.33, 1.56 ]
Subtotal (95% CI) 796 782 76.3 % 0.86 [ 0.42, 1.75 ]
Total events: 14 (Gefitinib), 16 (Chemo)
Heterogeneity: Chi2 = 1.40, df = 1 (P = 0.24); I2 =29%
Test for overall effect: Z = 0.41 (P = 0.68)
Total (95% CI) 933 920 100.0 % 0.70 [ 0.36, 1.36 ]
Total events: 14 (Gefitinib), 20 (Chemo)
Heterogeneity: Chi2 = 2.98, df = 3 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Chi2 = 1.64, df = 2 (P = 0.44), I2 =0.0%
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Analysis 4.23. Comparison 4 Gefitinib versus chemotherapy, Outcome 23 Thrombocytopenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 23 Thrombocytopenia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs docetaxel = 1st line
Morere 2010 IFCT-0301 0/43 0/42 Not estimable
Subtotal (95% CI) 43 42 Not estimable
Total events: 0 (Gefitinib), 0 (Chemo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 G vs docetaxel = 2nd line
Cufer 2006 SIGN 1/67 0/67 100.0 % 3.00 [ 0.12, 72.35 ]
Subtotal (95% CI) 67 67 100.0 % 3.00 [ 0.12, 72.35 ]
Total events: 1 (Gefitinib), 0 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI) 110 109 100.0 % 3.00 [ 0.12, 72.35 ]
Total events: 1 (Gefitinib), 0 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 4.24. Comparison 4 Gefitinib versus chemotherapy, Outcome 24 Hypokalaemia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 24 Hypokalaemia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 1/94 1/96 100.0 % 1.02 [ 0.06, 16.09 ]
Total (95% CI) 94 96 100.0 % 1.02 [ 0.06, 16.09 ]
Total events: 1 (Gefitinib), 1 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 4.25. Comparison 4 Gefitinib versus chemotherapy, Outcome 25 Pyrexia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 25 Pyrexia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 1/94 1/96 19.7 % 1.02 [ 0.06, 16.09 ]
Subtotal (95% CI) 94 96 19.7 % 1.02 [ 0.06, 16.09 ]
Total events: 1 (Gefitinib), 1 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
2 G vs docetaxel = 2nd line
Cufer 2006 SIGN 0/68 0/71 Not estimable
Kim 2008 INTEREST 2/729 4/715 80.3 % 0.49 [ 0.09, 2.67 ]
Subtotal (95% CI) 797 786 80.3 % 0.49 [ 0.09, 2.67 ]
Total events: 2 (Gefitinib), 4 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Total (95% CI) 891 882 100.0 % 0.59 [ 0.14, 2.47 ]
Total events: 3 (Gefitinib), 5 (Chemo)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.66), I2 =0.0%
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Analysis 4.26. Comparison 4 Gefitinib versus chemotherapy, Outcome 26 Overall response rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 26 Overall response rate
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs docetaxel = 2nd line
Cufer 2006 SIGN 9/68 10/73 14.7 % 0.97 [ 0.42, 2.23 ]
Kim 2008 INTEREST 67/733 56/733 85.3 % 1.20 [ 0.85, 1.68 ]
Subtotal (95% CI) 801 806 100.0 % 1.16 [ 0.85, 1.59 ]
Total events: 76 (Gefitinib), 66 (Chemo)
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 4.27. Comparison 4 Gefitinib versus chemotherapy, Outcome 27 Disease control rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 27 Disease control rate
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G vs docetaxel = 1st line
Crino 2008 INVITE 41/94 51/96 100.0 % 0.82 [ 0.61, 1.10 ]
Subtotal (95% CI) 94 96 100.0 % 0.82 [ 0.61, 1.10 ]
Total events: 41 (Gefitinib), 51 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
2 G vs docetaxel = 2nd line
Cufer 2006 SIGN 43/68 43/73 100.0 % 1.07 [ 0.82, 1.40 ]
Subtotal (95% CI) 68 73 100.0 % 1.07 [ 0.82, 1.40 ]
Total events: 43 (Gefitinib), 43 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Chi2 = 1.75, df = 1 (P = 0.19), I2 =43%
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Analysis 4.28. Comparison 4 Gefitinib versus chemotherapy, Outcome 28 FACT-L QOL improvement rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 28 FACT-L QOL improvement rate
Study or subgroup Gefitinib Chemo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 94 24.3 (18.01) 96 10.9 (18.2) 3.4 % 13.40 [ 8.25, 18.55 ]
Subtotal (95% CI) 94 96 3.4 % 13.40 [ 8.25, 18.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.10 (P < 0.00001)
2 G vs docetaxel = 2nd line
Kim 2008 INTEREST 733 25.1 (9.46) 733 14.7 (9.46) 96.6 % 10.40 [ 9.43, 11.37 ]
Subtotal (95% CI) 733 733 96.6 % 10.40 [ 9.43, 11.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 21.05 (P < 0.00001)
Total (95% CI) 827 829 100.0 % 10.50 [ 9.55, 11.45 ]
Heterogeneity: Chi2 = 1.26, df = 1 (P = 0.26); I2 =21%
Test for overall effect: Z = 21.63 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.26, df = 1 (P = 0.26), I2 =21%
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Analysis 4.29. Comparison 4 Gefitinib versus chemotherapy, Outcome 29 LCS QOL improvement rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 29 LCS QOL improvement rate
Study or subgroup Gefitinib Chemo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 94 42.9 (4.92) 96 39.1 (4.77) 16.3 % 3.80 [ 2.42, 5.18 ]
Subtotal (95% CI) 94 96 16.3 % 3.80 [ 2.42, 5.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.40 (P < 0.00001)
2 G vs docetaxel = 2nd line
Kim 2008 INTEREST 733 20.4 (5.94) 733 16.8 (5.94) 83.7 % 3.60 [ 2.99, 4.21 ]
Subtotal (95% CI) 733 733 83.7 % 3.60 [ 2.99, 4.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 11.60 (P < 0.00001)
Total (95% CI) 827 829 100.0 % 3.63 [ 3.08, 4.19 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 12.80 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
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Analysis 4.30. Comparison 4 Gefitinib versus chemotherapy, Outcome 30 TOI QOL improvement rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 30 TOI QOL improvement rate
Study or subgroup Gefitinib Chemo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 94 22.9 (41.92) 96 6.3 (42.4) 29.8 % 16.60 [ 4.61, 28.59 ]
Subtotal (95% CI) 94 96 29.8 % 16.60 [ 4.61, 28.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.71 (P = 0.0067)
2 G vs docetaxel = 2nd line
Kim 2008 INTEREST 733 17.3 (10.08) 733 10.3 (10.1) 70.2 % 7.00 [ 5.97, 8.03 ]
Subtotal (95% CI) 733 733 70.2 % 7.00 [ 5.97, 8.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 13.28 (P < 0.00001)
Total (95% CI) 827 829 100.0 % 9.87 [ 1.26, 18.48 ]
Heterogeneity: Tau2 = 27.23; Chi2 = 2.44, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 2.25 (P = 0.025)
Test for subgroup differences: Chi2 = 2.44, df = 1 (P = 0.12), I2 =59%
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Analysis 4.31. Comparison 4 Gefitinib versus chemotherapy, Outcome 31 PSI QOL improvement rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 4 Gefitinib versus chemotherapy
Outcome: 31 PSI QOL improvement rate
Study or subgroup Gefitinib Chemo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 G vs vinorelbine = 1st line
Crino 2008 INVITE 94 36.6 (7.17) 96 31 (7.25) 100.0 % 5.60 [ 3.55, 7.65 ]
Total (95% CI) 94 96 100.0 % 5.60 [ 3.55, 7.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.35 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 1 HR Overall
survival = 1st line.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 1 HR Overall survival = 1st line
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 G vs carboplatin + paclitaxel
Mitsudomi 2010 WJTOG3405 0.493476 (0.3817282) 2.9 % 1.64 [ 0.78, 3.46 ]
Mok 2009 IPASS -0.09431 (0.08673) 57.1 % 0.91 [ 0.77, 1.08 ]
Subtotal (95% CI) 60.1 % 1.09 [ 0.64, 1.84 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 2.25, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 0.30 (P = 0.76)
2 G vs gemcitabine + cisplatin
Han 2012 First SIGNAL -0.0704225 (0.1331242) 24.2 % 0.93 [ 0.72, 1.21 ]
Subtotal (95% CI) 24.2 % 0.93 [ 0.72, 1.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
3 G vs pemetrexed + cisplatin
Yang 2014 -0.0618754 (0.1655782) 15.7 % 0.94 [ 0.68, 1.30 ]
Subtotal (95% CI) 15.7 % 0.94 [ 0.68, 1.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Total (95% CI) 100.0 % 0.94 [ 0.82, 1.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.26, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 0.27, df = 2 (P = 0.87), I2 =0.0%
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Analysis 5.2. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 2 HR Overall
survival = 2nd line.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 2 HR Overall survival = 2nd line
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 G vs docetaxel
Lee 2010 ISTANA -0.1392621 (0.1770886) 26.0 % 0.87 [ 0.61, 1.23 ]
Maruyama 2008 V-15-32 0.0099503 (0.1167072) 59.9 % 1.01 [ 0.80, 1.27 ]
Subtotal (95% CI) 86.0 % 0.97 [ 0.80, 1.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
2 G vs pemetrexed
Sun 2012 KCSG-LU08-01 -0.2231436 (0.2412908) 14.0 % 0.80 [ 0.50, 1.28 ]
Subtotal (95% CI) 14.0 % 0.80 [ 0.50, 1.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Total (95% CI) 100.0 % 0.94 [ 0.79, 1.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.02, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Chi2 = 0.52, df = 1 (P = 0.47), I2 =0.0%
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Analysis 5.3. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 3 HR Overall
survival = Maintenance.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 3 HR Overall survival = Maintenance
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 G vs pemetrexed
Ahn 2012 0.7659329 (0.4832698) 100.0 % 2.15 [ 0.83, 5.55 ]
Total (95% CI) 100.0 % 2.15 [ 0.83, 5.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 4 HR Progression-
free survival = 1st line.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 4 HR Progression-free survival = 1st line
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 G vs carboplatin + paclitaxel
Maemondo 2010 NEJ002 -1.2039728 (0.1572044) 19.5 % 0.30 [ 0.22, 0.41 ]
Mok 2009 IPASS -0.3011051 (0.0677434) 21.5 % 0.74 [ 0.65, 0.85 ]
Subtotal (95% CI) 41.1 % 0.48 [ 0.20, 1.15 ]
Heterogeneity: Tau2 = 0.39; Chi2 = 27.82, df = 1 (P<0.00001); I2 =96%
Test for overall effect: Z = 1.64 (P = 0.10)
2 G vs cisplatin + docetaxel
Mitsudomi 2010 WJTOG3405 -0.7153928 (0.1889277) 18.6 % 0.49 [ 0.34, 0.71 ]
Subtotal (95% CI) 18.6 % 0.49 [ 0.34, 0.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.79 (P = 0.00015)
3 G vs gemcitabine + cisplatin
Han 2012 First SIGNAL 0.1806535 (0.1202877) 20.5 % 1.20 [ 0.95, 1.52 ]
Subtotal (95% CI) 20.5 % 1.20 [ 0.95, 1.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
4 G vs pemetrexed + cisplatin
Yang 2014 -0.1625189 (0.1475387) 19.8 % 0.85 [ 0.64, 1.14 ]
Subtotal (95% CI) 19.8 % 0.85 [ 0.64, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 100.0 % 0.65 [ 0.43, 0.98 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 54.54, df = 4 (P<0.00001); I2 =93%
Test for overall effect: Z = 2.07 (P = 0.038)
Test for subgroup differences: Chi2 = 18.15, df = 3 (P = 0.00), I2 =83%
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Analysis 5.5. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 5 HR Progression-
free survival = 2nd line.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 5 HR Progression-free survival = 2nd line
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 G vs docetaxel
Lee 2010 ISTANA -0.3160815 (0.1563595) 31.5 % 0.73 [ 0.54, 0.99 ]
Maruyama 2008 V-15-32 -0.210721 (0.1137842) 44.5 % 0.81 [ 0.65, 1.01 ]
Subtotal (95% CI) 76.0 % 0.78 [ 0.65, 0.94 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.69 (P = 0.0072)
2 G vs pemetrexed
Sun 2012 KCSG-LU08-01 -0.6161861 (0.191548) 24.0 % 0.54 [ 0.37, 0.79 ]
Subtotal (95% CI) 24.0 % 0.54 [ 0.37, 0.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.22 (P = 0.0013)
Total (95% CI) 100.0 % 0.71 [ 0.57, 0.88 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.31, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 3.02, df = 1 (P = 0.08), I2 =67%
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Analysis 5.6. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 6 HR Progression-
free survival = Maintenance.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 6 HR Progression-free survival = Maintenance
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 G vs pemetrexed
Ahn 2012 -0.6292339 (0.3396497) 100.0 % 0.53 [ 0.27, 1.04 ]
Total (95% CI) 100.0 % 0.53 [ 0.27, 1.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.064)
Test for subgroup differences: Not applicable
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Analysis 5.7. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 7 1-year survival
rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 7 1-year survival rate
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Han 2012 First SIGNAL 118/159 114/150 19.3 % 0.98 [ 0.86, 1.11 ]
Maemondo 2010 NEJ002 97/114 99/114 16.3 % 0.98 [ 0.88, 1.09 ]
Mok 2009 IPASS 416/609 392/608 64.5 % 1.06 [ 0.98, 1.15 ]
Subtotal (95% CI) 882 872 100.0 % 1.03 [ 0.97, 1.09 ]
Total events: 631 (Gefitinib), 605 (Chemo)
Heterogeneity: Chi2 = 2.03, df = 2 (P = 0.36); I2 =1%
Test for overall effect: Z = 0.98 (P = 0.33)
2 2nd line
Kim 2016 20/48 17/47 10.5 % 1.15 [ 0.69, 1.91 ]
Li 2010 18/49 15/48 9.2 % 1.18 [ 0.67, 2.05 ]
Maruyama 2008 V-15-32 117/244 132/245 80.3 % 0.89 [ 0.75, 1.06 ]
Subtotal (95% CI) 341 340 100.0 % 0.94 [ 0.81, 1.11 ]
Total events: 155 (Gefitinib), 164 (Chemo)
Heterogeneity: Chi2 = 1.62, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
3 Maintenance
Ahn 2012 29/39 29/31 100.0 % 0.79 [ 0.65, 0.98 ]
Subtotal (95% CI) 39 31 100.0 % 0.79 [ 0.65, 0.98 ]
Total events: 29 (Gefitinib), 29 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
Test for subgroup differences: Chi2 = 6.23, df = 2 (P = 0.04), I2 =68%
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Analysis 5.8. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 8 Nausea.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 8 Nausea
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Han 2012 First SIGNAL 0/159 4/150 13.3 % 0.10 [ 0.01, 1.93 ]
Mitsudomi 2010 WJTOG3405 1/87 3/88 8.6 % 0.34 [ 0.04, 3.18 ]
Mok 2009 IPASS 2/607 9/589 26.3 % 0.22 [ 0.05, 0.99 ]
Yang 2014 0/118 4/114 13.2 % 0.11 [ 0.01, 1.97 ]
Subtotal (95% CI) 971 941 61.3 % 0.19 [ 0.06, 0.54 ]
Total events: 3 (Gefitinib), 20 (Chemo)
Heterogeneity: Chi2 = 0.59, df = 3 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 3.11 (P = 0.0019)
2 2nd line
Dai 2013 0/23 0/23 Not estimable
Kim 2016 1/48 1/47 2.9 % 0.98 [ 0.06, 15.20 ]
Lee 2010 ISTANA 0/81 0/76 Not estimable
Maruyama 2008 V-15-32 5/244 9/239 26.2 % 0.54 [ 0.19, 1.60 ]
Sun 2012 KCSG-LU08-01 0/68 0/67 Not estimable
Subtotal (95% CI) 464 452 29.1 % 0.59 [ 0.22, 1.60 ]
Total events: 6 (Gefitinib), 10 (Chemo)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
3 Maintenance
Ahn 2012 2/39 3/31 9.6 % 0.53 [ 0.09, 2.98 ]
Subtotal (95% CI) 39 31 9.6 % 0.53 [ 0.09, 2.98 ]
Total events: 2 (Gefitinib), 3 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 1474 1424 100.0 % 0.34 [ 0.17, 0.64 ]
Total events: 11 (Gefitinib), 33 (Chemo)
Heterogeneity: Chi2 = 3.15, df = 6 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 3.28 (P = 0.0010)
Test for subgroup differences: Chi2 = 2.61, df = 2 (P = 0.27), I2 =23%
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Analysis 5.9. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 9 Vomiting.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 9 Vomiting
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 1st line
Han 2012 First SIGNAL 0/159 11/150 14.5 % 0.04 [ 0.00, 0.69 ]
Mok 2009 IPASS 1/607 16/589 20.5 % 0.06 [ 0.01, 0.46 ]
Yang 2014 1/118 6/114 19.8 % 0.16 [ 0.02, 1.32 ]
Subtotal (95% CI) 884 853 54.9 % 0.08 [ 0.02, 0.29 ]
Total events: 2 (Gefitinib), 33 (Chemo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.75, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 3.81 (P = 0.00014)
2 2nd line
Lee 2010 ISTANA 0/81 0/76 Not estimable
Maruyama 2008 V-15-32 4/244 3/239 25.7 % 1.31 [ 0.30, 5.77 ]
Subtotal (95% CI) 325 315 25.7 % 1.31 [ 0.30, 5.77 ]
Total events: 4 (Gefitinib), 3 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
3 Maintenance
Ahn 2012 1/39 4/31 19.5 % 0.20 [ 0.02, 1.69 ]
Subtotal (95% CI) 39 31 19.5 % 0.20 [ 0.02, 1.69 ]
Total events: 1 (Gefitinib), 4 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Total (95% CI) 1248 1199 100.0 % 0.19 [ 0.05, 0.77 ]
Total events: 7 (Gefitinib), 40 (Chemo)
Heterogeneity: Tau2 = 1.37; Chi2 = 9.12, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 2.33 (P = 0.020)
Test for subgroup differences: Chi2 = 7.72, df = 2 (P = 0.02), I2 =74%
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Analysis 5.10. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 10 Anorexia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 10 Anorexia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Han 2012 First SIGNAL 22/159 86/150 63.8 % 0.24 [ 0.16, 0.36 ]
Maemondo 2010 NEJ002 6/114 7/113 5.1 % 0.85 [ 0.29, 2.45 ]
Mok 2009 IPASS 9/607 16/589 11.7 % 0.55 [ 0.24, 1.23 ]
Yang 2014 0/118 1/114 1.1 % 0.32 [ 0.01, 7.83 ]
Subtotal (95% CI) 998 966 81.7 % 0.32 [ 0.23, 0.45 ]
Total events: 37 (Gefitinib), 110 (Chemo)
Heterogeneity: Chi2 = 6.75, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 6.58 (P < 0.00001)
2 2nd line
Dai 2013 0/23 1/23 1.1 % 0.33 [ 0.01, 7.78 ]
Kim 2016 0/48 2/47 1.8 % 0.20 [ 0.01, 3.98 ]
Lee 2010 ISTANA 0/81 2/76 1.9 % 0.19 [ 0.01, 3.85 ]
Maruyama 2008 V-15-32 10/244 17/239 12.4 % 0.58 [ 0.27, 1.23 ]
Sun 2012 KCSG-LU08-01 1/68 0/67 0.4 % 2.96 [ 0.12, 71.31 ]
Subtotal (95% CI) 464 452 17.5 % 0.53 [ 0.27, 1.02 ]
Total events: 11 (Gefitinib), 22 (Chemo)
Heterogeneity: Chi2 = 2.12, df = 4 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.059)
3 Maintenance
Ahn 2012 1/39 1/31 0.8 % 0.79 [ 0.05, 12.20 ]
Subtotal (95% CI) 39 31 0.8 % 0.79 [ 0.05, 12.20 ]
Total events: 1 (Gefitinib), 1 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
Total (95% CI) 1501 1449 100.0 % 0.36 [ 0.27, 0.49 ]
Total events: 49 (Gefitinib), 133 (Chemo)
Heterogeneity: Chi2 = 10.99, df = 9 (P = 0.28); I2 =18%
Test for overall effect: Z = 6.70 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.02, df = 2 (P = 0.36), I2 =1%
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Analysis 5.11. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 11 Fatigue.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 11 Fatigue
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Han 2012 First SIGNAL 16/159 68/150 71.1 % 0.22 [ 0.14, 0.36 ]
Maemondo 2010 NEJ002 3/114 1/113 1.0 % 2.97 [ 0.31, 28.16 ]
Mitsudomi 2010 WJTOG3405 2/87 2/88 2.0 % 1.01 [ 0.15, 7.02 ]
Yang 2014 0/118 8/114 8.8 % 0.06 [ 0.00, 0.97 ]
Subtotal (95% CI) 478 465 82.9 % 0.26 [ 0.17, 0.40 ]
Total events: 21 (Gefitinib), 79 (Chemo)
Heterogeneity: Chi2 = 7.89, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 6.04 (P < 0.00001)
2 2nd line
Dai 2013 0/23 1/23 1.5 % 0.33 [ 0.01, 7.78 ]
Kim 2016 1/48 2/47 2.1 % 0.49 [ 0.05, 5.22 ]
Maruyama 2008 V-15-32 1/244 6/239 6.2 % 0.16 [ 0.02, 1.35 ]
Sun 2012 KCSG-LU08-01 0/68 0/67 Not estimable
Subtotal (95% CI) 383 376 9.7 % 0.26 [ 0.06, 1.03 ]
Total events: 2 (Gefitinib), 9 (Chemo)
Heterogeneity: Chi2 = 0.49, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
3 Maintenance
Ahn 2012 1/39 2/31 2.3 % 0.40 [ 0.04, 4.18 ]
Xu 2015 7/94 5/94 5.1 % 1.40 [ 0.46, 4.25 ]
Subtotal (95% CI) 133 125 7.3 % 1.09 [ 0.41, 2.89 ]
Total events: 8 (Gefitinib), 7 (Chemo)
Heterogeneity: Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
Total (95% CI) 994 966 100.0 % 0.32 [ 0.22, 0.46 ]
Total events: 31 (Gefitinib), 95 (Chemo)
Heterogeneity: Chi2 = 15.96, df = 8 (P = 0.04); I2 =50%
Test for overall effect: Z = 5.99 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.10, df = 2 (P = 0.03), I2 =72%
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Analysis 5.12. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 12
Arthralgia/myalgia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 12 Arthralgia/myalgia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Maemondo 2010 NEJ002 1/114 8/113 56.9 % 0.12 [ 0.02, 0.97 ]
Mok 2009 IPASS 1/607 6/589 43.1 % 0.16 [ 0.02, 1.34 ]
Subtotal (95% CI) 721 702 100.0 % 0.14 [ 0.03, 0.61 ]
Total events: 2 (Gefitinib), 14 (Chemo)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 2.61 (P = 0.0090)
2 2nd line
Lee 2010 ISTANA 0/81 0/76 Not estimable
Maruyama 2008 V-15-32 0/244 0/239 Not estimable
Subtotal (95% CI) 325 315 Not estimable
Total events: 0 (Gefitinib), 0 (Chemo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1046 1017 100.0 % 0.14 [ 0.03, 0.61 ]
Total events: 2 (Gefitinib), 14 (Chemo)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 2.61 (P = 0.0090)
Test for subgroup differences: Not applicable
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Analysis 5.13. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 13 Asthenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 13 Asthenia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Maemondo 2010 NEJ002 0/114 7/113 33.8 % 0.07 [ 0.00, 1.14 ]
Mitsudomi 2010 WJTOG3405 1/87 0/88 2.2 % 3.03 [ 0.13, 73.47 ]
Mok 2009 IPASS 2/607 11/589 50.1 % 0.18 [ 0.04, 0.79 ]
Subtotal (95% CI) 808 790 86.1 % 0.21 [ 0.07, 0.61 ]
Total events: 3 (Gefitinib), 18 (Chemo)
Heterogeneity: Chi2 = 3.39, df = 2 (P = 0.18); I2 =41%
Test for overall effect: Z = 2.88 (P = 0.0040)
2 2nd line
Lee 2010 ISTANA 1/81 3/76 13.9 % 0.31 [ 0.03, 2.94 ]
Subtotal (95% CI) 81 76 13.9 % 0.31 [ 0.03, 2.94 ]
Total events: 1 (Gefitinib), 3 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 889 866 100.0 % 0.22 [ 0.08, 0.58 ]
Total events: 4 (Gefitinib), 21 (Chemo)
Heterogeneity: Chi2 = 3.46, df = 3 (P = 0.33); I2 =13%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.75), I2 =0.0%
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Analysis 5.14. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 14 Neurotoxicity.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 14 Neurotoxicity
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Han 2012 First SIGNAL 0/159 6/150 18.5 % 0.07 [ 0.00, 1.28 ]
Mok 2009 IPASS 2/607 29/589 81.5 % 0.07 [ 0.02, 0.28 ]
Subtotal (95% CI) 766 739 100.0 % 0.07 [ 0.02, 0.24 ]
Total events: 2 (Gefitinib), 35 (Chemo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 4.12 (P = 0.000038)
2 2nd line
Lee 2010 ISTANA 0/81 0/76 Not estimable
Sun 2012 KCSG-LU08-01 0/68 0/67 Not estimable
Subtotal (95% CI) 149 143 Not estimable
Total events: 0 (Gefitinib), 0 (Chemo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 915 882 100.0 % 0.07 [ 0.02, 0.24 ]
Total events: 2 (Gefitinib), 35 (Chemo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 4.12 (P = 0.000038)
Test for subgroup differences: Not applicable
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Analysis 5.15. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 15 Neutropenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 15 Neutropenia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 1st line
Han 2012 First SIGNAL 3/159 82/150 13.0 % 0.03 [ 0.01, 0.11 ]
Maemondo 2010 NEJ002 1/114 37/113 9.0 % 0.03 [ 0.00, 0.19 ]
Mitsudomi 2010 WJTOG3405 0/87 74/88 6.2 % 0.01 [ 0.00, 0.11 ]
Mok 2009 IPASS 22/607 387/589 16.1 % 0.06 [ 0.04, 0.08 ]
Yang 2014 0/118 17/114 6.1 % 0.03 [ 0.00, 0.45 ]
Subtotal (95% CI) 1085 1054 50.3 % 0.05 [ 0.03, 0.07 ]
Total events: 26 (Gefitinib), 597 (Chemo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.45, df = 4 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 15.83 (P < 0.00001)
2 2nd line
Dai 2013 0/23 1/23 5.2 % 0.33 [ 0.01, 7.78 ]
Maruyama 2008 V-15-32 20/244 176/239 16.0 % 0.11 [ 0.07, 0.17 ]
Sun 2012 KCSG-LU08-01 0/68 1/67 5.1 % 0.33 [ 0.01, 7.92 ]
Subtotal (95% CI) 335 329 26.4 % 0.12 [ 0.08, 0.18 ]
Total events: 20 (Gefitinib), 178 (Chemo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.88, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 10.09 (P < 0.00001)
3 Maintenance
Ahn 2012 7/39 5/31 13.4 % 1.11 [ 0.39, 3.17 ]
Xu 2015 3/94 2/94 9.9 % 1.50 [ 0.26, 8.77 ]
Subtotal (95% CI) 133 125 23.3 % 1.20 [ 0.49, 2.96 ]
Total events: 10 (Gefitinib), 7 (Chemo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 1553 1508 100.0 % 0.11 [ 0.05, 0.27 ]
Total events: 56 (Gefitinib), 782 (Chemo)
Heterogeneity: Tau2 = 1.17; Chi2 = 51.19, df = 9 (P<0.00001); I2 =82%
Test for overall effect: Z = 4.90 (P < 0.00001)
Test for subgroup differences: Chi2 = 43.67, df = 2 (P = 0.00), I2 =95%
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Analysis 5.16. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 16 Anaemia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 16 Anaemia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Han 2012 First SIGNAL 3/159 21/150 18.6 % 0.13 [ 0.04, 0.44 ]
Maemondo 2010 NEJ002 0/114 6/113 5.6 % 0.08 [ 0.00, 1.34 ]
Mitsudomi 2010 WJTOG3405 0/87 15/88 13.3 % 0.03 [ 0.00, 0.54 ]
Mok 2009 IPASS 13/607 61/589 53.3 % 0.21 [ 0.11, 0.37 ]
Yang 2014 0/118 3/114 3.1 % 0.14 [ 0.01, 2.64 ]
Subtotal (95% CI) 1085 1054 93.8 % 0.16 [ 0.10, 0.26 ]
Total events: 16 (Gefitinib), 106 (Chemo)
Heterogeneity: Chi2 = 2.35, df = 4 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 7.26 (P < 0.00001)
2 2nd line
Dai 2013 0/23 0/23 Not estimable
Kim 2016 1/48 5/47 4.3 % 0.20 [ 0.02, 1.61 ]
Subtotal (95% CI) 71 70 4.3 % 0.20 [ 0.02, 1.61 ]
Total events: 1 (Gefitinib), 5 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
3 Maintenance
Ahn 2012 1/39 1/31 1.0 % 0.79 [ 0.05, 12.20 ]
Xu 2015 2/94 1/94 0.9 % 2.00 [ 0.18, 21.68 ]
Subtotal (95% CI) 133 125 1.8 % 1.36 [ 0.24, 7.87 ]
Total events: 3 (Gefitinib), 2 (Chemo)
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Total (95% CI) 1289 1249 100.0 % 0.18 [ 0.12, 0.29 ]
Total events: 20 (Gefitinib), 113 (Chemo)
Heterogeneity: Chi2 = 7.28, df = 7 (P = 0.40); I2 =4%
Test for overall effect: Z = 7.36 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.39, df = 2 (P = 0.07), I2 =63%
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Analysis 5.17. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 17 Leukopenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 17 Leukopenia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 1st line
Mitsudomi 2010 WJTOG3405 0/87 43/88 12.4 % 0.01 [ 0.00, 0.19 ]
Mok 2009 IPASS 9/607 202/589 37.4 % 0.04 [ 0.02, 0.08 ]
Yang 2014 0/118 2/114 10.9 % 0.19 [ 0.01, 3.98 ]
Subtotal (95% CI) 812 791 60.7 % 0.04 [ 0.02, 0.08 ]
Total events: 9 (Gefitinib), 247 (Chemo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.89, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 9.84 (P < 0.00001)
2 2nd line
Maruyama 2008 V-15-32 15/244 94/239 39.3 % 0.16 [ 0.09, 0.26 ]
Subtotal (95% CI) 244 239 39.3 % 0.16 [ 0.09, 0.26 ]
Total events: 15 (Gefitinib), 94 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 7.06 (P < 0.00001)
Total (95% CI) 1056 1030 100.0 % 0.07 [ 0.02, 0.23 ]
Total events: 24 (Gefitinib), 341 (Chemo)
Heterogeneity: Tau2 = 0.82; Chi2 = 13.18, df = 3 (P = 0.004); I2 =77%
Test for overall effect: Z = 4.45 (P < 0.00001)
Test for subgroup differences: Chi2 = 9.69, df = 1 (P = 0.00), I2 =90%
0.001 0.01 0.1 1 10 100 1000
Favours Gefitinib Favours Chemo
192Gefitinib for advanced non-small cell lung cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.18. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 18
Thrombocytopenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 18 Thrombocytopenia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Han 2012 First SIGNAL 2/159 13/150 58.2 % 0.15 [ 0.03, 0.63 ]
Maemondo 2010 NEJ002 0/114 4/113 19.7 % 0.11 [ 0.01, 2.02 ]
Subtotal (95% CI) 273 263 77.9 % 0.14 [ 0.04, 0.51 ]
Total events: 2 (Gefitinib), 17 (Chemo)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 2.97 (P = 0.0029)
2 2nd line
Dai 2013 0/23 2/23 10.9 % 0.20 [ 0.01, 3.95 ]
Kim 2016 0/48 1/47 6.6 % 0.33 [ 0.01, 7.82 ]
Sun 2012 KCSG-LU08-01 0/68 0/67 Not estimable
Subtotal (95% CI) 139 137 17.5 % 0.25 [ 0.03, 2.15 ]
Total events: 0 (Gefitinib), 3 (Chemo)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
3 Maintenance
Ahn 2012 1/39 0/31 2.4 % 2.40 [ 0.10, 56.95 ]
Xu 2015 2/94 0/94 2.2 % 5.00 [ 0.24, 102.77 ]
Subtotal (95% CI) 133 125 4.6 % 3.63 [ 0.42, 31.44 ]
Total events: 3 (Gefitinib), 0 (Chemo)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Total (95% CI) 545 525 100.0 % 0.32 [ 0.14, 0.72 ]
Total events: 5 (Gefitinib), 20 (Chemo)
Heterogeneity: Chi2 = 6.45, df = 5 (P = 0.26); I2 =22%
Test for overall effect: Z = 2.74 (P = 0.0061)
Test for subgroup differences: Chi2 = 6.54, df = 2 (P = 0.04), I2 =69%
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Analysis 5.19. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 19 Febrile
neutropenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 19 Febrile neutropenia
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Mok 2009 IPASS 1/607 17/589 50.1 % 0.06 [ 0.01, 0.43 ]
Subtotal (95% CI) 607 589 50.1 % 0.06 [ 0.01, 0.43 ]
Total events: 1 (Gefitinib), 17 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.79 (P = 0.0053)
2 2nd line
Maruyama 2008 V-15-32 2/244 17/239 49.9 % 0.12 [ 0.03, 0.49 ]
Subtotal (95% CI) 244 239 49.9 % 0.12 [ 0.03, 0.49 ]
Total events: 2 (Gefitinib), 17 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.91 (P = 0.0036)
Total (95% CI) 851 828 100.0 % 0.09 [ 0.03, 0.28 ]
Total events: 3 (Gefitinib), 34 (Chemo)
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 4.09 (P = 0.000043)
Test for subgroup differences: Chi2 = 0.31, df = 1 (P = 0.58), I2 =0.0%
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Analysis 5.20. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 20 Skin rash.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 20 Skin rash
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 1st line
Han 2012 First SIGNAL 47/159 3/150 15.3 % 14.78 [ 4.70, 46.47 ]
Maemondo 2010 NEJ002 6/114 3/115 13.8 % 2.02 [ 0.52, 7.87 ]
Mitsudomi 2010 WJTOG3405 2/87 0/88 6.1 % 5.06 [ 0.25, 103.83 ]
Mok 2009 IPASS 19/607 5/589 16.4 % 3.69 [ 1.39, 9.81 ]
Yang 2014 3/118 0/114 6.3 % 6.76 [ 0.35, 129.52 ]
Subtotal (95% CI) 1085 1056 57.8 % 5.09 [ 2.21, 11.72 ]
Total events: 77 (Gefitinib), 11 (Chemo)
Heterogeneity: Tau2 = 0.29; Chi2 = 5.98, df = 4 (P = 0.20); I2 =33%
Test for overall effect: Z = 3.83 (P = 0.00013)
2 2nd line
Lee 2010 ISTANA 3/81 0/76 6.3 % 6.57 [ 0.35, 125.19 ]
Maruyama 2008 V-15-32 1/244 1/239 6.9 % 0.98 [ 0.06, 15.57 ]
Sun 2012 KCSG-LU08-01 1/68 0/67 5.6 % 2.96 [ 0.12, 71.31 ]
Subtotal (95% CI) 393 382 18.8 % 2.54 [ 0.46, 13.95 ]
Total events: 5 (Gefitinib), 1 (Chemo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.89, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
3 Maintenance
Ahn 2012 2/39 0/31 6.1 % 4.00 [ 0.20, 80.39 ]
Xu 2015 8/94 12/94 17.3 % 0.67 [ 0.29, 1.56 ]
Subtotal (95% CI) 133 125 23.4 % 0.91 [ 0.24, 3.44 ]
Total events: 10 (Gefitinib), 12 (Chemo)
Heterogeneity: Tau2 = 0.37; Chi2 = 1.29, df = 1 (P = 0.26); I2 =23%
Test for overall effect: Z = 0.15 (P = 0.88)
Total (95% CI) 1611 1563 100.0 % 3.11 [ 1.28, 7.55 ]
Total events: 92 (Gefitinib), 24 (Chemo)
Heterogeneity: Tau2 = 1.00; Chi2 = 22.53, df = 9 (P = 0.01); I2 =60%
Test for overall effect: Z = 2.50 (P = 0.012)
Test for subgroup differences: Chi2 = 4.67, df = 2 (P = 0.10), I2 =57%
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Analysis 5.21. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 21 Diarrhoea.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 21 Diarrhoea
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Han 2012 First SIGNAL 4/159 2/150 13.1 % 1.89 [ 0.35, 10.15 ]
Maemondo 2010 NEJ002 1/114 0/113 3.2 % 2.97 [ 0.12, 72.24 ]
Mitsudomi 2010 WJTOG3405 1/87 0/88 3.2 % 3.03 [ 0.13, 73.47 ]
Mok 2009 IPASS 23/607 8/589 51.6 % 2.79 [ 1.26, 6.19 ]
Yang 2014 4/118 1/114 6.5 % 3.86 [ 0.44, 34.05 ]
Subtotal (95% CI) 1085 1054 77.5 % 2.74 [ 1.43, 5.27 ]
Total events: 33 (Gefitinib), 11 (Chemo)
Heterogeneity: Chi2 = 0.29, df = 4 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 3.04 (P = 0.0024)
2 2nd line
Dai 2013 1/23 0/23 3.2 % 3.00 [ 0.13, 70.02 ]
Kim 2016 2/48 0/47 3.2 % 4.90 [ 0.24, 99.38 ]
Lee 2010 ISTANA 1/81 0/76 3.3 % 2.82 [ 0.12, 68.11 ]
Maruyama 2008 V-15-32 5/244 2/239 12.8 % 2.45 [ 0.48, 12.50 ]
Sun 2012 KCSG-LU08-01 0/68 0/67 Not estimable
Subtotal (95% CI) 464 452 22.5 % 2.93 [ 0.88, 9.73 ]
Total events: 9 (Gefitinib), 2 (Chemo)
Heterogeneity: Chi2 = 0.16, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.079)
Total (95% CI) 1549 1506 100.0 % 2.79 [ 1.57, 4.94 ]
Total events: 42 (Gefitinib), 13 (Chemo)
Heterogeneity: Chi2 = 0.46, df = 8 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 3.51 (P = 0.00046)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
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Analysis 5.22. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 22 Increased ALT.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 22 Increased ALT
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Han 2012 First SIGNAL 9/159 1/150 10.6 % 8.49 [ 1.09, 66.21 ]
Maemondo 2010 NEJ002 30/114 1/113 10.3 % 29.74 [ 4.13, 214.37 ]
Mitsudomi 2010 WJTOG3405 24/87 2/88 20.4 % 12.14 [ 2.96, 49.80 ]
Yang 2014 8/118 2/114 20.9 % 3.86 [ 0.84, 17.81 ]
Subtotal (95% CI) 478 465 62.2 % 11.66 [ 5.13, 26.49 ]
Total events: 71 (Gefitinib), 6 (Chemo)
Heterogeneity: Chi2 = 2.96, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 5.87 (P < 0.00001)
2 2nd line
Dai 2013 0/23 0/23 Not estimable
Maruyama 2008 V-15-32 27/244 2/239 20.7 % 13.22 [ 3.18, 54.99 ]
Subtotal (95% CI) 267 262 20.7 % 13.22 [ 3.18, 54.99 ]
Total events: 27 (Gefitinib), 2 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.55 (P = 0.00038)
3 Maintenance
Ahn 2012 0/39 1/31 17.1 % 0.27 [ 0.01, 6.33 ]
Subtotal (95% CI) 39 31 17.1 % 0.27 [ 0.01, 6.33 ]
Total events: 0 (Gefitinib), 1 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Total (95% CI) 784 758 100.0 % 10.03 [ 5.23, 19.26 ]
Total events: 98 (Gefitinib), 9 (Chemo)
Heterogeneity: Chi2 = 7.94, df = 5 (P = 0.16); I2 =37%
Test for overall effect: Z = 6.93 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.31, df = 2 (P = 0.07), I2 =62%
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Analysis 5.23. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 23 Increased AST.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 23 Increased AST
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Han 2012 First SIGNAL 18/159 3/150 75.6 % 5.66 [ 1.70, 18.83 ]
Mitsudomi 2010 WJTOG3405 14/87 1/88 24.4 % 14.16 [ 1.90, 105.37 ]
Yang 2014 0/118 0/114 Not estimable
Subtotal (95% CI) 364 352 100.0 % 7.73 [ 2.78, 21.46 ]
Total events: 32 (Gefitinib), 4 (Chemo)
Heterogeneity: Chi2 = 0.61, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 3.93 (P = 0.000087)
2 2nd line
Dai 2013 0/23 0/23 Not estimable
Subtotal (95% CI) 23 23 Not estimable
Total events: 0 (Gefitinib), 0 (Chemo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 387 375 100.0 % 7.73 [ 2.78, 21.46 ]
Total events: 32 (Gefitinib), 4 (Chemo)
Heterogeneity: Chi2 = 0.61, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 3.93 (P = 0.000087)
Test for subgroup differences: Not applicable
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Analysis 5.24. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 24 Overall
response rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 24 Overall response rate
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 1st line
Han 2012 First SIGNAL 88/159 69/150 20.1 % 1.20 [ 0.96, 1.50 ]
Lou 2014 9/25 11/26 8.0 % 0.85 [ 0.43, 1.69 ]
Maemondo 2010 NEJ002 84/114 35/114 17.7 % 2.40 [ 1.78, 3.23 ]
Mitsudomi 2010 WJTOG3405 36/58 19/59 13.8 % 1.93 [ 1.26, 2.94 ]
Mok 2009 IPASS 262/609 196/608 22.3 % 1.33 [ 1.15, 1.55 ]
Yang 2014 56/118 49/118 18.0 % 1.14 [ 0.86, 1.52 ]
Subtotal (95% CI) 1083 1075 100.0 % 1.43 [ 1.13, 1.82 ]
Total events: 535 (Gefitinib), 379 (Chemo)
Heterogeneity: Tau2 = 0.06; Chi2 = 21.00, df = 5 (P = 0.00081); I2 =76%
Test for overall effect: Z = 2.94 (P = 0.0032)
2 2nd line
Dai 2013 4/23 3/23 8.1 % 1.33 [ 0.34, 5.30 ]
Kim 2016 4/48 6/47 10.0 % 0.65 [ 0.20, 2.17 ]
Lee 2010 ISTANA 23/82 6/79 16.0 % 3.69 [ 1.59, 8.59 ]
Li 2010 11/49 9/48 17.4 % 1.20 [ 0.55, 2.63 ]
Maruyama 2008 V-15-32 45/200 24/187 27.4 % 1.75 [ 1.11, 2.76 ]
Sun 2012 KCSG-LU08-01 14/68 15/67 21.1 % 0.92 [ 0.48, 1.75 ]
Subtotal (95% CI) 470 451 100.0 % 1.43 [ 0.92, 2.22 ]
Total events: 101 (Gefitinib), 63 (Chemo)
Heterogeneity: Tau2 = 0.13; Chi2 = 9.29, df = 5 (P = 0.10); I2 =46%
Test for overall effect: Z = 1.58 (P = 0.11)
3 Maintenance
Ahn 2012 18/39 11/31 48.7 % 1.30 [ 0.73, 2.33 ]
Xu 2015 17/94 28/94 51.3 % 0.61 [ 0.36, 1.03 ]
Subtotal (95% CI) 133 125 100.0 % 0.88 [ 0.41, 1.87 ]
Total events: 35 (Gefitinib), 39 (Chemo)
Heterogeneity: Tau2 = 0.21; Chi2 = 3.64, df = 1 (P = 0.06); I2 =73%
Test for overall effect: Z = 0.33 (P = 0.74)
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Analysis 5.25. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 25 Stable disease.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 25 Stable disease
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 1st line
Han 2012 First SIGNAL 18/159 48/150 21.6 % 0.35 [ 0.22, 0.58 ]
Lou 2014 6/25 11/26 10.9 % 0.57 [ 0.25, 1.30 ]
Maemondo 2010 NEJ002 18/114 56/114 23.1 % 0.32 [ 0.20, 0.51 ]
Mitsudomi 2010 WJTOG3405 18/58 27/59 22.5 % 0.68 [ 0.42, 1.09 ]
Yang 2014 20/118 35/118 21.9 % 0.57 [ 0.35, 0.93 ]
Subtotal (95% CI) 474 467 100.0 % 0.47 [ 0.34, 0.64 ]
Total events: 80 (Gefitinib), 177 (Chemo)
Heterogeneity: Tau2 = 0.05; Chi2 = 7.07, df = 4 (P = 0.13); I2 =43%
Test for overall effect: Z = 4.76 (P < 0.00001)
2 2nd line
Dai 2013 5/23 4/23 19.5 % 1.25 [ 0.38, 4.07 ]
Li 2010 16/49 15/48 80.5 % 1.04 [ 0.58, 1.87 ]
Subtotal (95% CI) 72 71 100.0 % 1.08 [ 0.64, 1.82 ]
Total events: 21 (Gefitinib), 19 (Chemo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
3 Maintenance
Ahn 2012 9/39 13/31 28.4 % 0.55 [ 0.27, 1.12 ]
Xu 2015 23/94 34/94 71.6 % 0.68 [ 0.43, 1.06 ]
Subtotal (95% CI) 133 125 100.0 % 0.64 [ 0.44, 0.93 ]
Total events: 32 (Gefitinib), 47 (Chemo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Chi2 = 7.42, df = 2 (P = 0.02), I2 =73%
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Analysis 5.26. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 26 Disease control
rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 26 Disease control rate
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 1st line
Lou 2014 15/25 22/26 9.6 % 0.71 [ 0.49, 1.02 ]
Maemondo 2010 NEJ002 102/114 91/113 23.8 % 1.11 [ 0.99, 1.24 ]
Mitsudomi 2010 WJTOG3405 54/58 46/59 20.9 % 1.19 [ 1.03, 1.39 ]
Mok 2009 IPASS 444/609 482/608 26.6 % 0.92 [ 0.86, 0.98 ]
Yang 2014 76/118 84/118 19.2 % 0.90 [ 0.76, 1.08 ]
Subtotal (95% CI) 924 924 100.0 % 0.99 [ 0.86, 1.13 ]
Total events: 691 (Gefitinib), 725 (Chemo)
Heterogeneity: Tau2 = 0.02; Chi2 = 19.96, df = 4 (P = 0.00051); I2 =80%
Test for overall effect: Z = 0.18 (P = 0.86)
2 2nd line
Dai 2013 9/23 7/23 8.5 % 1.29 [ 0.58, 2.86 ]
Kim 2016 17/48 21/47 22.1 % 0.79 [ 0.48, 1.30 ]
Maruyama 2008 V-15-32 68/200 62/187 69.4 % 1.03 [ 0.77, 1.36 ]
Subtotal (95% CI) 271 257 100.0 % 0.99 [ 0.78, 1.25 ]
Total events: 94 (Gefitinib), 90 (Chemo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.24, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
3 Maintenance
Xu 2015 40/94 62/94 100.0 % 0.65 [ 0.49, 0.85 ]
Subtotal (95% CI) 94 94 100.0 % 0.65 [ 0.49, 0.85 ]
Total events: 40 (Gefitinib), 62 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.11 (P = 0.0019)
Test for subgroup differences: Chi2 = 7.73, df = 2 (P = 0.02), I2 =74%
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Analysis 5.27. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 27 FACT-L QOL
improvement rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 27 FACT-L QOL improvement rate
Study or subgroup Gefitinib Chemo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1st line
Mok 2009 IPASS 590 48 (0) 561 40.8 (0) Not estimable
Subtotal (95% CI) 590 561 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 2nd line
Lee 2010 ISTANA 82 27.9 (0) 79 27.3 (0) Not estimable
Maruyama 2008 V-15-32 185 23.4 (7.6) 173 13.9 (7.35) 100.0 % 9.50 [ 7.95, 11.05 ]
Subtotal (95% CI) 267 252 100.0 % 9.50 [ 7.95, 11.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 12.02 (P < 0.00001)
Total (95% CI) 857 813 100.0 % 9.50 [ 7.95, 11.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 12.02 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.28. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 28 LCS QOL
improvement rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 28 LCS QOL improvement rate
Study or subgroup Gefitinib Chemo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1st line
Mok 2009 IPASS 590 51.5 (0) 561 48.5 (0) Not estimable
Subtotal (95% CI) 590 561 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 2nd line
Lee 2010 ISTANA 82 39.7 (0) 79 37.9 (0) Not estimable
Maruyama 2008 V-15-32 225 22.7 (4.17) 211 20.4 (4.04) 100.0 % 2.30 [ 1.53, 3.07 ]
Subtotal (95% CI) 307 290 100.0 % 2.30 [ 1.53, 3.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.85 (P < 0.00001)
Total (95% CI) 897 851 100.0 % 2.30 [ 1.53, 3.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.85 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.29. Comparison 5 Gefitinib versus chemotherapy (Asian subgroup), Outcome 29 TOI QOL
improvement rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 5 Gefitinib versus chemotherapy (Asian subgroup)
Outcome: 29 TOI QOL improvement rate
Study or subgroup Gefitinib Chemo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1st line
Mok 2009 IPASS 590 46.4 (0) 561 32.8 (0) Not estimable
Subtotal (95% CI) 590 561 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 2nd line
Maruyama 2008 V-15-32 185 20.5 (12.91) 173 8.7 (12.5) 100.0 % 11.80 [ 9.17, 14.43 ]
Lee 2010 ISTANA 82 26.5 (0) 79 13.6 (0) Not estimable
Subtotal (95% CI) 267 252 100.0 % 11.80 [ 9.17, 14.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.79 (P < 0.00001)
Total (95% CI) 857 813 100.0 % 11.80 [ 9.17, 14.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.79 (P < 0.00001)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours Chemo Favours Gefitinib
204Gefitinib for advanced non-small cell lung cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.1. Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 1 HR Overall
survival = 1st line.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 6 Gefitinib versus chemotherapy (EGFR mutation)
Outcome: 1 HR Overall survival = 1st line
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Biomarker driven selection
Maemondo 2010 NEJ002 -0.1199103 (0.169602) 45.9 % 0.89 [ 0.64, 1.24 ]
Mitsudomi 2010 WJTOG3405 0.493476 (0.3817282) 9.1 % 1.64 [ 0.78, 3.46 ]
Subtotal (95% CI) 54.9 % 0.98 [ 0.72, 1.33 ]
Heterogeneity: Chi2 = 2.16, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.12 (P = 0.90)
2 Clinical feature driven selection
Han 2012 First SIGNAL 0.0421012 (0.3730801) 9.5 % 1.04 [ 0.50, 2.17 ]
Mok 2009 IPASS -0.2484614 (0.221078) 27.0 % 0.78 [ 0.51, 1.20 ]
Yang 2014 0.4510756 (0.391246) 8.6 % 1.57 [ 0.73, 3.38 ]
Subtotal (95% CI) 45.1 % 0.95 [ 0.68, 1.33 ]
Heterogeneity: Chi2 = 2.51, df = 2 (P = 0.29); I2 =20%
Test for overall effect: Z = 0.31 (P = 0.75)
Total (95% CI) 100.0 % 0.97 [ 0.77, 1.21 ]
Heterogeneity: Chi2 = 4.69, df = 4 (P = 0.32); I2 =15%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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Analysis 6.2. Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 2 HR Overall
survival = 2nd line.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 6 Gefitinib versus chemotherapy (EGFR mutation)
Outcome: 2 HR Overall survival = 2nd line
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 G vs docetaxel
Kim 2008 INTEREST -0.1863296 (0.354652) 100.0 % 0.83 [ 0.41, 1.66 ]
Total (95% CI) 100.0 % 0.83 [ 0.41, 1.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 3 HR Progression-
free survival = 1st line.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 6 Gefitinib versus chemotherapy (EGFR mutation)
Outcome: 3 HR Progression-free survival = 1st line
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Biomarker driven selection
Maemondo 2010 NEJ002 -1.1332037 (0.1561584) 26.6 % 0.32 [ 0.24, 0.44 ]
Mitsudomi 2010 WJTOG3405 -0.7153928 (0.1889277) 23.0 % 0.49 [ 0.34, 0.71 ]
Subtotal (95% CI) 49.6 % 0.39 [ 0.26, 0.59 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 2.91, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 4.50 (P < 0.00001)
2 Clinical feature driven selection
Han 2012 First SIGNAL -0.608806 (0.355645) 10.9 % 0.54 [ 0.27, 1.09 ]
Mok 2009 IPASS -0.7339692 (0.145294) 27.9 % 0.48 [ 0.36, 0.64 ]
Yang 2014 -0.1863296 (0.3408906) 11.6 % 0.83 [ 0.43, 1.62 ]
Subtotal (95% CI) 50.4 % 0.53 [ 0.41, 0.70 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.20, df = 2 (P = 0.33); I2 =9%
Test for overall effect: Z = 4.47 (P < 0.00001)
Total (95% CI) 100.0 % 0.47 [ 0.36, 0.61 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 8.48, df = 4 (P = 0.08); I2 =53%
Test for overall effect: Z = 5.53 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.52, df = 1 (P = 0.22), I2 =34%
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Analysis 6.4. Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 4 HR Progression-
free survival = 2nd line.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 6 Gefitinib versus chemotherapy (EGFR mutation)
Outcome: 4 HR Progression-free survival = 2nd line
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 G vs docetaxel
Kim 2008 INTEREST -1.8325815 (0.5763592) 36.0 % 0.16 [ 0.05, 0.50 ]
Subtotal (95% CI) 36.0 % 0.16 [ 0.05, 0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.18 (P = 0.0015)
2 G vs pemetrexed
Sun 2012 KCSG-LU08-01 -1.2039728 (0.4322517) 64.0 % 0.30 [ 0.13, 0.70 ]
Subtotal (95% CI) 64.0 % 0.30 [ 0.13, 0.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.79 (P = 0.0053)
Total (95% CI) 100.0 % 0.24 [ 0.12, 0.47 ]
Heterogeneity: Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 4.14 (P = 0.000035)
Test for subgroup differences: Chi2 = 0.76, df = 1 (P = 0.38), I2 =0.0%
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Analysis 6.5. Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 5 Overall response
rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 6 Gefitinib versus chemotherapy (EGFR mutation)
Outcome: 5 Overall response rate
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 First-line biomarker driven selection
Maemondo 2010 NEJ002 84/115 35/115 20.7 % 2.40 [ 1.78, 3.23 ]
Mitsudomi 2010 WJTOG3405 36/58 19/59 15.9 % 1.93 [ 1.26, 2.94 ]
Subtotal (95% CI) 173 174 36.5 % 2.23 [ 1.75, 2.85 ]
Total events: 120 (Gefitinib), 54 (Chemo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 6.47 (P < 0.00001)
2 First-line, clinical feature driven selection
Han 2012 First SIGNAL 22/26 6/16 9.6 % 2.26 [ 1.17, 4.34 ]
Mok 2009 IPASS 94/132 61/129 24.2 % 1.51 [ 1.22, 1.86 ]
Yang 2014 17/24 17/26 17.4 % 1.08 [ 0.74, 1.58 ]
Subtotal (95% CI) 182 171 51.3 % 1.45 [ 1.05, 1.99 ]
Total events: 133 (Gefitinib), 84 (Chemo)
Heterogeneity: Tau2 = 0.04; Chi2 = 4.27, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 2.27 (P = 0.023)
3 2nd line
Kim 2008 INTEREST 8/19 4/19 4.9 % 2.00 [ 0.72, 5.53 ]
Maruyama 2008 V-15-32 6/9 5/11 7.3 % 1.47 [ 0.66, 3.25 ]
Subtotal (95% CI) 28 30 12.2 % 1.65 [ 0.88, 3.09 ]
Total events: 14 (Gefitinib), 9 (Chemo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
Total (95% CI) 383 375 100.0 % 1.71 [ 1.34, 2.19 ]
Total events: 267 (Gefitinib), 147 (Chemo)
Heterogeneity: Tau2 = 0.05; Chi2 = 13.68, df = 6 (P = 0.03); I2 =56%
Test for overall effect: Z = 4.27 (P = 0.000020)
Test for subgroup differences: Chi2 = 4.66, df = 2 (P = 0.10), I2 =57%
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Analysis 6.6. Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 6 Stable disease.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 6 Gefitinib versus chemotherapy (EGFR mutation)
Outcome: 6 Stable disease
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 First-line, biomarker driven selection
Maemondo 2010 NEJ002 18/115 56/115 41.2 % 0.32 [ 0.20, 0.51 ]
Mitsudomi 2010 WJTOG3405 18/58 27/59 40.8 % 0.68 [ 0.42, 1.09 ]
Subtotal (95% CI) 173 174 82.0 % 0.47 [ 0.22, 0.98 ]
Total events: 36 (Gefitinib), 83 (Chemo)
Heterogeneity: Tau2 = 0.23; Chi2 = 4.99, df = 1 (P = 0.03); I2 =80%
Test for overall effect: Z = 2.02 (P = 0.043)
2 First-line, clinical feature driven selection
Yang 2014 4/24 5/26 18.0 % 0.87 [ 0.26, 2.85 ]
Subtotal (95% CI) 24 26 18.0 % 0.87 [ 0.26, 2.85 ]
Total events: 4 (Gefitinib), 5 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 197 200 100.0 % 0.52 [ 0.28, 0.97 ]
Total events: 40 (Gefitinib), 88 (Chemo)
Heterogeneity: Tau2 = 0.19; Chi2 = 5.96, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 2.06 (P = 0.039)
Test for subgroup differences: Chi2 = 0.75, df = 1 (P = 0.39), I2 =0.0%
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Analysis 6.7. Comparison 6 Gefitinib versus chemotherapy (EGFR mutation), Outcome 7 Disease control
rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 6 Gefitinib versus chemotherapy (EGFR mutation)
Outcome: 7 Disease control rate
Study or subgroup Gefitinib Chemo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 First-line, biomarker driven selection
Maemondo 2010 NEJ002 102/115 91/115 24.0 % 1.12 [ 1.00, 1.26 ]
Mitsudomi 2010 WJTOG3405 54/58 46/59 20.8 % 1.19 [ 1.03, 1.39 ]
Subtotal (95% CI) 173 174 44.7 % 1.15 [ 1.05, 1.26 ]
Total events: 156 (Gefitinib), 137 (Chemo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 2.93 (P = 0.0034)
2 First-line, clinical feature driven selection
Mok 2009 IPASS 444/609 482/608 27.8 % 0.92 [ 0.86, 0.98 ]
Yang 2014 21/24 22/26 15.4 % 1.03 [ 0.83, 1.29 ]
Subtotal (95% CI) 633 634 43.2 % 0.93 [ 0.87, 0.99 ]
Total events: 465 (Gefitinib), 504 (Chemo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.00, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 2.42 (P = 0.016)
3 Second-line
Maruyama 2008 V-15-32 68/200 62/187 12.1 % 1.03 [ 0.77, 1.36 ]
Subtotal (95% CI) 200 187 12.1 % 1.03 [ 0.77, 1.36 ]
Total events: 68 (Gefitinib), 62 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Total (95% CI) 1006 995 100.0 % 1.05 [ 0.93, 1.19 ]
Total events: 689 (Gefitinib), 703 (Chemo)
Heterogeneity: Tau2 = 0.01; Chi2 = 16.09, df = 4 (P = 0.003); I2 =75%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Chi2 = 14.35, df = 2 (P = 0.00), I2 =86%
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Analysis 7.1. Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 1 1-year survival rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 7 Gefitinib 250 mg versus gefitinib 500 mg
Outcome: 1 1-year survival rate
Study or subgroup Gefitinib 500 mg Gefitinib 250 mg Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2nd line
Fukuoka 2003 IDEAL I 30/105 37/103 55.8 % 0.80 [ 0.53, 1.18 ]
Kris 2003 IDEAL II 27/114 28/102 44.2 % 0.86 [ 0.55, 1.36 ]
Total (95% CI) 219 205 100.0 % 0.83 [ 0.61, 1.11 ]
Total events: 57 (Gefitinib 500 mg), 65 (Gefitinib 250 mg)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 2 Skin rash.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 7 Gefitinib 250 mg versus gefitinib 500 mg
Outcome: 2 Skin rash
Study or subgroup Gefitinib 500 mg Gefitinib 250 mg Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2nd line
Fukuoka 2003 IDEAL I 7/106 1/103 63.2 % 6.80 [ 0.85, 54.32 ]
Subtotal (95% CI) 106 103 63.2 % 6.80 [ 0.85, 54.32 ]
Total events: 7 (Gefitinib 500 mg), 1 (Gefitinib 250 mg)
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.071)
2 Maintenance
Xue 2015 7/48 0/33 36.8 % 10.41 [ 0.61, 176.21 ]
Subtotal (95% CI) 48 33 36.8 % 10.41 [ 0.61, 176.21 ]
Total events: 7 (Gefitinib 500 mg), 0 (Gefitinib 250 mg)
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.10)
Total (95% CI) 154 136 100.0 % 8.13 [ 1.51, 43.72 ]
Total events: 14 (Gefitinib 500 mg), 1 (Gefitinib 250 mg)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
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Analysis 7.3. Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 3 Acne.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 7 Gefitinib 250 mg versus gefitinib 500 mg
Outcome: 3 Acne
Study or subgroup Gefitinib 500 mg Gefitinib 250 mg Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2nd line
Fukuoka 2003 IDEAL I 2/106 0/103 100.0 % 4.86 [ 0.24, 100.02 ]
Total (95% CI) 106 103 100.0 % 4.86 [ 0.24, 100.02 ]
Total events: 2 (Gefitinib 500 mg), 0 (Gefitinib 250 mg)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 7.4. Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 4 Pruritus.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 7 Gefitinib 250 mg versus gefitinib 500 mg
Outcome: 4 Pruritus
Study or subgroup Gefitinib 500 mg Gefitinib 250 mg Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2nd line
Fukuoka 2003 IDEAL I 1/106 0/103 100.0 % 2.92 [ 0.12, 70.77 ]
Total (95% CI) 106 103 100.0 % 2.92 [ 0.12, 70.77 ]
Total events: 1 (Gefitinib 500 mg), 0 (Gefitinib 250 mg)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 7.5. Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 5 Diarrhoea.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 7 Gefitinib 250 mg versus gefitinib 500 mg
Outcome: 5 Diarrhoea
Study or subgroup Gefitinib 500 mg Gefitinib 250 mg Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2nd line
Fukuoka 2003 IDEAL I 7/106 0/103 32.5 % 14.58 [ 0.84, 252.04 ]
Kris 2003 IDEAL II 6/114 1/102 67.5 % 5.37 [ 0.66, 43.84 ]
Xue 2015 0/48 0/48 Not estimable
Total (95% CI) 268 253 100.0 % 8.36 [ 1.58, 44.34 ]
Total events: 13 (Gefitinib 500 mg), 1 (Gefitinib 250 mg)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 2.49 (P = 0.013)
Test for subgroup differences: Not applicable
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Analysis 7.6. Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 6 Nausea.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 7 Gefitinib 250 mg versus gefitinib 500 mg
Outcome: 6 Nausea
Study or subgroup Gefitinib 500 mg Gefitinib 250 mg Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2nd line
Fukuoka 2003 IDEAL I 1/106 1/103 100.0 % 0.97 [ 0.06, 15.33 ]
Total (95% CI) 106 103 100.0 % 0.97 [ 0.06, 15.33 ]
Total events: 1 (Gefitinib 500 mg), 1 (Gefitinib 250 mg)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 7.7. Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 7 Vomiting.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 7 Gefitinib 250 mg versus gefitinib 500 mg
Outcome: 7 Vomiting
Study or subgroup Gefitinib 500 mg Gefitinib 250 mg Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2nd line
Fukuoka 2003 IDEAL I 0/106 0/103 Not estimable
Total (95% CI) 106 103 Not estimable
Total events: 0 (Gefitinib 500 mg), 0 (Gefitinib 250 mg)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 7.8. Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 8 Anorexia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 7 Gefitinib 250 mg versus gefitinib 500 mg
Outcome: 8 Anorexia
Study or subgroup Gefitinib 500 mg Gefitinib 250 mg Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2nd line
Fukuoka 2003 IDEAL I 1/106 0/103 100.0 % 2.92 [ 0.12, 70.77 ]
Total (95% CI) 106 103 100.0 % 2.92 [ 0.12, 70.77 ]
Total events: 1 (Gefitinib 500 mg), 0 (Gefitinib 250 mg)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 7.9. Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 9 Asthenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 7 Gefitinib 250 mg versus gefitinib 500 mg
Outcome: 9 Asthenia
Study or subgroup Gefitinib 500 mg Gefitinib 250 mg Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2nd line
Fukuoka 2003 IDEAL I 1/106 0/103 100.0 % 2.92 [ 0.12, 70.77 ]
Total (95% CI) 106 103 100.0 % 2.92 [ 0.12, 70.77 ]
Total events: 1 (Gefitinib 500 mg), 0 (Gefitinib 250 mg)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 7.10. Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 10 Overall response rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 7 Gefitinib 250 mg versus gefitinib 500 mg
Outcome: 10 Overall response rate
Study or subgroup Gefitinib 500 mg Gefitinib 250 mg Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2nd line
Fukuoka 2003 IDEAL I 20/105 19/103 60.2 % 1.03 [ 0.59, 1.82 ]
Kris 2003 IDEAL II 10/114 12/102 39.8 % 0.75 [ 0.34, 1.65 ]
Subtotal (95% CI) 219 205 100.0 % 0.92 [ 0.58, 1.46 ]
Total events: 30 (Gefitinib 500 mg), 31 (Gefitinib 250 mg)
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
2 Maintenance
Xue 2015 6/48 6/48 100.0 % 1.00 [ 0.35, 2.88 ]
Subtotal (95% CI) 48 48 100.0 % 1.00 [ 0.35, 2.88 ]
Total events: 6 (Gefitinib 500 mg), 6 (Gefitinib 250 mg)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 7.11. Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 11 Partial response.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 7 Gefitinib 250 mg versus gefitinib 500 mg
Outcome: 11 Partial response
Study or subgroup Gefitinib 500 mg Gefitinib 250 mg Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2nd line
Kris 2003 IDEAL II 10/114 12/102 100.0 % 0.75 [ 0.34, 1.65 ]
Total (95% CI) 114 102 100.0 % 0.75 [ 0.34, 1.65 ]
Total events: 10 (Gefitinib 500 mg), 12 (Gefitinib 250 mg)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 7.12. Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 12 FACT-L Symptom
improvement rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 7 Gefitinib 250 mg versus gefitinib 500 mg
Outcome: 12 FACT-L Symptom improvement rate
Study or subgroup Gefitinib 250 mg Gefitinib 500 mg
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 2nd line
Fukuoka 2003 IDEAL I 67 40.3 (51.16) 73 37 (50.35) 42.6 % 3.30 [ -13.54, 20.14 ]
Kris 2003 IDEAL II 102 44 (51.5) 114 40 (57.2) 57.4 % 4.00 [ -10.50, 18.50 ]
Total (95% CI) 169 187 100.0 % 3.70 [ -7.28, 14.69 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 7.13. Comparison 7 Gefitinib 250 mg versus gefitinib 500 mg, Outcome 13 TOI QOL improvement
rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 7 Gefitinib 250 mg versus gefitinib 500 mg
Outcome: 13 TOI QOL improvement rate
Study or subgroup Gefitinib 250 mg Gefitinib 500 mg
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 2nd line
Fukuoka 2003 IDEAL I 103 20.9 (55.92) 105 17.8 (48.88) 45.9 % 3.10 [ -11.18, 17.38 ]
Kris 2003 IDEAL II 102 34 (50.19) 114 23 (48.13) 54.1 % 11.00 [ -2.15, 24.15 ]
Total (95% CI) 205 219 100.0 % 7.38 [ -2.30, 17.05 ]
Heterogeneity: Chi2 = 0.64, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 1 HR Progression-free
survival.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 1 HR Progression-free survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 1st line
Cheng 2016 -0.3710637 (0.1698303) 100.0 % 0.69 [ 0.49, 0.96 ]
Subtotal (95% CI) 100.0 % 0.69 [ 0.49, 0.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
2 2nd line
Chen 2011 -0.4307829 (0.205432) 100.0 % 0.65 [ 0.43, 0.97 ]
Subtotal (95% CI) 100.0 % 0.65 [ 0.43, 0.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 8.2. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 2 1-year survival rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 2 1-year survival rate
Study or subgroup G + Chemo Gefitinib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2nd line
Chen 2007 16/21 14/27 24.5 % 1.47 [ 0.95, 2.27 ]
Chen 2011 39/57 38/58 75.5 % 1.04 [ 0.81, 1.35 ]
Total (95% CI) 78 85 100.0 % 1.15 [ 0.92, 1.43 ]
Total events: 55 (G + Chemo), 52 (Gefitinib)
Heterogeneity: Chi2 = 1.76, df = 1 (P = 0.18); I2 =43%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 3 1-year progression-free
survival.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 3 1-year progression-free survival
Study or subgroup G + Chemo Gefitinib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2nd line
Chen 2007 12/21 6/27 34.6 % 2.57 [ 1.16, 5.71 ]
Chen 2011 21/57 10/58 65.4 % 2.14 [ 1.11, 4.13 ]
Total (95% CI) 78 85 100.0 % 2.29 [ 1.38, 3.80 ]
Total events: 33 (G + Chemo), 16 (Gefitinib)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.19 (P = 0.0014)
Test for subgroup differences: Not applicable
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Analysis 8.4. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 4 Skin rash.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 4 Skin rash
Study or subgroup G + Chemo Gefitinib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
An 2016 2/45 2/45 47.7 % 1.00 [ 0.15, 6.79 ]
Cheng 2016 2/126 1/65 31.5 % 1.03 [ 0.10, 11.17 ]
Subtotal (95% CI) 171 110 79.1 % 1.01 [ 0.23, 4.51 ]
Total events: 4 (G + Chemo), 3 (Gefitinib)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.99)
2 2nd line
Chen 2007 2/21 1/27 20.9 % 2.57 [ 0.25, 26.47 ]
Subtotal (95% CI) 21 27 20.9 % 2.57 [ 0.25, 26.47 ]
Total events: 2 (G + Chemo), 1 (Gefitinib)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Total (95% CI) 192 137 100.0 % 1.34 [ 0.39, 4.57 ]
Total events: 6 (G + Chemo), 4 (Gefitinib)
Heterogeneity: Chi2 = 0.44, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Chi2 = 0.44, df = 1 (P = 0.51), I2 =0.0%
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Analysis 8.5. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 5 Diarrhoea.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 5 Diarrhoea
Study or subgroup G + Chemo Gefitinib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
An 2016 2/45 1/45 43.1 % 2.00 [ 0.19, 21.28 ]
Cheng 2016 1/126 1/65 56.9 % 0.52 [ 0.03, 8.11 ]
Subtotal (95% CI) 171 110 100.0 % 1.16 [ 0.21, 6.34 ]
Total events: 3 (G + Chemo), 2 (Gefitinib)
Heterogeneity: Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
2 2nd line
Chen 2007 0/21 0/27 Not estimable
Subtotal (95% CI) 21 27 Not estimable
Total events: 0 (G + Chemo), 0 (Gefitinib)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 192 137 100.0 % 1.16 [ 0.21, 6.34 ]
Total events: 3 (G + Chemo), 2 (Gefitinib)
Heterogeneity: Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 8.6. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 6 Constipation.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 6 Constipation
Study or subgroup G + Chemo Gefitinib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2nd line
Chen 2007 0/21 1/27 100.0 % 0.42 [ 0.02, 9.92 ]
Total (95% CI) 21 27 100.0 % 0.42 [ 0.02, 9.92 ]
Total events: 0 (G + Chemo), 1 (Gefitinib)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 8.7. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 7 Fatigue.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 7 Fatigue
Study or subgroup G + Chemo Gefitinib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
An 2016 2/45 2/45 75.2 % 1.00 [ 0.15, 6.79 ]
Cheng 2016 7/126 0/65 24.8 % 7.80 [ 0.45, 134.39 ]
Subtotal (95% CI) 171 110 100.0 % 2.68 [ 0.60, 11.90 ]
Total events: 9 (G + Chemo), 2 (Gefitinib)
Heterogeneity: Chi2 = 1.56, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 1.30 (P = 0.19)
2 2nd line
Chen 2007 0/21 0/27 Not estimable
Subtotal (95% CI) 21 27 Not estimable
Total events: 0 (G + Chemo), 0 (Gefitinib)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 192 137 100.0 % 2.68 [ 0.60, 11.90 ]
Total events: 9 (G + Chemo), 2 (Gefitinib)
Heterogeneity: Chi2 = 1.56, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 8.8. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 8 Leukopenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 8 Leukopenia
Study or subgroup G + Chemo Gefitinib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
An 2016 5/45 4/45 90.1 % 1.25 [ 0.36, 4.35 ]
Subtotal (95% CI) 45 45 90.1 % 1.25 [ 0.36, 4.35 ]
Total events: 5 (G + Chemo), 4 (Gefitinib)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
2 2nd line
Chen 2007 1/21 0/27 9.9 % 3.82 [ 0.16, 89.24 ]
Subtotal (95% CI) 21 27 9.9 % 3.82 [ 0.16, 89.24 ]
Total events: 1 (G + Chemo), 0 (Gefitinib)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.40)
Total (95% CI) 66 72 100.0 % 1.50 [ 0.48, 4.70 ]
Total events: 6 (G + Chemo), 4 (Gefitinib)
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Chi2 = 0.42, df = 1 (P = 0.52), I2 =0.0%
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Analysis 8.9. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 9 Anaemia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 9 Anaemia
Study or subgroup G + Chemo Gefitinib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
An 2016 2/45 1/45 47.7 % 2.00 [ 0.19, 21.28 ]
Cheng 2016 4/126 0/65 31.4 % 4.68 [ 0.26, 85.56 ]
Subtotal (95% CI) 171 110 79.0 % 3.06 [ 0.49, 19.15 ]
Total events: 6 (G + Chemo), 1 (Gefitinib)
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
2 2nd line
Chen 2007 1/21 0/27 21.0 % 3.82 [ 0.16, 89.24 ]
Subtotal (95% CI) 21 27 21.0 % 3.82 [ 0.16, 89.24 ]
Total events: 1 (G + Chemo), 0 (Gefitinib)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.40)
Total (95% CI) 192 137 100.0 % 3.22 [ 0.66, 15.72 ]
Total events: 7 (G + Chemo), 1 (Gefitinib)
Heterogeneity: Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
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Analysis 8.10. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 10 Thrombocytopenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 10 Thrombocytopenia
Study or subgroup G + Chemo Gefitinib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
An 2016 0/45 0/45 Not estimable
Subtotal (95% CI) 45 45 Not estimable
Total events: 0 (G + Chemo), 0 (Gefitinib)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 2nd line
Chen 2007 0/21 0/27 Not estimable
Subtotal (95% CI) 21 27 Not estimable
Total events: 0 (G + Chemo), 0 (Gefitinib)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 66 72 Not estimable
Total events: 0 (G + Chemo), 0 (Gefitinib)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 8.11. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 11 Neutropenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 11 Neutropenia
Study or subgroup G + Chemo Gefitinib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
An 2016 10/45 9/45 83.6 % 1.11 [ 0.50, 2.47 ]
Cheng 2016 6/126 1/65 12.3 % 3.10 [ 0.38, 25.17 ]
Subtotal (95% CI) 171 110 95.9 % 1.36 [ 0.65, 2.88 ]
Total events: 16 (G + Chemo), 10 (Gefitinib)
Heterogeneity: Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.42)
2 2nd line
Chen 2007 1/21 0/27 4.1 % 3.82 [ 0.16, 89.24 ]
Subtotal (95% CI) 21 27 4.1 % 3.82 [ 0.16, 89.24 ]
Total events: 1 (G + Chemo), 0 (Gefitinib)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.40)
Total (95% CI) 192 137 100.0 % 1.47 [ 0.71, 3.02 ]
Total events: 17 (G + Chemo), 10 (Gefitinib)
Heterogeneity: Chi2 = 1.30, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 0.39, df = 1 (P = 0.53), I2 =0.0%
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Analysis 8.12. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 12 Increased ALT.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 12 Increased ALT
Study or subgroup G + Chemo Gefitinib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
An 2016 6/45 5/45 65.5 % 1.20 [ 0.39, 3.65 ]
Cheng 2016 20/126 2/65 34.5 % 5.16 [ 1.24, 21.39 ]
Total (95% CI) 171 110 100.0 % 2.57 [ 1.09, 6.04 ]
Total events: 26 (G + Chemo), 7 (Gefitinib)
Heterogeneity: Chi2 = 2.72, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Not applicable
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Analysis 8.13. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 13 Increased AST.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 13 Increased AST
Study or subgroup G + Chemo Gefitinib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
An 2016 5/45 4/45 60.3 % 1.25 [ 0.36, 4.35 ]
Cheng 2016 7/126 2/65 39.7 % 1.81 [ 0.39, 8.44 ]
Total (95% CI) 171 110 100.0 % 1.47 [ 0.56, 3.88 ]
Total events: 12 (G + Chemo), 6 (Gefitinib)
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 8.14. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 14 Vomiting.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 14 Vomiting
Study or subgroup G + Chemo Gefitinib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Cheng 2016 1/126 0/65 100.0 % 1.56 [ 0.06, 37.74 ]
Total (95% CI) 126 65 100.0 % 1.56 [ 0.06, 37.74 ]
Total events: 1 (G + Chemo), 0 (Gefitinib)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 8.15. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 15 Nausea.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 15 Nausea
Study or subgroup G + Chemo Gefitinib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Cheng 2016 1/126 0/65 100.0 % 1.56 [ 0.06, 37.74 ]
Total (95% CI) 126 65 100.0 % 1.56 [ 0.06, 37.74 ]
Total events: 1 (G + Chemo), 0 (Gefitinib)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 8.16. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 16 Overall response rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 16 Overall response rate
Study or subgroup G + Chemo Gefitinib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
An 2016 33/45 36/45 36.2 % 0.92 [ 0.73, 1.15 ]
Cheng 2016 101/126 48/65 63.8 % 1.09 [ 0.92, 1.29 ]
Total (95% CI) 171 110 100.0 % 1.02 [ 0.89, 1.17 ]
Total events: 134 (G + Chemo), 84 (Gefitinib)
Heterogeneity: Chi2 = 1.36, df = 1 (P = 0.24); I2 =26%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 8.17. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 17 Partial response.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 17 Partial response
Study or subgroup G + Chemo Gefitinib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
An 2016 33/45 36/45 27.2 % 0.92 [ 0.73, 1.15 ]
Cheng 2016 99/126 48/65 47.9 % 1.06 [ 0.90, 1.26 ]
Subtotal (95% CI) 171 110 75.1 % 1.01 [ 0.88, 1.16 ]
Total events: 132 (G + Chemo), 84 (Gefitinib)
Heterogeneity: Chi2 = 1.05, df = 1 (P = 0.31); I2 =4%
Test for overall effect: Z = 0.15 (P = 0.88)
2 2nd line
Chen 2007 11/21 15/27 9.9 % 0.94 [ 0.56, 1.60 ]
Chen 2011 21/57 20/58 15.0 % 1.07 [ 0.65, 1.75 ]
Subtotal (95% CI) 78 85 24.9 % 1.02 [ 0.71, 1.47 ]
Total events: 32 (G + Chemo), 35 (Gefitinib)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Total (95% CI) 249 195 100.0 % 1.01 [ 0.88, 1.16 ]
Total events: 164 (G + Chemo), 119 (Gefitinib)
Heterogeneity: Chi2 = 1.16, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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Analysis 8.18. Comparison 8 Gefitinib versus gefitinib + chemotherapy, Outcome 18 Stable disease.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 8 Gefitinib versus gefitinib + chemotherapy
Outcome: 18 Stable disease
Study or subgroup G + Chemo Gefitinib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
An 2016 6/45 8/45 16.6 % 0.75 [ 0.28, 1.99 ]
Cheng 2016 16/126 13/65 35.6 % 0.63 [ 0.33, 1.24 ]
Subtotal (95% CI) 171 110 52.1 % 0.67 [ 0.39, 1.16 ]
Total events: 22 (G + Chemo), 21 (Gefitinib)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
2 2nd line
Chen 2007 7/21 6/27 10.9 % 1.50 [ 0.59, 3.80 ]
Chen 2011 22/57 18/58 37.0 % 1.24 [ 0.75, 2.06 ]
Subtotal (95% CI) 78 85 47.9 % 1.30 [ 0.84, 2.03 ]
Total events: 29 (G + Chemo), 24 (Gefitinib)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Total (95% CI) 249 195 100.0 % 0.97 [ 0.69, 1.37 ]
Total events: 51 (G + Chemo), 45 (Gefitinib)
Heterogeneity: Chi2 = 3.59, df = 3 (P = 0.31); I2 =16%
Test for overall effect: Z = 0.16 (P = 0.88)
Test for subgroup differences: Chi2 = 3.37, df = 1 (P = 0.07), I2 =70%
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Analysis 9.1. Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 1 HR Overall
survival.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 9 Gefitinib + chemotherapy versus chemotherapy
Outcome: 1 HR Overall survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 1st line [Asian]
Takeda 2010 WJTOG0203 -0.1508229 (0.0904199) 91.1 % 0.86 [ 0.72, 1.03 ]
Yu 2014 -0.174353 (0.2896628) 8.9 % 0.84 [ 0.48, 1.48 ]
Subtotal (95% CI) 100.0 % 0.86 [ 0.72, 1.02 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.076)
2 2nd line [EGFRm]
Soria 2015 IMPRESS 0.4824261 (0.221078) 100.0 % 1.62 [ 1.05, 2.50 ]
Subtotal (95% CI) 100.0 % 1.62 [ 1.05, 2.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
Test for subgroup differences: Chi2 = 7.17, df = 1 (P = 0.01), I2 =86%
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Analysis 9.2. Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 2 HR Progression-
free survival.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 9 Gefitinib + chemotherapy versus chemotherapy
Outcome: 2 HR Progression-free survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 1st line [Asian]
Takeda 2010 WJTOG0203 -0.38566 (0.05867) 93.7 % 0.68 [ 0.61, 0.76 ]
Yu 2014 -0.127833 (0.2259165) 6.3 % 0.88 [ 0.57, 1.37 ]
Subtotal (95% CI) 100.0 % 0.69 [ 0.62, 0.77 ]
Heterogeneity: Chi2 = 1.22, df = 1 (P = 0.27); I2 =18%
Test for overall effect: Z = 6.50 (P < 0.00001)
2 2nd line [EGFRm]
Soria 2015 IMPRESS -0.150823 (0.1396466) 100.0 % 0.86 [ 0.65, 1.13 ]
Subtotal (95% CI) 100.0 % 0.86 [ 0.65, 1.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Chi2 = 2.10, df = 1 (P = 0.15), I2 =52%
0.5 0.7 1 1.5 2
Favours G + Chemo Favours Chemo
238Gefitinib for advanced non-small cell lung cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 9.3. Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 3 1-year survival
rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 9 Gefitinib + chemotherapy versus chemotherapy
Outcome: 3 1-year survival rate
Study or subgroup Gefitinib + Chemo Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Giaccone 2004 INTACT I 150/365 160/363 52.8 % 0.93 [ 0.79, 1.10 ]
Herbst 2004 INTACT II 140/342 143/341 47.2 % 0.98 [ 0.82, 1.17 ]
Total (95% CI) 707 704 100.0 % 0.95 [ 0.84, 1.08 ]
Total events: 290 (Gefitinib + Chemo), 303 (Chemo)
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 9.4. Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 4 Skin rash.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 9 Gefitinib + chemotherapy versus chemotherapy
Outcome: 4 Skin rash
Study or subgroup Gefitinib + Chemo Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Giaccone 2004 INTACT I 13/362 4/355 35.0 % 3.19 [ 1.05, 9.68 ]
Herbst 2004 INTACT II 11/342 5/341 43.4 % 2.19 [ 0.77, 6.25 ]
Subtotal (95% CI) 704 696 78.3 % 2.64 [ 1.23, 5.63 ]
Total events: 24 (Gefitinib + Chemo), 9 (Chemo)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.50 (P = 0.012)
2 1st line [Asian]
Takeda 2010 WJTOG0203 1/300 2/298 17.4 % 0.50 [ 0.05, 5.45 ]
Yu 2014 9/58 0/59 4.3 % 19.32 [ 1.15, 324.49 ]
Subtotal (95% CI) 358 357 21.7 % 4.23 [ 1.08, 16.54 ]
Total events: 10 (Gefitinib + Chemo), 2 (Chemo)
Heterogeneity: Chi2 = 4.19, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 2.07 (P = 0.038)
3 2nd line [EGFRm]
Soria 2015 IMPRESS 0/132 0/132 Not estimable
Subtotal (95% CI) 132 132 Not estimable
Total events: 0 (Gefitinib + Chemo), 0 (Chemo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1194 1185 100.0 % 2.98 [ 1.54, 5.77 ]
Total events: 34 (Gefitinib + Chemo), 11 (Chemo)
Heterogeneity: Chi2 = 4.18, df = 3 (P = 0.24); I2 =28%
Test for overall effect: Z = 3.24 (P = 0.0012)
Test for subgroup differences: Chi2 = 0.35, df = 1 (P = 0.55), I2 =0.0%
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Analysis 9.5. Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 5 Acne.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 9 Gefitinib + chemotherapy versus chemotherapy
Outcome: 5 Acne
Study or subgroup Gefitinib + Chemo Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Giaccone 2004 INTACT I 5/362 1/355 50.2 % 4.90 [ 0.58, 41.76 ]
Herbst 2004 INTACT II 3/342 0/341 24.9 % 6.98 [ 0.36, 134.61 ]
Subtotal (95% CI) 704 696 75.1 % 5.59 [ 0.99, 31.60 ]
Total events: 8 (Gefitinib + Chemo), 1 (Chemo)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.051)
2 2nd line [EGFRm]
Soria 2015 IMPRESS 1/132 0/132 24.9 % 3.00 [ 0.12, 72.98 ]
Subtotal (95% CI) 132 132 24.9 % 3.00 [ 0.12, 72.98 ]
Total events: 1 (Gefitinib + Chemo), 0 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Total (95% CI) 836 828 100.0 % 4.95 [ 1.09, 22.51 ]
Total events: 9 (Gefitinib + Chemo), 1 (Chemo)
Heterogeneity: Chi2 = 0.15, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 2.07 (P = 0.039)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
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Analysis 9.6. Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 6 Diarrhoea.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 9 Gefitinib + chemotherapy versus chemotherapy
Outcome: 6 Diarrhoea
Study or subgroup Gefitinib + Chemo Chemo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 1st line
Giaccone 2004 INTACT I 13/362 8/355 30.4 % 1.59 [ 0.67, 3.80 ]
Herbst 2004 INTACT II 34/342 10/341 41.8 % 3.39 [ 1.70, 6.75 ]
Subtotal (95% CI) 704 696 72.2 % 2.44 [ 1.17, 5.09 ]
Total events: 47 (Gefitinib + Chemo), 18 (Chemo)
Heterogeneity: Tau2 = 0.13; Chi2 = 1.79, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 2.38 (P = 0.017)
2 1st line [Asian]
Takeda 2010 WJTOG0203 5/300 6/298 18.9 % 0.83 [ 0.26, 2.68 ]
Yu 2014 1/58 0/59 3.0 % 3.05 [ 0.13, 73.39 ]
Subtotal (95% CI) 358 357 21.9 % 0.97 [ 0.32, 2.92 ]
Total events: 6 (Gefitinib + Chemo), 6 (Chemo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
3 2nd line [EGFRm]
Soria 2015 IMPRESS 3/132 1/132 5.9 % 3.00 [ 0.32, 28.47 ]
Subtotal (95% CI) 132 132 5.9 % 3.00 [ 0.32, 28.47 ]
Total events: 3 (Gefitinib + Chemo), 1 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 1194 1185 100.0 % 2.04 [ 1.17, 3.58 ]
Total events: 56 (Gefitinib + Chemo), 25 (Chemo)
Heterogeneity: Tau2 = 0.07; Chi2 = 4.81, df = 4 (P = 0.31); I2 =17%
Test for overall effect: Z = 2.50 (P = 0.012)
Test for subgroup differences: Chi2 = 2.04, df = 2 (P = 0.36), I2 =2%
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Analysis 9.7. Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 7 Pruritus.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 9 Gefitinib + chemotherapy versus chemotherapy
Outcome: 7 Pruritus
Study or subgroup Gefitinib + Chemo Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Giaccone 2004 INTACT I 0/362 0/355 Not estimable
Herbst 2004 INTACT II 2/342 1/341 100.0 % 1.99 [ 0.18, 21.89 ]
Total (95% CI) 704 696 100.0 % 1.99 [ 0.18, 21.89 ]
Total events: 2 (Gefitinib + Chemo), 1 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 9.8. Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 8 Vomiting.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 9 Gefitinib + chemotherapy versus chemotherapy
Outcome: 8 Vomiting
Study or subgroup Gefitinib + Chemo Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Giaccone 2004 INTACT I 10/362 8/355 21.8 % 1.23 [ 0.49, 3.07 ]
Herbst 2004 INTACT II 7/342 8/341 21.6 % 0.87 [ 0.32, 2.38 ]
Subtotal (95% CI) 704 696 43.4 % 1.05 [ 0.53, 2.06 ]
Total events: 17 (Gefitinib + Chemo), 16 (Chemo)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
2 1st line [Asian]
Takeda 2010 WJTOG0203 17/300 13/298 35.2 % 1.30 [ 0.64, 2.63 ]
Yu 2014 6/58 5/59 13.4 % 1.22 [ 0.39, 3.78 ]
Subtotal (95% CI) 358 357 48.5 % 1.28 [ 0.70, 2.32 ]
Total events: 23 (Gefitinib + Chemo), 18 (Chemo)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
3 2nd line [EGFRm]
Soria 2015 IMPRESS 6/132 3/132 8.1 % 2.00 [ 0.51, 7.83 ]
Subtotal (95% CI) 132 132 8.1 % 2.00 [ 0.51, 7.83 ]
Total events: 6 (Gefitinib + Chemo), 3 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Total (95% CI) 1194 1185 100.0 % 1.24 [ 0.81, 1.89 ]
Total events: 46 (Gefitinib + Chemo), 37 (Chemo)
Heterogeneity: Chi2 = 0.96, df = 4 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.32)
Test for subgroup differences: Chi2 = 0.71, df = 2 (P = 0.70), I2 =0.0%
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Analysis 9.9. Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 9 Nausea.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 9 Gefitinib + chemotherapy versus chemotherapy
Outcome: 9 Nausea
Study or subgroup Gefitinib + Chemo Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Giaccone 2004 INTACT I 9/362 7/355 11.2 % 1.26 [ 0.47, 3.35 ]
Herbst 2004 INTACT II 6/342 7/341 11.1 % 0.85 [ 0.29, 2.52 ]
Subtotal (95% CI) 704 696 22.3 % 1.06 [ 0.51, 2.18 ]
Total events: 15 (Gefitinib + Chemo), 14 (Chemo)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
2 1st line [Asian]
Takeda 2010 WJTOG0203 29/300 38/298 60.4 % 0.76 [ 0.48, 1.20 ]
Yu 2014 3/58 5/59 7.8 % 0.61 [ 0.15, 2.44 ]
Subtotal (95% CI) 358 357 68.2 % 0.74 [ 0.48, 1.14 ]
Total events: 32 (Gefitinib + Chemo), 43 (Chemo)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
3 2nd line [EGFRm]
Soria 2015 IMPRESS 5/132 6/132 9.5 % 0.83 [ 0.26, 2.66 ]
Subtotal (95% CI) 132 132 9.5 % 0.83 [ 0.26, 2.66 ]
Total events: 5 (Gefitinib + Chemo), 6 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Total (95% CI) 1194 1185 100.0 % 0.82 [ 0.58, 1.17 ]
Total events: 52 (Gefitinib + Chemo), 63 (Chemo)
Heterogeneity: Chi2 = 1.04, df = 4 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Chi2 = 0.69, df = 2 (P = 0.71), I2 =0.0%
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Analysis 9.10. Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 10 Anorexia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 9 Gefitinib + chemotherapy versus chemotherapy
Outcome: 10 Anorexia
Study or subgroup Gefitinib + Chemo Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Giaccone 2004 INTACT I 2/362 1/355 2.0 % 1.96 [ 0.18, 21.53 ]
Herbst 2004 INTACT II 2/342 1/341 2.0 % 1.99 [ 0.18, 21.89 ]
Subtotal (95% CI) 704 696 4.0 % 1.98 [ 0.36, 10.76 ]
Total events: 4 (Gefitinib + Chemo), 2 (Chemo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
2 1st line [Asian]
Takeda 2010 WJTOG0203 35/300 43/298 86.1 % 0.81 [ 0.53, 1.23 ]
Yu 2014 1/58 2/59 4.0 % 0.51 [ 0.05, 5.46 ]
Subtotal (95% CI) 358 357 90.0 % 0.80 [ 0.53, 1.20 ]
Total events: 36 (Gefitinib + Chemo), 45 (Chemo)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.27)
3 2nd line [EGFRm]
Soria 2015 IMPRESS 1/132 3/132 6.0 % 0.33 [ 0.04, 3.16 ]
Subtotal (95% CI) 132 132 6.0 % 0.33 [ 0.04, 3.16 ]
Total events: 1 (Gefitinib + Chemo), 3 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 1194 1185 100.0 % 0.82 [ 0.55, 1.20 ]
Total events: 41 (Gefitinib + Chemo), 50 (Chemo)
Heterogeneity: Chi2 = 1.81, df = 4 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Chi2 = 1.67, df = 2 (P = 0.43), I2 =0.0%
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Analysis 9.11. Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 11 Asthenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 9 Gefitinib + chemotherapy versus chemotherapy
Outcome: 11 Asthenia
Study or subgroup Gefitinib + Chemo Chemo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 1st line
Giaccone 2004 INTACT I 7/362 3/355 41.8 % 2.29 [ 0.60, 8.78 ]
Herbst 2004 INTACT II 1/342 4/341 24.5 % 0.25 [ 0.03, 2.22 ]
Subtotal (95% CI) 704 696 66.3 % 0.90 [ 0.10, 7.76 ]
Total events: 8 (Gefitinib + Chemo), 7 (Chemo)
Heterogeneity: Tau2 = 1.63; Chi2 = 2.90, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 0.10 (P = 0.92)
2 2nd line [EGFRm]
Soria 2015 IMPRESS 2/132 4/132 33.7 % 0.50 [ 0.09, 2.68 ]
Subtotal (95% CI) 132 132 33.7 % 0.50 [ 0.09, 2.68 ]
Total events: 2 (Gefitinib + Chemo), 4 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Total (95% CI) 836 828 100.0 % 0.80 [ 0.21, 2.99 ]
Total events: 10 (Gefitinib + Chemo), 11 (Chemo)
Heterogeneity: Tau2 = 0.62; Chi2 = 3.65, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 0.34 (P = 0.74)
Test for subgroup differences: Chi2 = 0.18, df = 1 (P = 0.67), I2 =0.0%
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Analysis 9.12. Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 12 Dyspnoea.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 9 Gefitinib + chemotherapy versus chemotherapy
Outcome: 12 Dyspnoea
Study or subgroup Gefitinib + Chemo Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Herbst 2004 INTACT II 2/342 1/341 25.0 % 1.99 [ 0.18, 21.89 ]
Subtotal (95% CI) 342 341 25.0 % 1.99 [ 0.18, 21.89 ]
Total events: 2 (Gefitinib + Chemo), 1 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
2 2nd line [EGFRm]
Soria 2015 IMPRESS 2/132 3/132 75.0 % 0.67 [ 0.11, 3.93 ]
Subtotal (95% CI) 132 132 75.0 % 0.67 [ 0.11, 3.93 ]
Total events: 2 (Gefitinib + Chemo), 3 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Total (95% CI) 474 473 100.0 % 1.00 [ 0.25, 3.96 ]
Total events: 4 (Gefitinib + Chemo), 4 (Chemo)
Heterogeneity: Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Chi2 = 0.52, df = 1 (P = 0.47), I2 =0.0%
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Analysis 9.13. Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 13 Anaemia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 9 Gefitinib + chemotherapy versus chemotherapy
Outcome: 13 Anaemia
Study or subgroup Gefitinib + Chemo Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line [Asian]
Takeda 2010 WJTOG0203 40/300 65/298 91.6 % 0.61 [ 0.43, 0.88 ]
Yu 2014 2/58 1/59 1.4 % 2.03 [ 0.19, 21.83 ]
Subtotal (95% CI) 358 357 93.0 % 0.63 [ 0.44, 0.90 ]
Total events: 42 (Gefitinib + Chemo), 66 (Chemo)
Heterogeneity: Chi2 = 0.97, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 2.53 (P = 0.011)
2 2nd line [EGFRm]
Soria 2015 IMPRESS 11/132 5/132 7.0 % 2.20 [ 0.79, 6.16 ]
Subtotal (95% CI) 132 132 7.0 % 2.20 [ 0.79, 6.16 ]
Total events: 11 (Gefitinib + Chemo), 5 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Total (95% CI) 490 489 100.0 % 0.74 [ 0.53, 1.03 ]
Total events: 53 (Gefitinib + Chemo), 71 (Chemo)
Heterogeneity: Chi2 = 6.09, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 1.78 (P = 0.076)
Test for subgroup differences: Chi2 = 5.04, df = 1 (P = 0.02), I2 =80%
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Analysis 9.14. Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 14 Neutropenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 9 Gefitinib + chemotherapy versus chemotherapy
Outcome: 14 Neutropenia
Study or subgroup Gefitinib + Chemo Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Giaccone 2004 INTACT I 21/362 17/355 6.2 % 1.21 [ 0.65, 2.26 ]
Herbst 2004 INTACT II 23/342 20/341 7.2 % 1.15 [ 0.64, 2.05 ]
Subtotal (95% CI) 704 696 13.4 % 1.18 [ 0.77, 1.80 ]
Total events: 44 (Gefitinib + Chemo), 37 (Chemo)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
2 1st line [Asian]
Takeda 2010 WJTOG0203 212/300 226/298 81.6 % 0.93 [ 0.85, 1.03 ]
Yu 2014 6/58 7/59 2.5 % 0.87 [ 0.31, 2.44 ]
Subtotal (95% CI) 358 357 84.1 % 0.93 [ 0.84, 1.03 ]
Total events: 218 (Gefitinib + Chemo), 233 (Chemo)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
3 2nd line [EGFRm]
Soria 2015 IMPRESS 9/132 7/132 2.5 % 1.29 [ 0.49, 3.35 ]
Subtotal (95% CI) 132 132 2.5 % 1.29 [ 0.49, 3.35 ]
Total events: 9 (Gefitinib + Chemo), 7 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Total (95% CI) 1194 1185 100.0 % 0.97 [ 0.87, 1.08 ]
Total events: 271 (Gefitinib + Chemo), 277 (Chemo)
Heterogeneity: Chi2 = 1.89, df = 4 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Chi2 = 1.52, df = 2 (P = 0.47), I2 =0.0%
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Analysis 9.15. Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 15 Leukopenia.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 9 Gefitinib + chemotherapy versus chemotherapy
Outcome: 15 Leukopenia
Study or subgroup Gefitinib + Chemo Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Giaccone 2004 INTACT I 12/362 9/355 7.0 % 1.31 [ 0.56, 3.06 ]
Herbst 2004 INTACT II 7/342 7/341 5.4 % 1.00 [ 0.35, 2.81 ]
Subtotal (95% CI) 704 696 12.3 % 1.17 [ 0.61, 2.26 ]
Total events: 19 (Gefitinib + Chemo), 16 (Chemo)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
2 1st line [Asian]
Takeda 2010 WJTOG0203 119/300 111/298 85.4 % 1.06 [ 0.87, 1.30 ]
Subtotal (95% CI) 300 298 85.4 % 1.06 [ 0.87, 1.30 ]
Total events: 119 (Gefitinib + Chemo), 111 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
3 2nd line [EGFRm]
Soria 2015 IMPRESS 3/132 3/132 2.3 % 1.00 [ 0.21, 4.86 ]
Subtotal (95% CI) 132 132 2.3 % 1.00 [ 0.21, 4.86 ]
Total events: 3 (Gefitinib + Chemo), 3 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 1136 1126 100.0 % 1.08 [ 0.89, 1.31 ]
Total events: 141 (Gefitinib + Chemo), 130 (Chemo)
Heterogeneity: Chi2 = 0.24, df = 3 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Chi2 = 0.08, df = 2 (P = 0.96), I2 =0.0%
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Analysis 9.16. Comparison 9 Gefitinib + chemotherapy versus chemotherapy, Outcome 16 Overall
response rate.
Review: Gefitinib for advanced non-small cell lung cancer
Comparison: 9 Gefitinib + chemotherapy versus chemotherapy
Outcome: 16 Overall response rate
Study or subgroup Gefitinib + Chemo Chemo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1st line
Giaccone 2004 INTACT I 172/336 153/324 37.8 % 1.08 [ 0.93, 1.27 ]
Herbst 2004 INTACT II 104/342 98/341 23.8 % 1.06 [ 0.84, 1.33 ]
Subtotal (95% CI) 678 665 61.6 % 1.07 [ 0.94, 1.22 ]
Total events: 276 (Gefitinib + Chemo), 251 (Chemo)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
2 1st line [Asian]
Takeda 2010 WJTOG0203 102/298 87/297 21.1 % 1.17 [ 0.92, 1.48 ]
Yu 2014 27/54 27/57 6.4 % 1.06 [ 0.72, 1.55 ]
Subtotal (95% CI) 352 354 27.5 % 1.14 [ 0.93, 1.40 ]
Total events: 129 (Gefitinib + Chemo), 114 (Chemo)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
3 2nd line [EGFRm]
Soria 2015 IMPRESS 42/133 45/132 10.9 % 0.93 [ 0.66, 1.31 ]
Subtotal (95% CI) 133 132 10.9 % 0.93 [ 0.66, 1.31 ]
Total events: 42 (Gefitinib + Chemo), 45 (Chemo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI) 1163 1151 100.0 % 1.08 [ 0.97, 1.20 ]
Total events: 447 (Gefitinib + Chemo), 410 (Chemo)
Heterogeneity: Chi2 = 1.23, df = 4 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
Test for subgroup differences: Chi2 = 1.06, df = 2 (P = 0.59), I2 =0.0%
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A D D I T I O N A L T A B L E S
Table 1. Included studies
Author/
Year
(Study
name)
Journal N Comparison Inclusion
criteria
Phase Asian EGFR
mutation
Line?
1. Gefitinib versus placebo
Goss 2009
(INSTEP)
JCO 27(13)
:2253-2260
201 Placebo Poor PS II N Subgroup 1st line
Thatcher
2005 (ISEL)
Lancet 366:
1527-37
1692 Placebo - III Subset (Chang) Subgroup
(Hirsch)
2nd line
Gaafar 2011
(EORTC08021)
Eur J
Cancer (47):
2331-2340
173 Placebo Maintenance III N N Maintenance
Kelly 2008
(SWOGS0023)
JCO 26(15)
:2450-2456
243 Placebo Consolida-
tion
III N N Maintenance
Zhang 2012
(INFORM)
Lancet On-
cology 13:
466-475
296 Placebo Maintenance III Y Subgroup Maintenance
2. Gefitinib versus chemotherapy
Crino 2008
(INVITE)
JCO 26(26)
:4253-4260
196 Vinorelbine Elderly
patients
II N Subgroup 1st line
Lou 2014 Natl Med J
China 94
(30): 2337-
2341
51 Carboplatin
+ paclitaxel
Asian II Y N 1st line
Morere
2010
(IFCT0301)
Lung Can-
cer 70:301-
307
85 Docetaxel Poor PS II N N 1st line
Han
2013 (First-
SIGNAL)
JCO 30(10)
: 1122-1128
313 Gemcitabine
+ cisplatin
- III Y Planned
Subgroup
1st line
Mok 2009
(IPASS)
NEJM 361
(10):947-
957
1217 Carboplatin
+ paclitaxel
Asian, adeno-
carcinomas
III Y Subgroup 1st line
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Table 1. Included studies (Continued)
Maemondo
2010
(NEJ002)
NEJM 362
(25):2580-
2588
230 Carboplatin
+ paclitaxel
Asian, EGFR
mutation
III Y Y 1st line
Mitsudomi
2010 (WJ-
TOG3405)
Lancet On-
col 11:121-
128
177 Cisplatin +
docetaxel
Asian, EGFR
mutation
III Y Y 1st line
Yang 2014 Eur J Can-
cer 50:2219-
2230
236 Pemetrexed +
cisplatin
Asian III Y Subgroup 1st line + main-
tenance
Cufer 2006
(SIGN)
Anti-cancer
Drugs 14:
401-409
141 Docetaxel Open-label II N N 2nd line
Dai 2013 Chin J Lung
Cancer 16
(8):405-410
46 Pemetrexed Asian II Y N 2nd line
Kim 2016 Cancer Res
Treat 48(1):
80-87
95 Pemetrexed Asian II Y N 2nd/3rd line
Li 2010 Chinese
J Clin Onc
37:16-18
98 Docetaxel Asian II Y N 2nd line
Kim 2008
(INTER-
EST)
Lancet 372:
1809-1818
1466 Docetaxel - III N Subgroup
(Doulliard)
2nd line
Lee 2010
(ISTANA)
Clin Cancer
Res 16(4):
1307-1314
161 Docetaxel Asian III Y N 2nd/3rd line
Maruyama
2008 (V-15-
32)
JCO 26(26)
:4244-4252
489 Docetaxel Asian III Y Subgroup 2nd/3rd line
Sun 2012
(KSCG-
LU08-01)
Cancer 118:
6234-6242
141 Pemetrexed Adenocar-
cinoma, non-
smoker
III Y Subgroup 2nd line
Ahn 2012 Lung Can-
cer 77:346-
352
73 Pemetrexed Asian, never-
smokers
II Y N Maintenance
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Table 1. Included studies (Continued)
Xu 2015 Int J Clin
Exp Med 8
(4):6242-
6246
188 Pemetrexed Asian II Y N Maintenance
3. Gefitinib 250 mg versus gefitinib 500 mg
Fukuoka
2003
(IDEAL I)
JCO 21(12)
:2237-2246
210 G250 versus
G500
- II N N 2rd/3rd line
Kris 2003
(IDEAL II)
JAMA 290
(16):2149-
2158
216 G250 versus
G500
- II N N 3rd line
Xue 2015 Int J Clin
Exp Med 8
(4):6242-
6246
188 G250 versus
G500
Asian II Y N Maintenance
4. Gefitinib versus gefitinib + chemotherapy
An 2016 Pathol On-
col Res 22:
763-768
90 Gefitinib +
Pemetrexed
Asian, EGFR
mutation
II Y Y 1st line
Cheng 2016 JCO 34(27)
: 3258-3266
191 Gefitinib +
Pemetrexed
Asian, EGFR
mutation
II Y Y 1st line
Chen 2007 Cancer 109:
1821-8
48 Gefitinib +
Vinorelbine
Adenocarci-
noma
II N Subgroup 3rd line
Chen 2011 J Thor On-
col 6:1110-
1116
115 Gefitinib +
Tegafur
Adenocarci-
noma
II Y Subgroup 2nd/3rd line
5. Gefitinib + chemotherapy versus chemotherapy
Gi-
accone 2004
(INTACT I)
JCO 22(5):
777-784
1093 Gemcitabine
+ Cisplatin
- III N N 1st line
Herbst 2004
(INTACT
II)
JCO 22(5):
785-794
1037 Carboplatin
+ paclitaxel
- III N N 1st line
Takeda
2010
(WTOG0203)
JCO 28(5):
753-760
604 Platinum
doublet
- III Y N 1st line
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Table 1. Included studies (Continued)
Yu 2014 Cancer Biol-
ogy & Ther-
apy 15:832-
839
117 Pemetrexed +
platinum
Asian II Y N 1st line
Soria 2015
(IMPRESS)
Lancet On-
cology 16:
990-98
265 Pemetrexed +
cisplatin
EGFR muta-
tion positive
III N Y 2nd line
EGFR: epidermal growth factor receptor
N: number of patients included
PS: performance status
Journals:
Cancer Res Treat: Cancer Research and Treatment
Chin J Lung Cancer: Chinese Journal of Lung Cancer
Chinese J Clin Onc: Chinese Journal of Clinical Oncology
Clin Cancer Res: Clinical Cancer Research
Eur J Cancer: European Journal of Cancer
Int J Clin Exp Med: International Journal of Clinical and Experimental Medicine
J Thor Oncol: Journal of Thoracic Oncology
JCO: Journal of Clinical Oncology
Natl Med J China: National Medical Journal of China
NMEJ: New England Journal of Medicine
Pathol Oncol Res: Pathology and Oncology Research
Table 2. Efficacy and survival data
Study ORR (%) PFS (months) OS (months)
1. Gefi-
tinib ver-
sus
placebo
Gefitinib Control P Gefitinib Control P Gefitinib Control P
1st line
Goss 2009 6 1.0 NS 1.43 1.37 NS 3.7 2.8 NS
2nd line
Thatcher
2005 ISEL
37.5 48.3 NS 3 2.6 0.0006 5.6 5.1 0.087
Maintenance therapy
Kelly 2008
SWOGS0023
- - - 8.3 11.7 NS 23 35 0.013
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Table 2. Efficacy and survival data (Continued)
Gaafar
2011
EORTC08021
12 1 0.004 4.1 2.9 0.0015 10.9 9.4 NS
2. Gefi-
tinib ver-
sus
placebo
(Asian
popula-
tion)
Gefitinib Control P Gefitinib Control P Gefitinib Control P
Chang
2006 ISEL
12.4 2.1 0.01 4.4 2.2 0.008 9.5 5.5 0.01
Zhang
2012 IN-
FORM
24 1 0.0001 4.8 2.6 < 0.0001 18.7 16.0 NS
3. Gefi-
tinib ver-
sus
placebo
(EGFR
mutation
positive)
Gefitinib Control P Gefitinib Control P Gefitinib Control P
Zhang
2012 IN-
FORM
- - - 16.6 2.8 0.0063 46.87 20.97 0.036
Gefitinib vs chemotherapy
4. General
popula-
tion
Gefitinib Chemo P Gefitinib Chemo P Gefitinib Chemo P
versus 1st line chemotherapy
Crino
2008 IN-
VITE
3.1 5.1 - 2.7 2.9 NS 5.9 8 NS
Morere
2010
IFCT0301
- - - 1.9 2 0.078 2.2 3.5 0.088
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Table 2. Efficacy and survival data (Continued)
Morere
2010
IFCT0301
(Adeno-
carci-
noma)
- - - 1.9 2.1 0.272 2.3 4.4 NS
versus 2nd line chemotherapy
Cufer
2006
SIGN
13.2 13.7 NS 7.5 7.1 NS 3 3.4 NS
Kim 2008
INTER-
EST
9.1 7.6 NS 2.2 2.7 NS 7.6 8 NS
Kim 2008
INTER-
EST
- - - - - - 8.5 8.9 NS
5. Asian
popula-
tion
Gefitinib Chemo P Gefitinib Chemo P Gefitinib Chemo P
versus 1st line chemotherapy
Lou 2014 36 42.3 NS 4.2 8.3 NS 14.4 15 NS
Mae-
mondo
2010
(EGFR
mutation
positive)
73.7 30.7 < 0.001 10.8 5.4 < 0.001 30.5 23.6 NS
Mitsu-
domi 2010
WJTOG
(EGFR
mutation
positive)
62.1 32.2 < 0.0001 9.2 6.3 < 0.0001 - - -
Mok 2009
IPASS
43 32.2 < 0.001 5.7 5.8 NS 18.6 17.3 NS
Han 2012
First-SIG-
NAL (ade-
55.4 46 NS 5.8 6.4 NS 22.3 22.9 NS
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Table 2. Efficacy and survival data (Continued)
nocarci-
noma)
Yang 2014
(Asian)
47.5 41.5 NS 9.63 8.38 NS 27.9 26.9 NS
versus 2nd
line
chemo-
therapy
Dai 2013 17.4 13 NS 4.4 3.1 NS - - -
Kim 2016 8 13 NS 2 2 NS 8.5 8.5 NS
Li 2010 22.4 18.8 NS - - - 7.1 6.9 NS
Kim 2008
INTER-
EST (sub-
group)
- - - - - - 10.4 12.2 NS
Lee 2010
ISTANA
28.1 7.6 0.0007 3.3 3.4 NS 14.1 12.2 NS
Maruyama
2008 V-
15-32
22.5 12.8 0.009 2 2 NS 11.5 14 NS
Sun 2012
KCSG-
LU08-
01 (adeno-
carcinoma,
subgroup)
58.8 22.4 < 0.001 9.0 3.0 0.0006 22.2 18.9 NS
versus maintenance therapy
Ahn 2012
(Asian)
46 35 NS 9.95 6.83 NS - - -
Xu 2015
(Asian)
18.1 29.8 NS - - - - - -
6. EGFR
mutation
positive
Gefitinib Chemo P Gefitinib Chemo P Gefitinib Chemo P
versus 1st line chemotherapy
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Table 2. Efficacy and survival data (Continued)
Mae-
mondo
2010
(EGFR
mutation
positive)
73.7 30.7 < 0.001 10.8 5.4 < 0.001 30.5 23.6 NS
Mitsu-
domi 2010
WJTOG
(EGFR
mutation
positive)
62.1 32.2 < 0.0001 9.2 6.3 < 0.0001 - - -
Mok 2009
IPASS
(subgroup)
71.2 47.3 < 0.001 - - - - - -
Han 2012
First-SIG-
NAL (sub-
group)
84.6 37.5 0.002 - - - - - -
Yang 2014
(subgroup)
70.8 65.4 NS 16.62 12.91 NS 45.7 32.4 0.255
versus 2nd line chemotherapy
INTER-
ESTDoul-
liard 2010
(subgroup)
42.1 21.1 0.04 7 4.1 0.001 14.2 16.6 NS
Maruyama
2008 (sub-
group)
67 46 - - - - - - -
Sun 2012
KCSG-
LU08-01
(subgroup)
- - - 15.7 2.9 0.005 - - -
7. Gefi-
tinib 250
mg versus
gefitinib
500 mg
250 mg 500 mg P 250 mg 500 mg P 250 mg 500 mg P
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Table 2. Efficacy and survival data (Continued)
2nd+ line
Fukuoka
2003
18.4 19 NS 2.7 2.8 NS 7.6 8 NS
Kris 2004 12 9 NS - - - 7 6 NS
Maintenance therapy
Xue 2015
(Asian)
12.5 12.5 NS - - - - - -
8. Gefi-
tinib ver-
sus
gefitinib +
chemo-
therapy
Gefitinib G +
Chemo
P Gefitinib G +
Chemo
P Gefitinib G+Chemo P
1st line
An 2016 73.33 80 NS 14 18 < 0.05 32 34 NS
Cheng
2016
74 80 NS 10.9 15.8 0.014 - - -
2nd+ line
Chen
2007
(Asian,
adenocar-
cinoma)
55.6 52.4 NS 7.1 12.8 NS 13.3 23.4 NS
Chen
2011
(Asian,
adenocar-
cinoma)
35 37 NS 5.3 8.3 0.04 - - -
Chen
2011
(EGFR
mutation
positive
subgroup)
- - - 7.6 14.4 0.0061 - - -
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Table 2. Efficacy and survival data (Continued)
9.
Gefitinib
+ chemo-
ther-
apy versus
chemo-
therapy
250 mg +
Chemo
Chemo P 250 mg +
Chemo
Chemo P 250 mg +
Chemo
Chemo P
1st line
Giaccone
2004
51.2 47.2 NS 5.8 6 NS 9.9 10.9 NS
Herbst
2004
30.4 28.7 NS 5.3 5 NS 9.8 9.9 NS
Takeda
2010
(Asian)
34.2 29.3 NS 4.3 4.6 < 0.001 12.9 13.7 NS
Yu 2014
(Asian)
47.4 50 NS 7.9 7 NS 25.4 20.5 NS
2nd line
Soria 2015
IMPRESS
(EGFR
mutation
positive)
32 34 NS 5.4 5.4 NS 14.8 17.2 NS
Chemo: chemotherapy
G: gefitinib
NS: non-significant
ORR: overall response rate
OS: overall survival
PFS: progression-free survival
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy (Cochrane Library 2017, Issue 2)
#1 MeSH descriptor: [Lung Neoplasms] explode all trees 5740
#2 MeSH descriptor: [Carcinoma, Non-Small-Cell Lung] explode all trees 2918
#3 (lung or pulmon*) and (neoplas* or cancer or carcinoma* or tumor or tumour) 17027
#4 #1 or #2 or #3 17106
#5 gefitinib or zd 1839 or zd1839 or iressa 490
#6 #4 and #5 360
Appendix 2. MEDLINE search strategy (PubMed; 17 February 2017)
#11 Add Search #9 AND #10 3906 00:07:34
#10 Add Search (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR drug
therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab]) NOT (animals [mh] NOT humans [mh]) 3415417 00:06:59
#9 Add Search #5 AND #8 5006 00:02:59
#8 Add Search #6 OR #7 11742 00:02:47
#7 Add Search gefitinib[tw] OR ZD1839[tw] OR ZD 1839[tw] OR Iressa[tw] 5828 00:02:34
#6 Add Search “Receptor, Epidermal Growth Factor/antagonists and inhibitors”[Mesh] 7886 00:01:43
#5 Add Search #1 OR #2 OR #3 OR #4 208140 00:01:13
#4 Add Search NSCLC[tiab] 28799 00:00:30
#3 Add Search Non Small Cell[tiab] 45118 00:00:14
#2 Add Search “Carcinoma, Non-Small-Cell Lung”[MeSH] 39657 23:59:42
#1 Add Search Lung Neoplasms[MeSH] 196596 23:59:14
Appendix 3. Embase search strategy (Ovid; 1980 to 2017 Week 08)
1 exp lung cancer/ (275,340)
2 exp lung non small cell cancer/ (102,369)
3 non small cell.ti,ab. (66,846)
4 NSCLC.ti,ab. (49,669)
5 1 or 2 or 3 or 4 (286,738)
6 exp GEFITINIB/ (19,445)
7 gefitinib.mp. (19,987)
8 (ZD1839 or ZD 1839 or iressa).mp. (4,876)
9 6 or 7 or 8 (20,033)
10 5 and 9 (11,699)
11 random:.tw. or placebo:.mp. or double-blind:.mp. (699,255)
12 10 and 11 (1,437)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The text of the protocol section of the review has been updated to included new subheadings.
We have added toxicity to the list of our primary outcomes.
We have included three ’Summary of findings’ tables giving overall survival and progression-free survival for gefitinib compared to
chemotherapy for first-line treatment of advanced NSCLC, gefitinib compared to chemotherapy for second-line treatment of advanced
NSCLC and the toxicity of gefitinib compared to chemotherapy for advanced NSCLC.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antineoplastic Agents [adverse effects; ∗therapeutic use]; Carcinoma, Non-Small-Cell Lung [∗drug therapy; ethnology; genetics];
Disease-Free Survival; Genes, erbB-1; Lung Neoplasms [∗drug therapy; ethnology; genetics]; Mutation; Quality of Life; Quinazolines
[adverse effects; ∗therapeutic use]; Randomized Controlled Trials as Topic; Treatment Failure
MeSH check words
Humans
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